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ABSTRACT 
 
In this thesis, A6K, A9K, G(IIKK)3I-NH2, the fluorescently FITC-labelled A9K and 
G(IIKK)3I-NH2 amphiphilic cationic peptides have been intensively studied to evaluate 
their interactions with eukaryotic cell and in particular their selectivity towards cancer 
cells. A possible usage of these cationic peptides as delivery vectors of small nucleic 
acids molecules was also investigated. Results showed that A9K and G(IIKK)3I-NH2 
could bind nucleic acids and selectively carry them in 2D and 3D cancer models. 
However, only G(IIKK)3I-NH2 could, once internalised, release its cargo allowing the 
modulation of gene expression. The toxicity of A9K and FITC-G(IIKK)3I-NH2 was 
further investigated in vivo using zebrafish embryos (Danio rerio) as animal model. 
A9K did not induce developmental changes during embryogenesis unless high 
concentrations were used (1 – 4 ng, corresponding to 1.25 – 5 mM). FITC-G(IIKK)3I-
NH2 resulted more toxic and induced the embryos’ death also at concentration as little 
as 6.25 pg (corresponding 3.125 μM). However, in both cases, the concentrations 
needed to induce toxicity in zebrafish were several times higher than the ones used in 
the optimised peptide-based cellular transfection, where the peptide concentration range 
was between 30 and 300 nM. Moreover, the peptides uptake was investigated, revealing 
that one or more active endocytic pathways are responsible for their intracellular 
internalisation. Overall, the results presented in this thesis gave an important 
contribution in the field of nanotechnologies, opening the doors to a possible clinical 
use of these amphiphilic cationic peptides. 
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1 INTRODUCTION 
This PhD project is focused on studying the interactions between small cationic 
amphipathic peptides and different living models (Human 2D and 3-D cell culture and 
Danio rerio embryos). The main purpose of this thesis is to highlight the biological 
mechanisms involved in peptide uptake and distribution, mode of action and whether 
there are any phenotypic changes caused by the peptides. Numerous experimental 
approaches are used; including imaging (wide-field, confocal, light-sheet fluorescent 
microscopy, SEM and TEM), high-throughput screening, in vitro and in vivo toxicity 
assays, RNAi, and nucleic acids transfections. The results obtained in this thesis will be 
helpful in determining the efficiency of peptides as therapeutic tools in a wide range of 
biomedical applications.  
 
In the following sections, an overview of what has been discovered so far regarding the 
origin, classification and modes of action of small peptides, together with exhaustive 
examples of drugs and successful treatments currently used in medicine with peptides as 
therapeutic agents. 
 
 
1.1 Oligopeptides: history, origins and classification  
 
Peptides are molecules composed of short chains of amino acids. If the total sequence 
length does not exceed 50 residues they are normally called oligopeptides which differ 
from larger polypeptides (proteins) for both physicochemical and biological properties. 
Natural oligopeptides are ubiquitously expressed in prokaryotic and eukaryotic species 
and considered essential biochemical regulators involved in almost every vital process. 
Oligopeptides can be divided into several functional classes: the most abundant are 
neuropeptides, hormones, toxins and antimicrobials (see Table 1). 
Interest in these small molecules increases every year as shown by the number of 
publications (>50000) listed in PubMed. Hundreds of oligopeptides have been identified 
and their structure fully characterised. Many online data banks are available; the EROP-
Moscow database 1 is one of the most complete, where almost 15000 oligopeptides are 
   
20 
 
classified according to their structure, function or species identification. Other databases 
are more specific and collect data only from one class of oligopeptides; for example, 
NeuroPep is the most complete database for neuropeptides 2, while CAMPR3, Collection 
of Anti-Microbial Peptides 3 and ADP, The Antimicrobial Peptide Database 4 focus on 
antimicrobial peptides. CancerPPD 5 instead, collects data from verified anticancer 
peptides (ACPs) and anticancer proteins. 
 
In the following sections, some of the most important studied classes of oligopeptides 
will be presented. More attention will be given to the antimicrobial peptides and their 
relevance in anticancer therapies since this crucial aspect provided inspiration for this 
PhD thesis. 
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Table 1. Examples of natural oligopeptides. Legend: HM hormone; NP neuropeptide; TX toxin; AM antimicrobial 
Peptide Type Sequence Function Species Reference 
α -amanitin TX IWGIGCNP Inhibition of RNA polymerase II Amanita Hallen et al., 6 
α-Defensin 
HNP3 
AM 
DCYCRIPACIAGERRYGTCIYQG
RLWAFCC 
Antibiotic, anti-fungi and antiviral activity H. sapiens Hill et al., 7 
Angiotensin 
I 
HM DRVYIHPFHL Regulate volume and mineral balance of body fluids Animalia Basso et al., 8 
β-endorphin NP 
YGGFMTSEKSQTPLVTLFKNAII
KNAYKKGE 
Reduce body stress and maintain homeostasis H. sapiens 
Dalayeun et 
al.,9 
Crotamin TX 
YKQCHKKGGHCFDKEKICLPPSS
DFGKMDCRWRWKCCKKGS 
Analgesic and myotoxic 
C.durissus 
terrificus 
Nicastro et al., 
10 
Gastrin HM WLEEEEEAYGWMDF 
Stimulation of HCl secretion by paretial cells in 
gastric mucosa 
H. sapiens 
Dockray et al., 
11 
Glucagon HM 
HSQGTFPSDYSKYLDSRRAQDF
VQWLMNT 
Promotion hydrolysis of glycogen and lipids; 
increase the blood sugar level 
Animalia Jiang et al., 12 
LL-37 AM 
LLGDFFRKSKEKIGKEFKRIVQRI
KDFLRNLVPRTES 
Antimicrobial activity against several Gram-positive 
and Gram-negative bacteria, spirochaete and yeast 
H. sapiens Dürr et al., 13 
Magainin-I AM GIGKFLHSAGKFGKAFVGEIMKS 
Growth inhibition of numerous of bacteria and fungi 
species and induction of osmotic lysis in protozoa 
X. laevis Zasloff 14 
Melittin AM 
GIGAVLKVLTTGLPALISWIKRK
RQQ 
Strong haemolytic activity 
A. 
mellifera 
Raghuraman 
et al., 15 
Oxytocin NP CYIQNCPLG 
Cause the contraction of the uterus smooth muscles 
and mammary glands 
Mammalia Ross et al., 16 
Substance P NP RPKPQQFFGLM 
Respond to painful or noxious stimuli. Associated 
with inflammatory processes and pain transmission 
Mammalia 
Harrison et al., 
17 
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1.1.2 Neuropeptides 
 
The term “neuropeptides” referrers to small molecules expressed and regulated 
exclusively by neurons that are involved in the neural chemical signalling mediated by 
receptors in the brain 18. The neuronal system is composed of an intricate cellular 
network that, to work efficiently, requires organised communication skills. This can be 
done via special chemical signals control released by neurons. The signalling molecules 
are very heterogeneous, starting from simple gases (such as NO) 19 and finishing with 
neuropeptides which are the largest and most diverse class of molecules that act like 
long range neurotransmitters, autocrine or paracrine regulators or hormones 18. The 
secretion of neuropeptides follows a strictly regulated pathway and the molecules, are 
controlled for release by external stimuli (for example increasing of intracellular Ca2+) 
20. So far, more than 100 genes in mammals (90 in humans) have been reported to 
encode for neuropeptides. These can be further divided in subfamilies, according to 
their precursor structure or function. Neuropeptides, but oligopeptides more in general, 
have a very complex biosynthesis, and they derive from larger inactive polypeptidic 
precursors, which need one or more post-translational processes to become functional. 
In some cases, one precursor can produce many different bioactive peptides, via 
differentiated cleavages in accordance to the tissue localisation. For instance, the 
processing of proopiomelanocortin (POMC) precursor gives a wide array of bioactive 
products in a tissue-specific manner. The encoded protein is expressed in corticotroph 
cells of the anterior pituitary gland, in the arcuate nucleus, in the nucleus tractus 
solitarius of the brainstem (NTS) and in several peripheral tissues. It can be cleaved on 
different sites producing adrenocorticotrophins (ACTH), melanocyte-stimulating 
hormones (MSHs), β-lipotropins and β-endorphins, which all have important roles in 
pain and energy homeostasis (appetite regulation), melanocyte stimulation, immune 
system modulation and sexual behaviour. Mutations in POMC gene have been 
associated with early onset obesity, adrenal insufficiency and red hair pigmentation 21.  
 
Many neuropeptides are hormones, expressed by neurons but then transported through 
the bloodstream to distant targeted tissues or organs. β-endorphin, for example, is 
secreted by arcuate neurons and derives from a post-translational cleavage of POMC 
precursor. It travels via the cerebral spinal fluid in the spinal cord to the peripheral 
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nervous system and to other different body locations. It can also be locally released in 
the brain, in areas such as the amygdala and the hypothalamus. β-endorphin has a wide 
variety of functions; from physiological to behavioural, such as reducing body stress, 
modulating pain perception, regulating food intake, controlling sexual behaviour and 
inducing euphoria or reward effects 22. Alterations in the hormone levels can often be 
associated with mental disorders like depression 23 and schizophrenia 24, or in alcohol 
and drug addiction 25, 26 .  
 
1.1.3 Peptide hormones 
 
Within an organism, cells at distant locations easily communicate with each other 
thanks to small signalling molecules that can travel via the circulatory system. These 
molecules, secreted by endocrine glands, are called hormones and are extremely 
important in the maintenance of the body homeostasis. Many oligopeptides have 
hormone function and are produced by several organs in the body; when produced by 
the neurons of hypothalamus and hypophysis (or pituitary gland) they are called 
neuropeptides (see previous paragraph), otherwise they are just defined as “peptide 
hormones”.  
 
Organs that form part of the digestive system such as the stomach, liver and pancreas 
secrete peptide hormones in order to regulate the digestion and movements of the food 
trough the gastrointestinal tract. Gastrin from the stomach, angiotensin-I from the liver 
or glucagon from the pancreas are just few examples, which will be discussed in the 
following paragraphs.   
 
Gastrin is a peptide hormone produced by gastrin (G) cells: trans-epithelial transducing 
cells of the gastric antral mucosa. It is a stimulant of acid secretions (HCl) through 
paracrine mechanisms and controls the proliferation of gastric epithelial cells 11. For this 
reason, when deregulated, gastrin could increase the risk of development of several 
gastrointestinal cancers, including gastric cancer 27. 
 
Angiotensin-I is secreted by the liver and derived from the precursor angiotensinogen. It 
is cleaved by renin; an enzyme produced by the kidneys, and together with other 
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hormones, is involved in the renin-angiotensin-system (RAS). The main function of 
RAS is to regulate the water and salt retention of the body via vasoconstriction 8. 
Angiotensin-I has no direct biological activity and its only purpose is to work as 
substrate for the angiotensin-converter enzyme (ACE), which cleaves the molecule in 
angiotensin-II. Inappropriate activations of RAS provoke renal and cardiovascular 
diseases such as hypertension, 28 atherosclerosis 29 and abdominal aortic aneurysms 30.  
 
Glucagon is a peptide hormone derived from the precursor proglucagon. It is processed 
and secreted in the pancreatic α-cells of the islets of Langerhans, and once released in 
the bloodstream it stimulates the hepatic glucose release to increase the blood glycaemic 
levels. Together with insulin, glucagon is responsible for the glucose homeostasis in the 
body 12. Elevated levels of this peptide hormone are associated with pancreatic cancer 
31, diabetes mellitus 32 and glucagonoma 33, while reduced levels cause hypoglycaemia 
which is often linked to diabetes 34.  
 
1.1.4 Toxins 
 
An oligopeptide could be defined as a toxin if it has poisonous effects once absorbed by 
an organism due to its interactions with other biomolecules. Toxins are found in some 
species of fungi but more commonly in the venom of several species of insect, snakes, 
scorpions and spiders. 
 
Amongst the fungi, the genus Amanita is definitely the most dangerous, accountable for 
more than 90% of the fatalities caused by mushroom poisoning events in humans, and 
in particular the Death Cap (Amanita phalloides) is responsible for 50% of all cases, 
normally because it is mistaken for an edible mushroom 6. The Amanita mushrooms 
contain three classes of toxins: amatoxins, phallotoxins and virotoxins. The first group 
is composed by at least 9 bicyclic octapeptides (included α-amanitin), which are 
extremely toxic. Amatoxins are resistant to heat therefore remain toxic whether eaten 
raw or cooked. Once ingested and absorbed by the liver, they strongly inhibit RNA 
polymerase II causing a slow but irreversible damage of the hepatocytes 35. Phallotoxins 
instead are bicyclic heptapeptides consisting of at least 7 compounds (including 
phalloidin). Their main mechanism of action is the stabilization of F-actin preventing 
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the depolymerisation and degradation, but due to poor absorption phallotoxins are 
poisonous only when administered parenterally. Phalloidin, due to its great affinity for 
F-actin is widely used in microscopy, conjugated with various fluorophores to 
selectively label actin 36, 37. Finally, Virotoxins are a class of 5 monocyclic 
oligopeptides. They are very similar to phallotoxins in terms of chemical structure, 
toxicity and biological action suggesting that these two classes probably share common 
precursor pathways 38. 
 
Another interesting example of toxin peptide is Crotamine, the major toxic component 
of venom of the South American rattlesnake Crotalus durissus terrificus. It induces hind 
limbs spastic paralysis in rodents, recognizable by a typical stretched posture with the 
limbs completely immobilised 39. For this reasons Crotamine is often considered a 
myotoxin. Pharmacological studies have shown that this toxin interacts with Na+ 
channels and induces membrane depolarisation in skeletal muscles cells by increasing 
the Na+ permeability 10. Low doses of Crotamine have instead an analgesic activity 40. 
Recently, Crotamine regained interest when studies reported that this small molecule 
has a much wider variety of functions including antimicrobial, antifungal and anticancer 
activities. Therefore it is sometimes considered like an antimicrobial peptide or a cell 
penetrating peptide as well 41. 
 
1.1.5 Antimicrobial peptides (AMPs) 
 
Among the several categories of oligonucleotides, the one composed by antimicrobial 
peptides (AMPs) is certainly the most appealing from a therapeutic point of view. These 
small molecules are ubiquitous in nature and can be found in almost every living 
organism 42. AMPs are essential components of the host defence mechanisms against 
infections. They can directly kill microbes via membrane disruption or intracellular 
targets, and indirectly via modulation of the innate immune response 43-45. The first 
AMPs were discovered in the late 80’s thanks to the pioneering works of Boman, 
Zasloff and Lehrer, who independently discovered and purified insect Cecropins, 
amphibian Magainins and mammalian Defensins, respectively 14, 46, 47. Despite being a 
heterogeneous group in terms of length, amino acid composition or secondary structure, 
AMPs share some common fixtures, such as a significant proportion of hydrophobicity, 
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a net charge or a relative small size 48. The classical way to categorise AMPs, is to 
follow their secondary structure, such as α-helical, β-sheet, extended or loop which are 
the commonly divided groups (Table 2) 49.   
 
Table 2. Classification of AMPs according to their secondary structures 49. 
Structure Peptide Tissue Species 
    
α-helical 
Buforins, 
Cecropins, 
Dermcidin 
LL-37 
Magainins 
Melittin 
Stomach 
Haemolymph 
Sweat glands 
Leukocytes 
Skin 
Apitoxin (bee venom) 
Bufo bufo gargarizans 
Hyalophora cecropia 
Homo sapiens 
Homo sapiens 
Xenopous laevis 
Apis mellifera 
β-sheet 
α-defensins 
β-defensins 
θ-defensins 
Lactoferricin B 
Tachyplesin 
Neutrophils, Paneth cells 
Leukocytes, epithelial cells 
Leukocytes 
Mammary glands 
Haemolymph 
Mammalia 
Mammalia 
Macaca mulata 
Bos taurus 
Tachypleus tridentatus 
Extended 
Histatins 
Indolicidin 
Tritrpticin 
Salivary glands 
Leukocytes 
Leukocytes 
Homo sapiens 
Bos taurus 
Sus scrofa 
Loop 
Bactenecins 
Thanatin 
Neutrophils 
 Haemolymph 
Bos taurus 
Podisus maculiventris 
 
1.1.5.1 AMPs’ secondary structures 
 
Most of the AMPs fall in the first two groups (α-helical and β-sheet peptides). α-helical 
AMPs, the most abundant and broadly studied, are generally linear with charged and the 
hydrophobic residues positioned at opposite faces of the helix. To reduce the toxicity 
towards host cells, these peptides often exist in aqueous solution as unstructured 
monomers, folding into α-helical structures only when in contact with bacterial lipid 
membranes 50.  
 
β-sheet peptides are characterized by rigid anti-parallel β-hairpin-like structures due to 
the presence of disulphide bonds between conserved cysteine residues. Different from 
α-helical AMPs, β-sheet peptides are more ordered in aqueous solution and do not 
drastically change conformation upon membrane interaction 51.  
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A smaller proportion of natural AMPs belong to the groups of extended peptides. 
Extended AMPs are so called because they lack regular secondary structures and adopt 
instead more variable conformations. They have an unusually high proportion of amino 
acids such as arginine, tryptophan, proline and/or histidine residues. Many of the 
extended peptides are not membrane active but instead have intracellular targets 48.  
 
Finally, the loop peptides are characterised by a distinct loop structure given by the 
presence of a single (either disulfide, amide or isopeptide) bond 49. 
 
AMPs are usually cationic due to the presence of positively charged residues such us 
lysine or arginine but some of them, like the human Dermcidin 52, are anionic 
(AAMPs). The net positive charge favours the initial electrostatic interactions with the 
negatively charged microbial membranes, while the amphipathicity promotes the 
insertion into the bacterial membranes leading to cell disruption 53. AAMPs mode of 
action is still not completely understood, but some evidence suggests that it is the 
cationic N-terminus that initially gets electrostatically attracted, albeit weakly, to the 
negatively charged bacterial membranes and initiates cell permeabilization 54. 
 
1.1.5.2 The problem of multidrug-resistant bacteria 
 
The rise of multidrug-resistant bacteria called “superbugs” has placed scientists in the 
position of urgently needing to develop alternatives to antibiotics. The so-called 
superbugs are bacterial strains, which are resistant to two or more conventional 
antibiotics. Just a few months ago, the WHO published a list of antibiotic-resistant 
"priority pathogens", considered the greatest menace to human health. At the top of the 
list there are the bacteria that can cause severe and often deadly infections in patients 
from hospitals and nursing homes, including Acinetobacter baumannii, Pseudomonas 
aeruginosa, and several enterobacteria. The list also includes increasingly drug-resistant 
bacteria that cause more common diseases such as Staphylococcus. aureus, 
Helicobacter pylori, Neisseria gonorrhoeae, Streptococcus pneumoniae and 
Haemophilus influenzae. Alternatives to conventional antibiotics have been intensively 
investigated and a few approaches are currently being investigated, in both clinical and 
nonclinical research. Amongst the possible novel drug candidates are antibodies, 
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bacteriophages, vaccines and of course antimicrobial peptides (both natural and 
synthetic) 55. 
 
1.1.5.3 Modes of action of AMPs 
 
The reason why AMPs have rapidly captured attention as substitutes to conventional 
antibiotics is linked to their distinctive mode of action in killing pathogens. As 
previously mentioned, AMPs have the unique ability to recognise and specifically target 
bacterial membranes thanks to electrostatic bonds between the cationic amino acidic 
residues and the negatively charged bacterial surfaces. This is in contrast with 
antibiotics, which usually target specific receptors and proteins. The cytoplasmic 
membranes of both Gram-positive and Gram-negative bacteria are indeed rich in 
phospholipids (phosphatidylglycerol, cardiolipin, and phosphatidylserine), which have 
negatively charged head groups. Additionally, more negative charges are also given by 
teichoic acids (cell wall of Gram-positives) and lipopolysaccharides (LPS) (outer 
membrane of Gram-negatives). In contrast, eukaryotic membranes are full of 
zwitterionic phospholipids asymmetrically distributed. The outer leaflet is 
predominantly composed of the neutral phosphatidylethanolamine, phosphatidylcholine, 
and sphingomyelin phospholipids, whereas the inner leaflet is composed of negatively 
charged phosphatydilserine. Furthermore, mammalian membranes are rich in 
cholesterol, which not only stabilises the phospholipid bilayer, but also drastically 
reduces the affinity for AMPs. These differences contribute to the AMPs’ selectivity for 
bacterial cells 48, 51, 56. 
 
Like the bacterial, fungal membranes are negatively charged due to the presence of 
phosphomannans and other related constituents, such as negatively charged 
phosphatidylinositol, phosphatidylserine and diphosphatidylglycerol, which make them 
susceptible to the AMP action 51. 
 
Many AMPs act rapidly and physically destroy the microbial membrane creating pores 
and causing the collapse of the transmembrane electrochemical gradients, while others, 
after the initial interaction, translocate across the membrane and accumulate into the 
cytoplasm where they target cellular functions such as DNA synthesis, cell wall 
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synthesis, protein synthesis and enzymatic activities 43, 49, 53. The amphipathic nature of 
AMPs is responsible for bacterial membrane permeabilization; with the hydrophobic 
residues interacting with the lipid constituents and the hydrophilic regions positioned in 
the lumen of the pore, or interacting with the phospholipid head groups 53. 
 
1.1.5.4 Mechanistic models of α-helical peptides 
 
In recent years, several mechanistic models have been proposed to explain how, after 
the initial electrostatic contact, AMPs provoke the permeabilization of bacterial 
membranes. These models are called “barrel-stave” “toroidal pore” or “carpet” and are 
generally associated with α-helical peptides, due to their ability to adopt to different 
conformations, depending on the surrounding environment.   
 
Barrel-stave model 
 
In the “barrel-stave model”, the peptide monomers initially aggregate on the bacterial 
surface and then insert perpendicularly into the lipid bilayer like staves in a barrel. The 
result is the formation of peptide-lined transmembrane pore in which the peptide 
hydrophobic residues face the acyl chains of membrane lipids while the hydrophilic 
regions face the pore lumen. As a consequence, cytoplasmic material starts leaking out 
from the pore causing cell death. This mechanism is unique, and it has been 
experimentally supported only for Alamethicin, a neutral α-helical peptide isolated from 
Trichoderma viride fungus 49, 51, 56, 57. 
  
Toroidal pore model 
 
The “toroidal pore model” is more common and can be associated with a great variety 
of peptides. Initially, the peptides accumulate parallel to the membrane surface and start 
accumulating. Once the critical concentration is reached, AMPs perpendicularly insert 
into the membrane and force the membrane phospholipids to bend continuously from 
one leaflet to the other. This process causes the spontaneous formation of pores 
composed by the peptides and membranous phospholipid head groups which are likely 
to cover the cationic peptide charges 43, 56. Recently, a version of this model called 
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“disordered toroidal pore” was proposed. In this model, the phospholipid bilayer is still 
bending inwards, but only one or two peptides are effectively inserted into the pore and 
interact with head groups while the majority of AMPs stay on the pore edges 58. 
Mellitin, Magainins and human Cathelicidin LL-37 are all examples of peptides that 
form toroidal transmembrane pores 13, 59, 60. 
 
Carpet model 
 
Finally, in the “carpet model” AMPs do not insert into the bacterial membrane but 
accumulate and align parallel (like carpets) to the phospholipid bilayer and ultimately 
disrupt the membrane in a detergent-like manner. During this process, the peptides stay 
in contact with the lipid head groups and, at the same time, coat the membranes. This 
specific orientation causes local disturbances in membrane stability, which can lead to 
the formation of fractures, holes and eventually micelles from where cytoplasmic 
component can leak out. The model has been observed in vitro, for example on 
cecropins 61, and mostly applies when high concentrations of peptides are used. It is 
often seen as an extreme consequence of the “toroidal pore model” 48, 49, 56.  
 
Non-membrane lytic peptides 
 
However, not every α-helical peptide is membrane disruptive. Buforins, for example, 
which is a histone-derived AMP isolated from the stomach tissue of the Asian toad Bufo 
bufo gargarizans, translocates across the membrane without inducing significant 
membrane permeabilisation. The presence of a proline in the amino acidic sequence 
induces a kink in the α-helix structure and enhances the cell-penetrating properties of 
the peptide. Since in vitro studies showed that Buforins binds nucleic acids it has been 
hypothesised that the intracellular target of these AMPs might be indeed the DNA 62. 
 
1.1.5.5 Mode of action of β-sheet peptides 
 
The mode of action of β-sheet peptides is still poorly understood. For example, studies 
on the Defensins suggest that this class of AMPs are membrane lytic. However, the 
exact mechanism that leads to pore formation is not yet certain. Recent studies suggest 
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that they could be involved in several other biological functions such as chemo-
attraction and consequently linked to the innate and adaptive immunity 43, 45. 
Defensins, for example, are a family of antimicrobial peptides found in many species of 
invertebrates and vertebrates, humans included. They possess a characteristic β-sheet 
structure and a framework of six disulphide-linked cysteines 51. There are 3 main 
subfamilies, α- β- and θ-. While α- and β- defensins are widely distributed in nature, θ-
defensins, the only known class of cyclic peptides in mammals, have been isolated from 
3 species of primates; rhesus macaques (Macacca mulata), olive baboon (Papio anubis) 
and hamadryas baboon (Papio hamadryas). θ -defensin genes in humans are believed to 
exist as pseudogenes and are not functional 63. Defensins are normally expressed in cells 
and tissues involved in host defence against microbial infections, and are therefore 
considered as part of the innate immune system. The highest concentrations are 
synthesized in the bone marrow and then accumulate in leukocytes granules, i.e. 
neutrophils, but smaller amounts are found also in epithelial cells and in the intestinal 
Paneth cells 64. 
 
Experimental evidence suggests that certain β-sheet AMPs are not only membrane 
active, but possess intracellular targets. Marine Tachyplesin I and bovine Lactoferricin 
B are two such examples 48. Tachyplesin I, derived from the Japanese horseshoe crab 
(Tachypleus tridentatus), is a cationic antimicrobial peptide with a typical cyclic 
antiparallel β-sheet structure. The AMP’s primary target is the bacterial membrane 
which is destroyed by toroidal pores, however, Tachyplesin I can also translocate across 
the membrane and inhibit the intracellular protein synthesis 65. The difference in the 
Tachyplesin I interactions with the bacterial membrane is still poorly understood, 
however it seems that high concentrations of the peptide favour pore formation, while 
low concentrations promote activation of the intracellular  translocation 66.   
 
Lactoferricin B instead, is generated by gastric pepsin cleavage of bovine Lactoferrin 
and has several antimicrobial properties, including intracellular activities. The precise 
mode of action is not fully elucidated, but evidence suggests that this AMP can 
accumulate in the bacterial cytoplasm 67. A recent study reported that one of the 
possible targets is the pyruvate metabolism 68. 
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1.1.5.6 Mode of action of extended and loop peptides 
 
AMPs with extended or loop structures, due to their lack of a classical secondary 
structure, are believed to have mainly intracellular targets. Indolicidin is probably the 
best characterised representative of the extended AMPs family. It was isolated from 
cytoplasmic granules of bovine neutrophils, and is the peptide with the highest content 
of tryptophan. Studies showed that it can bind DNA duplexes causing the inhibition of 
DNA synthesis 69. Thanatin, a loop peptide isolated from the spined soldier bug 
(Podisus maculiventris), does not permeabilise the bacterial membrane, but instead 
blocks the cells’ motility inducing their aggregation 70. 
 
 
1.2. Cell penetrating peptides (CPPs) 
 
Peptides with the ability to transport a variety of cargos into cells and their intracellular 
compartments (such as cytoplasm, mitochondria and even nucleus) are referred to the 
term cell-penetrating peptides (CPPs). They are generally small (less than 40 aa long), 
often cationic and amphipathic. The importance of CPPs resides in their ability to 
transport into the cell cargoes such as proteins, nucleic acids, drugs and other peptides. 
The conjugation with the cargoes normally occurs either via covalent or non-covalent 
bonds 71, 72. The mechanisms of cellular uptake are currently under investigation and the 
pathways involved in this process have not been fully elucidated. However, there are 
two main possibilities; energy-independent direct penetration, or energy-dependent 
endocytosis mediated. The direct translocation across the cellular membrane follows the 
same models described for AMPs (barrel-stave, toroidal pore, carpet), while the energy-
dependent internalisation follows one of the endocytic pathways (macropinocytosis, 
clathrin- or caveolin-mediated endocytosis, and clathrin/caveolin- independent 
endocytosis). The same CPP can use both mechanisms, sometimes simultaneously, and 
the balance between the pathways strongly depends on the peptide sequence and 
extracellular concentration, cargo-conjugation, cell surface composition, temperature 
and exposure time 73, 74. High concentrations of CPPs are often associated with a direct 
translocation, while low concentrations especially when cargo-conjugated preferably 
follow an active endocytic pathway 75, 76. 
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The first isolated CPPs were Tat, corresponding to the basic domain of the viral HIV-1 
Trans-Activator of Transcription (Tat) and Penetratin, corresponding to the third helix 
of the Antennapedia homeodomain, a transcription factor of the fruit fly (Drosophilia 
melanogaster). HIV-1 Tat protein is internalised by cells in vitro and once in the 
nucleus it promotes viral gene expression, while Antennapedia enters nerve cells and 
regulates the neural morphogenesis 77, 78. 
 
CPPs can be classified in three big groups; peptides derived from truncated versions of 
full length proteins, chimeric peptides composed by combined natural sequences of 
different proteins, or synthetic peptides from rationally designed sequences developed 
using predictive programs 79.  
 
Crotamine, the already mentioned toxin is sometimes referred as a CCP because in 
recent studies it has been shown that this peptide has the ability to bind plasmid DNA 
molecules and carry them into actively proliferating cells 80, 81. 
 
 
1.3. Bacterial resistance to AMPs 
 
For years it has been speculated that microbes are unable to produce resistance against 
AMPs because it would involve deep modifications of the bacterial membrane, which in 
terms of genetics and physiological functions would be really difficult to achieve. 
Another common reason is that a host can produce many AMPs and it would be 
virtually impossible for a pathogen to develop resistance against all the AMPs at the 
same time 51. Nevertheless, recent studies have showed that this is not true; host and 
pathogen have continued to co-evolve for thousands of years following mutual 
inhibition and adaption strategies 82. Common defence mechanisms to avoid the 
peptides’ action include, production of proteases and peptidases, alterations in net 
surface charges and membrane composition (lipid and proteins), secretion of specific 
proteins that bind AMPs, and expression of efflux pumps 83.  
 
Bacteria have specific sensors that can perceive AMPs in the environment and enhance 
the resistance mechanisms. For example, Gram-positive Staphylococcus aureus can 
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recognise, the presence of AMPs such as human beta defensin 3. To avoid degradation, 
it changes the net surface charges by activating the D-alanylation of teichoic acids and 
by inclusion of lysylphosphatidylglycerolin in the bacterial membrane. Alternatively, it 
expresses the vraFG AMP efflux pump to export the AMPs outside the cytoplasm and 
away from the membrane 84. Increased expression levels of efflux systems are found 
also in Gram-negative Neisseria strains (N. gonorrhoeae and N. meningitidis) which 
give high resistance not only to AMPs, but also antibiotics 85.  
Gram-negative Salmonella typhimurium instead can remodel the bacterial envelop 
modifying the composition of lipid A (acidic moiety of lipopolysaccharide) via 
palmitoylation, hydroxylation and deacylation 86. The most common method of AMP 
inactivation is mediating proteases and peptidases that can degrade the peptides. Linear 
and α-helical AMPs are the ones more easily targeted. Human Cathelicidin LL-37 for 
example, is cleaved by Salmonella enterica serovar Typhimurium outer-membrane 
protease PgtE or by the V8 and aureolysin proteases from Staphyloccocus aureus 87, 88. 
To circumvent enzymatic degradation, AMPs evolved in more stable structures thanks 
to the addition of disulphide bridges, proline residues in the amino acid sequence, 
amidation of the C-terminal and acetylation of the N-terminal. Normally the capture and 
extrusion of AMPs by bacterial proteins and efflux pumps depend on direct recognition 
of specific peptide sequences or structural motifs. For this reason, many related families 
of AMPs are produced with modifications in their sequences that will not alter the 
antimicrobial functions but can mislead bacterial defence systems. Finally, to maintain 
the affinity for bacterial membranes even when the net anionic surface charge is 
reduced, AMPs have progressively increased their net positive charges 82. 
 
Nevertheless, most of the bacterial resistance against AMPs observed so far was related 
with in vitro experiments, where the conditions experienced by bacteria are, by default, 
very different compared to those in nature. Indeed, in a natural environment, pathogens 
are not continuously exposed, generation after generation, to the same AMP, but instead 
they interact with several peptides that can belong to different hosts and tissues. The 
exposure normally lasts for a limited amount of time and it is generally accompanied by 
other components of the host immunity system given that AMPs can modulate the 
innate immune response. These conditions drastically reduce the selection pressure that 
generally causes the development of resistance 51. 
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1.4 De novo synthetic AMPs; approaches for the design of 
new molecules 
 
The systematic study of natural AMP sequences and secondary structures together with 
their biological functionalities allowed the design of de novo synthetic oligopeptides 
that could be used for targeting drugs-resistant pathogens. The main goal is to improve 
not only the antimicrobial activity, but also the stability and especially the safety against 
the host organism when compared to natural AMPs 89. Indeed, when an AMP is selected 
as a therapeutic agent it should theoretically have great affinity for bacterial cells but, at 
the same time, not show any toxic effects on mammalian cells. In reality, the 
interactions between natural peptides and host membranes can vary for each particular 
AMP, and to a certain extent every single AMP shows some toxicity towards 
mammalian cells. Normally, cytotoxicity is reported as AMP erythrocytes haemolytic 
activity or by decreases in the cells viability (often on fibroblasts) 90. Sometimes it is 
referred to as Therapeutic Index (TI), which is the ratio of the haemolytic activity and 
the minimal inhibitory concentration (MIC) 91. 
 
Several methods are currently used to improve the AMP cells specificity. The 
optimisation of the various physicochemical parameters (net charge, amphipathicity, 
helicity etc..) is definitely the most important, followed by the introduction of D-amino 
acids (which have opposite chirality), fluorinated or unusual amino acids (peptoids such 
as N-substituted glycines). Constraining of the peptide conformations (cyclization of 
linear peptides) and modification of peptides by polymer (PEGylation) gave promising 
results as well 92. 
 
There are many approaches to designing new synthetic AMPs. The easiest method is to 
choose a well-known AMP with proven good antimicrobial activity and use its amino 
acidic sequence as a template. Analogues of the template are then synthesised with just 
single or double amino acidic substitutions 89. A good example of this methodology is 
reveled by Pexiganan, a synthetic analogue of the amphibian AMP Magainin-2. This 
peptide is currently in phase III of clinical trials as topical antimicrobial cream for the 
treatment of mild infections associated with diabetic foot ulcers 93. 
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Other typical methodologies use computational and virtual screenings 89. The 
biophysical modelling studies are centred around understanding of the AMP activity, 
when in contact with the bacterial membranes, and in designing improved variants of 
the same AMPs using molecular dynamics simulations and thermodynamic calculations 
of the peptide-membrane interactions. This type of approach helped in the design of 
Novispirins, a less toxic AMP analogue of the synthetic Ovispirin, an AMP derived 
from the bovine SMAP-29. Both Ovispirin and SMAP-29 have good antimicrobial 
activity, but they are unsuitable for therapeutic use due to their toxicity towards human 
erythrocytes and epithelial cells. Novispirins, on the other hand, showed a consistent 
decrease in toxicity without changing its antimicrobial properties 94.  
 
Finally, in the virtual screening methods, predictive algorithms are used to determine 
the peptide physicochemical properties according to the amino acidic sequence alone. 
Once the properties are defined, structure–activity relationship models (SAR) are used 
to evaluate all the possible biological activities of the peptide 89. 
 
 
1.5 Abilities of AMPs: more than simply antimicrobial 
agents 
 
The importance of AMPs is linked to their broad spectrum of activities against 
pathogens. Many peptides display not only antimicrobial properties against both Gram-
positive and Gram-negative bacteria, but have also antifungal, antiprotozoal antiviral 
and even anticancer effects 53. 
 
1.5.1 Antifungal activity 
 
Histatins, for example, are AMPs found in the saliva of humans and other higher 
primates, they have not only antibacterial properties, but also exhibit strong antifungal 
activity. They are constitutively expressed in the parotid and sublingual salivary glands 
and they have a pivotal role in controlling the infections in the oral cavity. Histatin 5 is, 
amongst the family, the peptide with the strongest effect against Candida albicans. 
  
37 
 
They are small histidine-rich peptides with an extended secondary structure and 
intracellular targets as their main mode of action. It has been shown that histatins can 
translocate across the fungal membrane into the cytoplasm, and target the mitochondria 
causing depletion of intracellular ATP content, which leads to energy loss and 
generation of ROS with consequent arrest of the cell cycle and ultimately death 95. In 
humans, Histatins seem to have also an important role as wound-closure stimulator 
factors 96. A synthetic analogue of Histatin 3 and Histatin 5 called PAC-113 was in the 
second phase of clinical trials as a mouth-wash to treat oral candidiasis in HIV 
seropositive patients (ClinicalTrials.gov Identifier: NCT00659971). 
 
1.5.2 Antiprotozoal activity 
 
Protozoal parasites such as Plasmodium spp Trypanosoma cruzi, Toxoplasma gondii, 
Cryptosporidium or Leishmania spp are responsible for severe diseases in humans 
(malaria, trypanosomiasis, toxoplasmosis, cryptosporidiosis, and leishmaniosis) which 
can be fatal in immunocompromised individuals. Because of their broad spectrum of 
activities, Amphibian AMPs such as Magainin 2 or Dermaseptins have been 
investigated as possible therapeutic agents against protozoa infections. A similar mode 
of action of AMPs towards protozoa has been discovered (membrane permeabilization 
or intracellular targets). Despite being eukaryotic, the cell membrane is characterised by 
the presence of anionic phospholipids and other sterols similar to the bacterial ones 
which make a perfect target for AMPs 97. 
 
1.5.3 Antiviral activity 
 
To date, few studies have been conducted on AMPs to explore their possible antiviral 
properties. Results showed that cationic host peptides can fight viral infections 
representing the first line of defence against viruses before the intervention of the 
adaptive immune response. It is still not clear if the peptide secondary structure is 
somehow related with the possession of antiviral activity since both classes of peptide 
α- helical and β- sheet have been found able to target viruses. The modes of action are 
complex and extremely variable and may include blocking of viral entry by the 
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interaction with receptors or heparan sulftate, inhibition of the virus cell-to-cell spread, 
and direct interactions with the viral envelope. Some peptides (α- and β-defensins) can 
induce cytokines and chemokines production and have chemotactic activity for T cells, 
monocytes and immature dendritic cells 53. 
Defensins and Cathelicidins are the most studied classes of AMPs for their antiviral 
activity. Human α- and β-defensins and primates θ-defensins are able to protect against 
several viral infections, included herpes simplex virus (HSV), influenza A virus (IAV), 
human papillomavirus (HPV) and human adenovirus (HAdV) 98-101. LL-37 instead, the 
only human member of the Cathelicidins family, has showed in vitro a direct antiviral 
activity against the Respiratory Syncytial virus (RSV), while giving protection against 
infection in mice and in humans 102, 103. Due to the importance of Defensins and 
Cathelidicins in fighting viral infections, few synthetic analogues have been engineered 
with the aim of enhancing the peptide antiviral activity 104. 
 
1.5.4 Anticancer activity 
 
AMPs with anticancer properties are referred to as anticancer peptides (ACPs) and have 
the potential of being novel entities 105. The majority of current anticancer drugs are 
based on alkylating agents and antimetabolites, which have poor selectivity against 
normal mammalian cells. They interact with intracellular targets, penetrating through 
membranes inside cells, but once they reach the cytosol many of these agents are 
immediately deactivated by intrinsic resistance mechanisms that transport the drugs out 
of the cell before they can effectively interact with their intracellular targets 106. 
Thus, the development of novel drugs and delivery systems with different modes of 
action and better cancer cell selectivity is crucial to battle drug resistance and reduce 
normal cell cytotoxicity. In this context, ACPs could be resourceful candidates and their 
possible usage as peptide therapeutics has been extensively explored over the years 106.  
Peptides that display anticancer properties are usually divided into two categories; 
peptides that have potent effects against bacteria and cancer cells but are harmless 
towards normal mammalian cells (e.g. Cecropins, Magainins) or peptides which exhibit 
indiscriminate toxicity towards bacteria, cancer and normal cells (e.g. Mellitin, 
Defensins and human LL-37) 107.  
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The specificity for cancer cells that some AMPs display is currently under investigation. 
Despite controversial theories, the general consensus in the field is that the differences 
in membrane composition between cancer and non-cancer cells are the main reason for 
the peptide selectivity. Cancerous cell plasma membrane electrostatic charge differs 
from normal cells due to the presence of anionic molecules such as phospholipid 
phosphatidylserine (PS), O-glycosylated mucins, sialylated gangliosides and heparin 
sulfate. These anionic molecules confer a net negative charge compared to the 
mammalian cell membranes normally rich in neutral zwitterionic phospholipids and 
sterols. Moreover, it has been shown that cancer cell membranes often have a reduced 
amount of cholesterol, which would normally protect mammalian cells from the 
insertion of lytic peptides. Therefore, altered levels of cholesterol increase the 
membrane fluidity, which may facilitate the binding of cationic peptides with their 
destabilising action. Furthermore, tumour cells, due to their extreme motility and 
invasive properties have on their membranes more filopodia, which give the malignant 
cells a higher total surface area available for the peptides to interact with 105, 106, 108. 
The specific mode of action against cancer cells is not completely understood, but some 
evidence suggests that it follows the same rules applied for bacteria, where peptides can 
kill tumour cells through membrane permeabilization or by targeting intracellular 
pathways. Mitochondria are common intracellular targets; peptides permeabilise their 
membrane inducing cytochrome-c release. Membranolytic peptides normally kill cells 
by necrosis while peptides targeting mitochondria kill cells inducing apoptosis 107. 
 
Nevertheless, peptides are not only cell death regulators, but can also interfere with 
several cancer-related signal transduction pathways, especially those involved in cell 
adhesion, receptor interaction and metastasis; peptides have been found to target 
hormone receptors, cell-adhesion proteins, protein kinases and their substrates 109. 
Peptides can even induce an immunomodulatory effect via stimulation of natural killer 
cells (NK cells), peripheral blood lymphocytes and interferon (IFN) 110. 
 
Among the natural AMPs with anticancer properties, Cecropins A-B and Magainin II 
are the most studied due to their good selectivity for cancer cells and their ability to kill 
them at concentrations not harmful for normal mammalian cells 111. For example, 
Cecropin A and B both inhibit the cell growth of four bladder cancer cell lines (RT4, 
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647V, J82 and 486P) via membrane permeabilization and lysis, while sparing normal 
murine and human fibroblasts 112. 
Magainin II activity was tested as well on bladder cancer cell lines (RT4, 647V, and 
486P) and on murine and human fibroblasts. Results clearly showed that the amphibian 
peptide had a cytotoxic and antiproliferative effect by pore formation in the bladder 
cancer cell lines, but it did not have this effect on the normal murine and human 
fibroblasts 113. 
Recently, Magainin II modified polydiacetylene (PDA) micelles were synthesised to 
enhance the anticancer activity of the peptide. The micelles were tested on A549 lung 
carcinoma, KB epidermal carcinoma and MCF-7 breast adenocarcinoma cells, showing 
a consistent decrease in cell viability. Images showed a cytoplasmic localisation of the 
micelles, and studies on the uptake ratios revealed that for KB cells the particle 
internalisation is temperature dependent, suggesting that an active process is involved 
(i.e. endocytosis). Moreover, the micelles effectively suppressed tumour growth in a 
murine xenograft model 114. 
 
Several hybrid or synthetic peptides have been designed trying to improve their 
selectivity and activity towards cancer cells. One of the main goals is certainly to reduce 
adverse side effects and resistance mechanisms which are a constant in normal 
chemotherapeutic drugs. Unfortunately, despite the efforts to date, very few ACPs are in 
clinical trials as possible anticancer drugs. This partial lack of success is due to many 
challenges related with the development of peptides as pharmaceutical drugs; big 
obstacles are the highly elevated production costs which come with the synthesis, 
followed by sensitivity to proteolytic degradation, a poor oral bioavailability, and 
reduced penetration through the intestinal membrane. To reduce the synthesis costs, the 
newly designed peptides tend to be shorter than the natural ones, and to increase 
resistance to protease activity natural amino acid can be substituted with unnatural ones, 
while more cell specificity and penetration could be achieved using cell penetrating 
peptides (CPPs) conjugated with drugs, antibodies or anticancer peptides 105, 108, 115. 
 
The synthetic A9K and G(IIKK)3I-NH2, two of the peptides described in this PhD 
project, were tested against several cancer and non-cancer cell lines to prove their 
selectivity towards one specific type of cells. Both peptides inhibited the growth of 
human HeLa and promyelocytic leukaemia HL60 cells. A9K remained benign to 
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monkey kidney Cos 7 cells, mouse fibroblast NIH3T3 and to human erythrocytes. 
G(IIKK)3I-NH2 instead did not induce toxicity in human dermal primary fibroblasts 
HDFa, mouse embryonic fibroblasts NIH/3T3 and in human erythrocytes 116, 117. 
Moreover, G(IIKK)3I-NH2 did not induce non-specific immunogenic responses in 
lymphocytes but showed noticeable inhibition of tumoral growth in nude mice 
following inoculation of HeLa cells 118.  
 
 
1.7 Current strategies and future developments 
 
In the last section of this introductive chapter, some examples of cationic amphipathic 
peptides that are going through clinical development will be presented, with important 
differentiations between antimicrobial or anticancer activities. AMPs-drugs based are 
usually topical creams or gels which can be locally applied to fight bacterial (or fungal) 
infections. Some exceptions include the already mentioned PAC-113, originally 
designed as a mouthwash for oral candidiasis in immune depressed patients. The 
product is currently available in Taiwan and will be soon released in South China as 
well under the name of P113+; an over-the-counter ("OTC") personal care product in 
the format of mouth rinse solution, oral mouth spray, feminine cleansing wash, feminine 
soothing spray and anti-bacterial hand cream. 
 
Surotomycin instead is a novel cyclic lipopeptide analogue of daptomycin (derived by 
microbial fermentation of S. roseosporus) designed to fight Clostridium difficile 
infections. It is orally administered and thanks to its stability, high aqueous solubility 
and low oral bioavailability, it accumulates in the gastrointestinal tract where it can 
exceed the minimum inhibitory concentration required for killing C. difficile 119. 
 
ACPs, as previously mentioned, are poorly adsorbed if orally administered, therefore all 
the peptides currently in clinical trials are formulated to be intravenously injected. 
Synthetic ACPs designed to inhibit the tumoral growth are often used as therapeutic 
cancer vaccines which are able to stimulate the immunity system to recognise and attack 
cancer cells.   
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ITK-1, for example, is a synthetic personalised peptide vaccine consisting of 14 
different tumour-associated peptide antigens derived from conserved human proteins 
involved in cellular proliferation and frequently overexpressed in cancer cells. Prior to 
vaccination, the cellular and specific humoral immunity responses in human leukocytes 
antigen (HLA)-A24–were assessed and the peptides showing the strongest reactions 
were then selected as personalised vaccines for patients with recurrent or progressive 
glioblastoma multiforme (GBM) and prostate cancer. ITK-1 is currently on phase III 
after successfully passed the previously clinical trials 120.  
 
To improve cancer cell selectivity and to simultaneously reduce adverse effects on 
normal host cells, the development of a drug delivery system using cell penetrating 
peptides (CPPs) or more specifically tumour targeting peptides (TPPs) as cargo carriers 
has been recently proposed 121. TPPs are a class of penetrating peptides that interact 
with receptors which are overexpressed on cancer cells. Studies on surface receptor 
differences between cancer cells and normal cells allow identification of those 
molecules which are overexpressed in cancer cells, thus making them perfect targets for 
TPPs 122. 
 
For example, Angiopep-2 (An2) is a 19-amino acid peptide able to cross the blood–
brain barrier (BBB) by receptor-mediated transcytosis. It binds to the low-density 
lipoprotein-like receptor-1 (LRP-1), which is overexpressed in several brain cancers. 
An2 has been recently conjugated with the antineoplastic drug paclitaxel or with the 
Anti-HER2 monoclonal antibody (mAb) to treat several brain tumours, including brain 
metastasis caused by breast cancer HER2+. The two drugs are respectively called 
ANG1005 and ANG4043; ANG1005 successfully completed phase II and soon will 
start phase III, while ANG4043 is in preclinical trials 123, 124. 
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1.8 Research motivation 
 
The purpose of this PhD project is to explore the cancer cell selectivity of three cationic 
amphiphilic peptides; A6K, A9K and G(IIKK)3I-NH2. The positive preliminary results 
achieved against both bacteria and cancer cells inspired a more in-depth investigation in 
order to better elucidate the cancer cell toxic effects previously observed. The peptides’ 
binding abilities for different negative nucleic acids’ molecules have been investigated 
as well. Both traditional monolayer cultures and innovative 3D models have been 
tested. The results obtained could be crucial in identifying if any of these molecules 
could be used as possible carriers for drug delivery specifically targeting cancerous 
cells. Moreover, an in vivo model (zebrafish, Danio rerio) has been used to observe the 
behaviour of the cationic small peptides in a more complex biological environment. 
Extensive toxicity assays have been performed and the health of animal embryos 
monitored. Finally, a complete evaluation of possible endocytic pathways used for the 
peptides internalisation has been carried out using several approaches including a high-
content genome screen.  
 
With the results obtained we hope to unravel aspects of the biological activities 
involved in the cationic peptides and eukaryotic cells which at the moment are still 
unclear and create a foundation for a step forward in anti-cancer treatments. 
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1.9 Thesis outline 
 
Chapter 1 gives a general introduction on natural and synthetic oligopeptides, 
emphasising on current medical and therapeutic applications and possible future 
developments of antimicrobial peptides in fields not related with microbiology. 
Chapter 2 is centred on describing the methodology adopted for the experimental part 
of this PhD project. 
Chapter 3 is focused on the synthetic β-sheet A6K and A9K peptides. Results of the 
experiments conducted on these two peptides are listed and fully explained. 
Chapter 4 is based on the synthetic α-helical peptide G(IIKK)3I-NH2. Detailed 
descriptions are given of the most significant and successfully performed experiments. 
Chapter 5 explains the data collect using A9K and FITC-G3(IIKK)I-NH2 peptides on 
the Danio rerio (zebrafish). A brief introduction on the importance of zebrafish as 
animal model is given as well, to facilitate the reader understanding the results. 
Chapter 6 treats the topic of high-throughput genome screens. Data collect from RNAi 
screens of cells exposed FITC-A9K and FITC-G(IIKK)3I-NH2 peptides are showed and 
explained in detail. 
Chapter 7 is the conclusive chapter of this manuscript. All the results obtained with 
A6K, A9K and G(IIKK)3I-NH2 are brought together. Ideas on future work and 
developmental strategies are also discussed.  
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2 MATERIALS AND METHODS 
In the following sections, the procedures adopted in the experimental part will be 
discussed; unless stated otherwise, the plates used in all the described experiments were 
Grenier Bio One 96 well plates (Cat n° 655088) or Perkin Elmer 384 well plates (Cat n° 
6007460). 
 
 
2.1 Peptides synthesis and stock solution preparation 
 
The β-sheet A6K and A9K peptides and the α-helical G(IIKK)3I-NH2 were synthesized 
using standard Fmoc solid phase synthesis, from natural L-amino acids, on a 
commercial CEM Liberty microwave peptide synthesizer. In order to obtain an 
amidated C-terminal, a Rink-amide MBHA resin (0.83 mM/g) was used at the 
beginning. After deprotection of the Rink-amide resin, Fmoc-Lys (Boc)-OH was 
introduced and coupled with resin, followed by Fmoc deprotection and coupling with 
Fmoc-Ala-OH. This cycle was repeated several times, until the peptides were generated. 
After Fmoc deprotection of the N-terminal residue, acetic anhydride was used to cap, 
prior to cleavage from the resin. The whole procedure lasted 3 hrs and was executed at 
room temperature. These modifications are important to enhance the resistance of the 
peptides from the peptidases action. G(IIKK)3I-NH2 peptide instead was capped at the 
N-terminus with a glycine (G), in this way, the chances of having α-helical hydrogen 
bonding are increased 125. The peptides were centrifuged at 10000 rpm for 20 minutes at 
4 °C and followed by cold ether precipitation of the supernatant, repeated at least 8 
times to get a high purity level. After purification, the solid products were dissolved in 
Milli-Q water, freeze-dried in a lyophilizer for 2 days and subjected to reverse-phase 
high performance liquid chromatography (RP-HPLC) and MALDI-TOF mass 
spectrometry analyses which revealed purity over 98% 117, 126. 
The synthesis of the fluorescent versions of A9K, and G(IIKK)3I-NH2 peptides were 
also performed using the standard Fmoc based solid phase protocol. To reduce 
degradation during the last cleavage step of the N-terminals FITC labelling, a 6-
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aminohexanoic acid (Ahx) group was introduced between the last amino acid (A or G) 
and the fluorescein motif 127. 
 
2.1.1 Solution preparation  
 
The synthesized peptides have relatively high water solubility and were dissolved in 
pure water (25 °C) and at pH 6.0.  Stock solutions were made at various concentrations, 
depending on the experiment, between 1 mM and 5 mM.  
For A6K and A9K the critical aggregation concentrations (CACs) determined to be 
about 0.2 mM and 0.02 mM respectively. Stock solutions of A6K, A9K and FITC-A9K 
were stored at 4 °C to aid the self-assembly process while G(IIKK) 3I-NH2 and FITC- 
G(IIKK) 3I-NH2 stocks were kept at -20 °C prior to use. 
 
 
2.2 Cell lines and culture methods 
 
A431, a human epithelial cancer cell line (obtained from Prof. Elizabeth Smythe, 
Professor of Molecular Cell Biology at the Department of Biomedical Science, 
University of Sheffield), HCT-116, another human epithelial cancer line and (obtained 
from Dr. Spencer Collis CRUK Senior Cancer Research Fellow at Department of 
Oncology & Metabolism, University of Sheffield Medical School), and HDFs human 
primary dermal fibroblasts (a kind gift of Dr. Zoe Hewitt, Project Manager UKRMP 
Pluripotent Stem Cell Platform, Centre for Stem Cell Biology, University of Sheffield) 
were the cells used to perform all the experiments described in this thesis. A431 and 
HCT-116 were selected as cancer models and the primary human dermal fibroblasts as 
control lines. Since both the cancer cell lines have epithelial origins the results obtained 
with them could be comparable.  
 
The A431 tumour cell line was established from an epidermoid squamous carcinoma 
extracted from a 85 years-old patient vulva 128. A431 cells are normally hypertriploids, 
they overexpress the epidermal growth factor (EGFR) due to an amplification of EGFR 
gene on chromosome 7, and they are mutant for p53 gene 129. 
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HCT-116 epithelial cancer cells derive from a colorectal carcinoma extracted from an 
adult male. This line has a mutation in codon 13 of K-Ras proto-oncogene on 
chromosome 12 and is positive for transforming growth factor β1 (TGF-β1) and β2 
(TGF-β2) 130-132.  
 
The HDFs are primary culture derived from the dermis of normal human neonatal 
foreskin.  
 
All the cell lines were cultured in DMEM (Dulbecco’s Modified Eagle Medium, 
GIBCO®, Thermo Fisher Technologies, Cat. No. 11965092) with high glucose (4500 
mg/ml), L-glutamine and without Sodium Pyruvate and HEPES, supplemented with 
10% heat-inactivated foetal bovine serum, FBS (Sigma-Aldrich®, Cat. No. F9665), 100 
U/ml penicillin and 100 µg/ml streptomycin (GIBCO®, Thermo Fisher Scientific, Cat. 
No. 15140122). 
  
2.2.1 Cell lines sub-culturing  
 
All cultures were carried out in complete sterile conditions, under a laminar flow 
cabinet (Esco Airstream® Class II Biological Safety Cabinet). Cell lines were kept in 
incubator (MCO-20AIC, Sanyo), with standard parameters (37 °C; 5% CO2; 95% air 
humidity) and normally sub-cultured in 75 cm2 flasks (treated flask, blue filtered cap, 
Nunc™, Cat. No. 156499) every 2-3 days or as soon as they reached the 70-80% of 
confluence. 
 
For passaging, the old complete culture medium was discarded, followed by washing 
with 10 ml of PBS (Phosphate Buffer Saline, 1x pH 7.2, without CaCl2 and MgCl2 ions, 
GIBCO®, Thermo Fisher Scientific, Cat. No. 10010023), pre-warmed at 37 °C. The 
PBS step is important, to remove Ca2+ ions involved in cellular adhesion. Subsequently 
1-2 ml of pre-warmed (37 °C) Trypsin-EDTA (0.05% GIBCO®, Thermo Fisher 
Scientific, Cat. No. 25300104) were added for the necessary time to allow the 
detachment of the cells from the flask bottom. 
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The cells were counted using an automated cell counter (Countess® II Automated Cell 
Counter, Life Technologies, Thermo Fisher Scientific); 10 μl of cells sample were 
mixed with 10 μl of 0.4% Trypan Blue (Invitrogen™, Thermo Fisher Scientific) and 
then pipetted into a Countess® Cell Counting Chamber Slide (Invitrogen™, Thermo 
Fisher Scientific, Cat. No. C10313). Cell number per ml was then calculated. Otherwise 
without counting and depending on the cell type, ratios between 1:3 and 1:6 were 
directly added in a new flask, together with 10 ml of complete culture medium. 
 
2.2.2 Freezing and thawing procedures 
 
To ensure that all the cells used in the experiments were originated from the same 
starting population, a frozen cell bank has been created from an early passage.  
 
For cryopreservation, cells at 70% of confluence were harvested and divided in aliquots 
to have at least 1x106 cells suspension in 1 ml of cryopreservation medium per cryovial 
(Starlab, Cat. No. E3110-6122). The freezing medium is composed of 90% of Foetal 
Bovine Serum, FBS and 10% of sterile DMSO (Dimethyl sulfoxide, CAS number: 67-
68-5, Thermo Fisher Scientific). The cryovials were then placed in the Mr. Frosty™ 
Freezing Container (Thermo Fisher Scientific), previously filled with isopropanol (CAS 
number: 67-63-0, Acros Organics), or in a CoolCell® LXCell Freezing Container 
(BioCision) and transferred to the -80 °C freezer overnight. The freezing containers are 
designed to have a control rate temperature of -1 C°/minute to allow gradual freezing. 
The following day, cryovials were quickly transferred to a liquid nitrogen tank for long-
term storage.  
 
To thaw the cells from the liquid nitrogen dewar, the cryovial was warmed 
approximately one minute in the 37 °C bath, until nearly thawed, then wiped with 70% 
ethanol to sterilise the outside surface and placed into the laminar flow cabinet. 
Subsequently, the whole cryovial content (1x106 cells suspension in 1 ml) was gently 
transferred in a 15 ml tube (BD Falcon™, Cat. No. 352096), previously filled with 9 ml 
of pre-warmed complete culture medium. The 15 ml Falcon was centrifuged at 200 x g 
for 5 minutes, then the supernatant removed, and 10 ml of complete culture medium 
added. Finally, the cell suspension was transferred into a T-25 flask (treated flask, blue 
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vent/close cap, Nunc™, Cat. No. 156499) and placed in the incubator. To ensure that 
any traces of DMSO were fully removed, the following day the complete culture 
medium was changed again. Afterwards cells could be split as usual after 2-3 days. 
 
 
2.3 Agarose gel electrophoresis 
 
The ability of A6K and A9K peptides to specifically bind DNA or RNA molecules was 
evaluated using the agarose gel electrophoresis technique. With this assay different 
sized nucleic acids and complexes of peptides and single stranded antisense DNA 
oligonucleotides (ODNs), labelled with 5’-FAM (carboxyfluorescein-5-succimidyl 
ester) (Eurogentec Ltd, Cat. No. MD-FL001-05004) were separated. 
 
2.3.1 Peptide/ODN complex formation 
 
The complexes were made at different cationic/anionic charge ratios (5/1; 3/1; 2/1; 1/1 
and 0.5/1). Briefly, ODNs solutions were prepared in UHQ water and diluted at 
appropriate concentrations in order to always have, after mixing with the peptides, a 
constant ODNs concentration of 0.1 µg/μl. Peptide solutions were instead diluted to the 
desired concentrations to achieve different cationic/anionic charge ratios which were 
based on the cationic charge on the lysine side chains and the anionic charges on the 
phosphate group of each nucleotide of the ODN.   
Each nucleotide has a slightly different molecular weight (A = 313.21, T = 304.2, C = 
289.18, G = 329.21) but for simplicity the value of 308 g/mol of anionic charges has 
been used as an average. The molecular weight of A6K molecule is 613.7 g/mol, so it 
means that roughly 1 mol of peptide corresponds to 2 mol of ODNs; the molecular 
weight of A9K is 826.89 g/mol, in this case 1 mol of peptide corresponds to 2.7 mol of 
ODNs. The amount of DNA has been fixed to be 1 µg per well (10 μl of a 0.1 µg/μl 
concentrated solution) and different calculations have been made to achieve different 
ratios (5/1; 3/1; 2/1; 1/1 and 0.5/1 between peptides and ODNs). For example, to 
achieve a charge ratio of 1/1, a same volume (10 µl) of A6K peptide with a 
concentration of 0.2 µg/μl (or 0.27 µg/μl in the case of A9K peptide) was mixed with 
the ODN solution. Once mixed together, peptides and DNA were left to equilibrate and 
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complex for at least 30 min at room temperature before use. Samples with only peptide 
or only DNA were included in the experimental set as controls. 
A peptide will bind the DNA through the charge interaction between its positive charges 
and the nucleic acids’ negative ones to achieve the neutralization complex formation. 
When an electrical field is applied if the net charge of the complexes is almost zero the 
complex will be observed inside the agarose well. Whilst the complexes that were not 
fully neutralized will instead migrate a certain length through the agarose gel. 
Therefore, different charge ratios of peptides-DNA complexes would result in different 
rates of DNA migration. 
 
2.3.2 Gel preparation 
 
The 1% w/v agarose gel (Agarose high resolution HS, BDH Laboratory Supplies, Cat. 
No. 43712 3Y) was made in 1x Tris-acetate-EDTA (TAE) buffer which was composed 
by 40 mM Tris-acetate and 1 mM EDTA (CAS number: 6381-92-6, Sigma-Aldrich®). 
Tris-acetate solution was prepared with Tris base (CAS number: 77-86-1, Thermo 
Fisher Scientific), glacial acetic acid (CAS number: 64-19-7, Thermo Fisher Scientific) 
and UHQ water. The TAE buffer pH was adjusted to about 8.0, as otherwise the EDTA 
powder wouldn’t dissolve completely in the water. To melt the agarose/buffer mixture, 
the solution was heated on a hot plate, until agarose was completely dissolved. 
Subsequently 5 μl of ethidium bromide (EtBr, CAS number: 1239-45-8, Sigma-
Aldrich®) at a concentration of 10 µg/µl was added to have a final concentration of 0.5 
µg/ml, and then the solution was let cooled down for 5 minutes. Ethidium bromide was 
added to the agarose gel to bind the nucleic acids and visualise the retarded complexes. 
After the gel tray was placed into the casting apparatus (Mini Plus Submarine Gel, 
Thermo Fisher Scientific), a comb was inserted at a suitable position to create wells and 
the molten agarose was poured into the gel mold. The gel was left at room temperature 
for 30 minutes until it was completely solidified. Then the comb was removed, and the 
casting apparatus was filled with 1x TAE solution until the gel was fully covered. 
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2.3.3 Gel running 
 
A gel loading buffer (Gel Loading Buffer II from the T7 MEGAscript kit, Ambion, Cat. 
No. AM1334) 6 times the starting volume was added to each sample. Then, the samples 
were carefully loaded into the wells previously created with the comb and the 
electrophoresis was run at 100 V for 30 minutes, Afterwards the gel was removed from 
the casting apparatus and visualized under a UV transilluminator. Safety goggles, 
gloves and lab coat were worn to protect the skin from UV light. 
 
 
2.4 DNA/RNA transfection 
 
DNA and RNA transfection experiments have been conducted on A431, HCT-116 and 
HDFs cell lines. Different conditions were tested to find the most suitable. For DNA 
transfection experiments, FAM-labelled oligonucleotides (FAM-ODNs) were used, 
while for RNA transfection experiments, a commercial double stranded siRNA, the red 
fluorescent siGLO (Red Transfection Indicator, Dharmacon, Cat. No. D-001630-02-05) 
was used. 
 
A wide range of complexes peptide/nucleic acids at different cationic/anionic charge 
ratios were tested (0.1/1; 0.25/1; 0.5/1; 1/1; 2/1 and 3/1). Transfection experiments 
using the same conditions have been performed as well with FITC-A9K, G(IIKK)3I-
NH2 and its fluorescent version, FITC-G(IIKK)3I-NH2.  
 
Cells were seeded initially in a 96 wells plate at a density of 2-5x103 cells per well, 
depending on the cell type, in 100 µl of complete culture medium (DMEM, 10% FBS 
and 1% Penicillin and Streptomycin (P/S)) and incubated overnight. The following day 
media was removed and replaced with 90 µl of fresh one.  
 
In the DNA transfection experiments, the amount of ODNs per well was kept fixed at 
0.05 µg, while for siRNA transfection experiments, the siGLO concentration was used 
at 75 nM while for knock down, in the range of 30-50 nM 133. The procedure to make 
peptides/ODNs or peptides/siRNA complexes was the same used for the agarose gel 
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electrophoresis assay and already described in the corresponding sections. The 
molecular weight of G(IIKK)3I-NH2 is 1635.6 therefore 1 mol of peptide should 
correspond to 5.3 mol of ODNs, but since the peptide has 6 positive lysines so to make 
1/1 cationic/anionic charge ratio, it has to be further diluted by 6 and 1 mol of peptide 
corresponds effectively to 0.88 mol of ODNs. 
After 30 minutes incubation at room temperature 10 µl of each peptides/nucleic acid 
mixed solution were added to the wells. FAM-ODNs, siGLO or peptides alone were 
included as negative controls, while the commercial Oligofectamine™ (Invitrogen™, 
Life Technologies, Cat. No. 12252011) or DharmaFECT 1 (DF1) (Dharmacon, Cat. No. 
T-2001-02) transfection reagents have been used as positive controls to transfect ODNs 
and siRNA, respectively. Both Oligofectamine™ and DharmaFECT1 were diluted 
following the suppliers’ instructions and mixed with the appropriate amount of ODNs 
or siRNA. Complexes of Oligofectamine™ and FAM-ODNs were left in incubation for 
15-20 minutes while complexes DharmaFECT1 and siGLO were incubated for 30 
minutes, then added to the correspondent wells and incubated overnight at 37 °C. 
According to the manufacturers protocols, DMEM only (without serum and antibiotics) 
was used in the case of ODNs and Oligofectamine™, while siRNA and DF1 complexes 
were dissolved in medium complemented with 10% FBS but without P/S. 
The following day, cells were washed once with pre-warmed PBS and then fixed in 4% 
paraformaldehyde fixative solution (37% Formaldehyde solution, CAS number: 50-00-
0, Sigma-Aldrich®, diluted in PBS) for 15 minutes. Hoechst 33342 (Thermo Fisher 
Scientific, Cat. No. 62249) was used and diluted in the fixative in a final working 
concentration of 2 µg/ml to stain nuclei. Cells were incubated and protected from light 
to avoid photo bleaching. Finally, the plates were washed twice with PBS to remove 
any aldehydes residues or excessive Hoechst 333342 stain and filled with at least 100 µl 
of PBS. A fluorescent automated wide field microscope (ImageXpress® Micro System) 
and MetaXpress® Software 5.3.01 (Molecular Devices) were used for the acquisition 
and segmentation analyses. 
FITC-A9K and FITC-G(IIKK)3I-NH2 transfection efficiencies were tested out only 
using the red fluorescent siGLO, because FITC and FAM have the same max 
excitation-emission wavelengths (490-525 nm). The two are effectively both derivatives 
of the same organic fluorescent compound, the fluorescein. 
 
  
53 
 
2.4.1 Cancer cells targeting experiment 
 
HCT-116 and HDFs cells have been co-cultured together and transfected with 50 nM of 
siGLO red fluorescent siRNA, using DF1 or G(IIKK)3I-NH2 at different ratios (0.5/1, 
2/1 and 3/1) to determine if the peptide would preferably transfect the cancer cells 
instead of the fibroblasts. Briefly, 5x103 HCT-116 and 2x104 HDFs cells were seeded on 
a 96 wells plate in 90 µl of complete culture medium. Next day, in each of the positive 
control wells (DF1) the complete medium was removed and substituted with 75 µl of 
DMEM complemented with 10% FBS but without P/S. Complexes with siGLO and 
DF1 were made following the supplier’s instructions (0.3 µl of DF1 mixed with 24.75 
µl of DMEM and 0.25 µl of red siGLO 20 µM) and incubated for 30 minutes at room 
temperature before being added to the cells. Peptide/siRNA complexes were made as 
previously described in the agarose gel electrophoresis section. After 30 minutes of 
incubation, 10 µl of complex mixture of different charge ratios were added to the 
correspondent wells. Control wells with only siRNA addition were prepared as well. 
Next day the plate was fixed and stained following the standard fixation procedure 
using 4% paraformaldehyde and Hoechst 33342 (2 µg/ml) solution and the images were 
taken with the IN Cell Analyzer 2200 (GE Healthcare) microscope in bright field mode. 
 
2.4.2 Confocal microscope 
 
To determine the subcellular localisation of the peptides-DNA/RNA complexes, a 
confocal microscope (Nikon A1+) was used and the data were analysed with NIS 
Element software. Briefly, cells were seeded in 1 ml of complete culture medium in a 
glass bottom dish (µ-Dish 35 mm, high, Ibidi, Cat. No. 81156). The quantity of FAM-
ODNs (0.3 µg) and the number of cells (25x103) seeded were adjusted according to the 
different growth surface areas. The amount of siGLO was kept constant to 75 nM. This 
experiment has been performed only with A9K peptide on A431 cancer cells. 
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2.4.3 3D spheroids 
 
3D cultures are becoming extremely useful in cancer research, especially for in vitro 
drug screenings, where the conventional 2D cellular monolayers simply can’t mimic the 
complex organisation and heterogeneity of solid tumours found in patients 134, 135. 
We therefore decide to grow spheroids first with A431 and subsequently with HCT-116 
cancer cells and test the transfection efficiency of both A9K and G(IIKK)3I-NH2 
peptides. Briefly, cells were seeded in ultra-low attachment 96 well plates (round clear, 
Corning, Cat. No. 3474) at the density of 1x104. Spheroids were allowed to grow for 48 
hrs and then transfected with 75 nM of red fluorescent siGLO using the commercial 
reagent DharmaFECT1 (DF1) or different charge ratios of A9K and G(IIKK)3I-NH2 
peptides (2/1 and 5/1). Complexes with the fluorescent siRNA and DF1 or peptides 
were made following the detailed procedure described previously in this chapter. Next 
day, spheroids were carefully fixed and stain in 4% paraformaldehyde solution and 
Hoechst 33342 (2 µg/ml final concentration). Images were acquired using the 
fluorescent automated wide field microscope (ImageXpress® Micro System) or a light 
sheet fluorescent microscope (Zeiss Lightsheet Z.1) and analysed with analysed ZEN 
2014 SP1 software. 
 
2.4.4 siRNAs transfection 
 
Once peptides were shown to enter cells, an assay was designed to test whether they 
were capable of transfecting cells, ie, carrying a cargo and releasing it so as to induce a 
phenotypic change in the target cell. siRNAs were chosen, as they are small nucleic 
acids and able to induce changes in gene expression through the endogenous RNAi 
pathway.  
ECT2 (Epithelial Cell Transforming 2) and PLK1 (Polo-Like Kinase 1) siRNAs were 
selected as functional molecules and experiments were performed on A431 and HCT-
116 cell lines, as both target genes caused a reduction in cell viability and growth 136-138. 
A9K and G(IIKK)3I-NH2 and both their fluorescent versions, FITC-A9K and FITC-
G(IIKK)3I-NH2, were tested. The FITC-A9K transfection experiments were performed 
with the help of Joanna Henry, a master student who worked, under my supervision, on 
this project as part of her MSc degree. 
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Transfection of ECT2 siRNA was performed on A431 using A9K and G(IIKK)3I-NH2, 
while transfection with PLK1 siRNA was carried out on HCT-116 using the fluorescent 
peptides. The siRNAs were from the On Target-Plus Dharmacon siRNA collection. 10 
µM stock solutions were made according to the instructions provided by the supplier. 
For these experiments, the reverse transfection protocol was adopted as described in 
Ivatt., et al., 139. Briefly, 384 wells plates were used in a reverse transfection; 5 µl of 
siRNA (from a stock of 150 nM) were added to the wells with 5 µl of DMEM 
containing 0.05 µl of DF1 (DharmaFECT1). siRNA and DharmaFECT1 were left to 
complex for 30 minutes at room temperature. After incubation, 15 µl of 2x103 cells 
were added to each well. Cells were resuspended in culture medium with 10% FBS 
without the antibiotics since the combination of DF1 and antibiotics causes cell death. 
The plate was sealed, to minimize evaporation, left on the bench for 30 minutes and 
then put in the incubator overnight at 37 °C. The following day, 25 µl of DMEM (with 
10% FBS and 2% P/S) were added to the plate and incubated again at 37 °C for other 2-
3 days. siRNAs uptake occurs within 30 mins but RNAi knock down in the cells 
requires 2-3 days for gene-silencing. After the knock down, cells were fixed and stain 
with 4% paraformaldehyde fixative solution in PBS and Hoechst 33342 (2 µg/ml) for 15 
minutes, as previously described. Fluorescent automated wide field microscope 
(ImageXpress® Micro System) was used for recording the high-resolution images. 
 
Transfection using the red fluorescent siGLO was added as a control to verify that cells 
were healthy and transfected and more important to prove that an eventual decrease in 
the cells number was exclusively due to the RNAi gene silencing and not to unrelated 
events, such as an increased sensitivity toward the transfection conditions.  
For the conjugation peptides/siRNAs the exact same procedure described above was 
adopted; peptides were diluted in 5 µl of DMEM in order to form complexes with the 
siRNAs at different cationic/anionic charge ratios from 0.5/1 to 10/1. Cells were 
subsequently added to the wells but in complete culture medium since the presence of 
antibiotics doesn’t interfere with the peptides uptake and doesn’t cause cell death. 
Inhibition of ECT2 or PLK1 in cancer cells causes apoptosis, therefore successfully 
transfected cells should have an apoptotic appearance and a significant reduction in cell 
number compared to the controls. To count and analyse the differences in cell number 
in each of the experimental conditions MetaXpress® Software 5.3.01 (Molecular 
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Devices) was used. Data collected from the various conditions were normalised and 
compared to the number of survived cells after being transfected with siGLO.  
 
 
2.5 MTT assay and cell counts 
 
To investigate the cell response after exposure to the amphiphilic peptides, the MTT 
assay was carried out, a technique normally used to evaluate cell viability.  
Yellow MTT (Sigma-Aldrich®, CAS number: 298-93-1), 3-(4,5,-Dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide, is a tetrazole which is reduced into vivid purple 
formazan only in living, and therefore, metabolically active cells 140-142. The MTT assay 
was performed on A431 and HDF cell lines, using 5 different concentrations of A6K 
and A9K between 6.25 µM and 100 µM at 24 hrs, 48 hrs and 72 hrs. Appropriate 
dilutions were made so as to add only 10 µl of each peptide solution to the cells. 
Briefly, cells were seeded in a 96 well plate (clear, flat bottom, Corning, Cat. No. 3596) 
with 90 µl of complete culture medium at a variable cell density, depending on the cell 
type and exposure times (5-7x103 cells per well for 24 hrs and 48 hrs or 4-6x103 cells 
for 72 hrs). The following day, 10 µl of the different peptides concentrations were 
added to the cells for the final volume to be 100 µl. Negative and positive controls were 
added to each experimental set; Na2CrO4 (Sodium chromate tetrahydrate, CAS number: 
10034-82-91, Sigma-Aldrich®) has been used as positive control at the concentration of 
200 µM, while the peptide diluent, UHQ water, as negative control. At the end of 
exposure to the peptide, the medium was removed and 90 µl of fresh media added with 
10 µl of a MTT solution (5 mg/ml per well) and the plate incubated for 3 hrs. After that, 
the medium was carefully removed, and 100 µl of DMSO were added to dissolve 
formazan crystals. The plate was placed on a vibrating plate shaker for 15 minutes and 
the absorbance read at 570 nm with a spectral scanning multimode reader (Varioskan 
Flash™, Thermo Fisher Scientific). 
 
A consistent discrepancy between the MTT assay results and the number of cells 
observed under the microscope was noticed. Therefore, it was decided to perform a cell 
counting experiment using High Content Analysis. Cells were seeded in a 96 well plate 
as described in the MTT section. After the exposure time, cells were washed once with 
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100 µl of pre-warmed PBS and fixed and stained for 15 minutes, as previously 
described, with 4% paraformaldehyde fixative solution and Hoechst 33342 (2 µg/ml). 
Images of the plates were acquired using the fluorescent automated wide field 
microscope (ImageXpress® Micro System) and the cells counted using MetaXpress® 
Software 5.3.01 (Molecular Devices). 
With G(IIKK)3I-NH2 the same range of concentrations (0-100 µM) and exposure time 
(24-72 hrs) was investigated, but instead of performing the MTT assay, cell counts were 
made of the plates after peptide exposure. The experiments were performed on HCT-
116 and HDFs cell lines.  A cell count experiment using the same conditions was made 
using FITC-A9K the fluorescent version of the peptide. For this part, the student Joanna 
Henry is responsible for the collection of the relevant data but always under my 
supervision. FITC-G(IIKK)3I-NH2 toxicity was assessed instead for 24 hrs only, on both 
HCT-116 and HDFs cell lines. 
 
 
2.6 Cell staining for imaging 
 
In this PhD project, several fluorescent dyes have been used to stain different cellular 
compartments; the already cited Hoechst 33342 was used to stain nuclei, MitoTracker® 
Red CMXRos (Thermo Fisher Scientific, Cat. No. M7512) and JC-1 (Thermo Fisher 
Scientific, Cat. No. T3168) both used to stain mitochondria and Alexa Fluor® 568 
Phalloidin (Thermo Fisher Scientific, Cat. No. A12380) used to stain the F-actin 
filaments. 
 
A431 or HCT-116 mitochondria were stained with MitoTracker® Red CMXRos. Three 
different concentrations (6.25 µM, 25 µM and 100 µM) of A6K and A9K were chosen as 
experimental points and 72 hrs as exposure time in A431 cells while HCT-116 cells 
were exposed to 6.25 µM, 12 µM and 25 µM of FITC-A9K for 48 hrs. Cells were 
seeded in a 96 well plate with 90 µl of complete media and the next day 10 µl of a 
peptide solution was added to the wells. After exposure, the media was removed from 
the wells and the cells were incubated for 30 minutes with 250 nM of MitoTracker® 
Red CMXRos at 37 °C. As this probe is susceptible to potential oxidation in serum, 
DMEM lacking FBS was used. After that, cells were washed once with pre-warmed 
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PBS and fixed and stained for 15 minutes at room temperature with 4% 
paraformaldehyde and Hoechst 3342 (2 µg/ml) solution. Cells were washed twice again 
with PBS to remove the excess of stain. 100 µl of PBS was added for imaging.  
 
JC-1 dye is normally used to monitor cell health because it can fluoresce differently 
depending on the variations of the mitochondrial membrane potential (Δψm), which is 
considered as a direct indicator of cells’ functional status JC-1 exists in an aqueous 
solution as monomer with excitation and emission peaks in the green but under specific 
conditions it can form aggregates shifting its emission in the red spectrum. 143 Cells 
were seeded in a 96 well plate and exposed to the different peptide concentrations as 
described earlier in this session. For JC-1 live staining, cells were washed once in pre-
warmed PBS and incubated at 37 ° C for 20 minutes with JC-1 diluted in complete 
growth medium (final concentration 2 µg/ml). Afterwards, cells were washed once with 
PBS to remove the excess dye, media added and live imaged under the fluorescent 
microscope.  
 
Finally, Alexa Fluor® 568 Phalloidin was used to stain F-actin filaments in cell lines 
after 24 hrs exposure to FITC-G(IIKK)3I-NH2 between 6.25 and 50 μM. Cells were 
seeded in a 96 wells plate (white, clear flat bottom, Greiner Bio One) and exposed to 
peptides concentrations, then washed once in pre-warmed PBS and fixed and stained for 
15 minutes using 4% paraformaldehyde and Hoechst 3342 (2 µg/ml). The fixed plate 
was subsequently washed twice with PBS and incubated with 150 nM of Alexa Fluor® 
568 Phalloidin for 20 minutes at room temperature. To avoid photo bleaching, the 
whole procedure was executed away from bright light sources. Afterwards, cells were 
washed twice with PBS and left in of 100 µl of PBS for imaging.  
 
 
2.7 SEM and TEM techniques   
 
To better investigate the fate of FITC-G(IIKK)3I-NH2 once internalised by the cells and 
evaluate its interaction with their membranes, Scanning Electron Microscopy or 
Transmission Electron Microscopy were performed on HCT-116 after exposure to the 
fluorescent peptide. 
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For SEM samples, HCT-116 cells were seeded in 12 well plates (clear flat, Corning, 
Cat. No. 3513) on glass cover-slips (13 mm diameter, thickness No. 1.5, VWR 
international, Cat. No. 631-0150) with 1 ml of complete culture medium at a density of 
3x105 cells per well and incubated at 37 °C overnight. Next day cells were exposed for 
24 hrs to different concentration of FITC-G(IIKK)3I-NH2 (0.3, 6.25 and 100 µM). An 
untreated control was prepared as well. Then cells were washed with pre-warmed PBS 
and fixed in 3% Glutaraldehyde (CAS number 111-30-8, Sigma-Aldrich®) in 0.1 M 
Sodium Cacodylate (CAS number 6131993, Sigma-Aldrich®) buffer (pH 7.4) 
overnight. Next day, the samples were rinsed in the Cacodylate buffer and post fixed 
using 2% aqueous Osmium tetroxide (CAS number 20816-12-0, Sigma-Aldrich®). 
Then, briefly washed in distilled water, dehydrated in a graded ethanol series and dried 
in a 50:50 mixture of 100% ethanol and Hexamethyldisilazane (HEX) (CAS number 
999-97-3, Sigma-Aldrich®). Finally, samples were dried in 100% HEX and left to dry 
in a fume hood, overnight. Next day samples were mounted onto a pin-stub using a gold 
coated Leit-C sticky tab and an Edwards S150B sputter coater and examined using a 
Philips XL-20 Scan Electron Microscope at 15 kV. 
TEM was used to visualize the internalized peptide in the cells and identify the cellular 
compartments in which FITC-G(IIKK)3I-NH2 is majorly localized. A mouse 
monoclonal antibody anti-FITC labelled with 10 nm gold nanoparticles was used 
(Aurion, Cat. No. 25583). 
Colloidal gold nanoparticles, due to their electron density can be visualized on a TEM 
as dark spherical dots, which make them perfect for immuno-labelling using electron 
microscopy 144, 145. Briefly, HCT-116 cancer cells were seeded in a 96 well plate at the 
density of 2x104 cells per well in 90 µl of complete culture medium and incubated 
overnight at 37 °C. After one day attachment, the cells were treated with 6.25 µM of 
FITC-G(IIKK)3I-NH2. Despite what suggested by the antibody manufacturer and the 
various immunogold labelling protocols available online, it was impossible to 
successfully label the samples with the monoclonal antibody. 
Ultimately, it was decided to mix the antibody with the peptide and then add the formed 
complexes to live cells. The mouse monoclonal antibody anti-FITC labelled with 10 nm 
gold nanoparticles was coupled with FITC-G(IIKK)3I-NH2 for 6 hrs in the fridge at a 
1/100 dilution and then added to cells for either 3 or 24 hrs. Controls with antibody only 
were prepared and tested. The cells were washed with pre-warmed PBS and fixed. 
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The samples were originally fixed as a pellet in 4% paraformaldehyde solution for 15 
minutes followed by ethanol dehydration in proportion 50:50 with the acrylic LR white 
resin and 100% ethanol and left overnight on a rotor to mix. Next day, fresh resin was 
changed twice, and the samples kept on the rotor to keep mixing for 8 hrs. The samples 
were embedded in fresh LR white resin and put in polyethylene capsules (TAAB, Cat. 
No. C094). The capsules were covered with parafilm, the lid firmly shut to avoid air and 
then placed in the oven to polymerise at 60 ˚C. Next day the resin was checked to be set 
and sample sections were cut. 
An alternative fixation method was performed on some samples, to enhance cellular 
contrast and reduce image darkness. In this case, specimens were fixed overnight as a 
pellet using 3% Glutaraldehyde in 0.1 M Sodium Cacodylate buffer (pH 7.4) then 
washed in the same buffer and post fixed with 2% Osmium Tetroxide. After a brief 
wash in distilled water, the samples were dehydrated through a series of ethanol 
solutions with increasing alcohol percentage, cleared in epoxypropane (EPP) (CAS 
Number 16088-62-3, Sigma-Aldrich®) and infiltrated in 50:50 araldite resin and EPP 
mixture on a rotor and left it overnight. The samples were replaced twice, over a period 
of 8 hrs with fresh araldite resin mixture before being embedded and curing in an oven 
at 60 ˚C for 48-72 hrs.  
For both the fixation procedures, when samples were ready, ultrathin section of 
approximately 85 nm thick were cut on a Leica UC 6 ultramicrotome onto 200 mesh 
copper grids and stained for 30 minutes with saturated aqueous Uranyl Acetate followed 
by Reynold’s Lead Citrate for 5 minutes. Sections were examined using a FEI Tecnai 
Transmission Electron Microscope at an accelerating voltage of 80 kV. The electron 
micrographs were recorded using a Gatan Orius 1000 digital camera and the Digital 
Micrograph software.  
 
Both SEM and TEM samples preparations (fixation, resin mounting and TEM sections 
cutting) were made by Chris Hill, from the Electron Microscopy Facility, University of 
Sheffield, but the remain of the procedure by me. 
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2.8 Zebrafish husbandry and injections procedure 
 
2.8.1 Adult fish maintenance  
 
Adult fish were raised in the Bateson Centre (University of Sheffield) aquaria and 
maintained in a recirculating system at 28.5 °C on a 14:10 hour light/dark cycle, in 
accordance with UK Home office regulations and under project licence 40/3708 issued 
to Dr. Fredericus van Eeden. 
Adults were fed three times daily with Artemia nauplii and maintained at a maximum 
density of five fish per litre of aquarium water. 
Embryos were collected only following natural spawning of adult wild type (WT) from 
the AB strain, in accordance with United Kingdom Animals (Scientific Procedures) Act 
1986 and staged as described by Kimmel 146. 
 
2.8.2 Transgenic line 
 
To investigate the fate of FITC-G(IIKK)3I-NH2 in the fish blood stream the transgenic 
line TG(kdrl:HRAS-mCherry), which has red fluorescent blood vessels, was used. 
The TG(kdrl:HRAS-mCherry) line was generated for the first time by Hogan et al., 
containing a 6.8 kb fragment of the kdr-like promoter upstream of a ras-cherry fusion 
element into one cell-stage embryos 147 . 
The transgenic line was kept as heterozygous carriers mediating outcrossing to healthy 
wild type fish. The fluorescent reporter transgene gives a dominant effect with an 
expected Mendelian ratio of 50% upon outcrossing heterozygous carriers. 
For these experiments, the transgenic fish were in crossed resulting in expected 
Mendelian ratio of 75% for mCherry phenotype. Prior to injection, the embryos were 
selected for transgene fluorescence to exclude those with the WT phenotype. 
 
2.8.2 E3 medium and Tricaine solution 
 
For embryo growth and incubation, we used E3 medium. A 10-fold stock solution was 
made using 28.7 g NaCl 5 mM (CAS number: 7467-14-5, Sigma-Aldrich®), 1.27 g KCl 
   
62 
 
 
0.17 mM (CAS number: 7447-40-7, Sigma-Aldrich®), 4.8g CaCl2 0.33 mM (CAS 
number: 10043-52-4, Sigma-Aldrich®), 8.17 g MgSO4 0.33 mM (CAS number: 7487-
88-9, Sigma-Aldrich®) and kept at room temperature. The working solution was made 
by diluting the stock in UHQ water and adding 100 µl of Methylene blue 0.05% (CAS 
number: 61-73-4, Sigma-Aldrich®) as fungicide. Ethyl 3-aminobenzoate 
methanesulfonate, commonly called Tricaine or MS-222 (CAS number: 886-86-2, 
Sigma-Aldrich®) was used as anaesthetic during imaging, injection procedures and as 
euthanasia agent. The stock solution contains 400 mg of Tricaine powder dissolved in 
97.9 ml of UHQ water and 2.1 ml of Tris base 1 M (CAS number: 77-86-1, Sigma-
Aldrich®) while the pH is adjusted to 7.0. The stock solution was stored in the freezer 
while for embryos manipulation and sedation a working dose of 40 mg/l was used and 
stored in the fridge. 
 
2.8.3 Peptides and siGLO microinjections 
 
The night prior to injections 4-5 zebrafish pairs were set up in breeding tanks with 
dividers in place. The dividers kept the males and females separated to avoid fish 
mating. The following morning the dividers were removed and the fish left undisturbed 
to mate for at least 20 minutes. With a strainer, eggs were collected and poured into a 
water filled Petri dish. Embryos were then sorted and lined up against a microscope 
slide in a Petri dish, forming a single long column. Embryos were injected using 1.0 
mm diameter borosilicate glass capillary needles (WPI Florida, USA, Cat. No. 
TIP02TW1F), previously pulled using a micropipette puller (Sutter instruments 
California, USA) and mounted on a microinjector PV820 pneumatic Picopump (World 
Precision Instruments Florida, USA). The needle tip was pinched off using a pair of 
sharp tweezers. It was left narrow enough to be able to pierce the chorion and yolk 
without damaging the embryo in the process. The volume of each injection was 
calibrated using a 10 mm/0.1 division stage micrometer immersed in oil and a 
dissection microscope S6E (Leica). Since a droplet with diameter of 0.1 mm contains 
500 pl of injection material, the pressure was adjusted to have drops of that size 148, 149. 
Needles were loaded using a microloader pipette and embryos were injected with 
volumes between 0.5 and 2 nl. Embryos were injected within the first 20 minutes after 
spawning, when they are still at the one-cell stage and before they start the cellular 
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divisions. In this way, there are higher chances to hit the cytoplasm and not the yolk 
together with the certainty that the injected solution will be equally distributed in all the 
embryo’s cells. 
At least 50 embryos per concentration were injected and several uninjected embryos 
were kept as controls. After completion of each column of eggs, they were moved into a 
Petri dish, filled with E3 medium. At the end of the injections procedure, all the Petri 
dishes were transferred in an incubator at 28 ˚C. Different concentration of A9K peptide 
(150 - 4000 pg) and FITC-G(IIKK)3I-NH2 (6.25-4000 pg) per embryo were injected.  5 
hours post fertilisation (hpf) the Petri dishes were checked and the unfertilised eggs 
removed to minimise the risk of bacterial and fungi infections. Embryos were checked 
after 1 and 3 days post fertilisation (dpf) and the number of survivors and dead embryos 
recorded. Before reaching 5.2 dpf embryos were anaesthetised using Tricaine (40 mg/l) 
and sacrificed in a bleach solution. 
 
siGLO red (Dharmacon) and complexes FITC-G(IIKK)3I-NH2 / siGLO were injected in 
one-cell stage embryos following the exactly same procedure just described. The 
fluorescent siRNA was injected in a concentration range of 20-80 pg per embryo while 
complexes were made with 20 pg of siGLO and 20 or 80 pg of peptide. 
 
A stereomicroscope, Leica MZ16, was used to check embryos at 5 hpf, 1 and 3 dpf 
while images of embryos were acquired using a Leica M165 FC stereomicroscope. 
Fluorescent images of embryos injected with siGLO and FITC-G(IIKK)3I-NH2 were 
taken using the fluorescent stereomicroscope Zeiss Axio Zoom V16. 
 
2.8.4 Caudal injections in 4 dpf larvae 
 
The transgenic line, TG(kdrl:HRAS-mCherry), was paired in breeding tanks and left to 
mate. Embryos were collected and transferred into a Petri dish filled with E3 medium. 
Unfertilised eggs were removed and embryos were left to develop for 4 days. On the 4th 
day, the embryos can be arbitrary referred as larvae. Larvae expressing the fluorescent 
transgene were selected for injection with either FITC-G(IIKK)3I-NH2 or just the 
control fluorophore FITC and were injected in the caudal vein at a concentration of 25 
pg/nl. The larvae were anesthetised with Tricaine (40 mg/l) and then mounted on a Petri 
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dish lid in 3% low-melting point agarose, containing Tricaine. Embryos were positioned 
laterally to allow access to the caudal vein before setting of the agarose 150. The needle 
was loaded with FITC or the peptide solution, mounted on microinjector PV820 
pneumatic Picopump (World Precision Instruments Florida, USA) and calibrated to 
dispense 0.5 nl per pulse, as described previously. 
Once injected, the embryos were checked under a fluorescent stereomicroscope (Leica 
M165 FC) and mounted in a glass capillary tube (Transferpettor caps, DE-M, 50 µl, 
green) with 3% low-melting point agarose and imaged using  a Zeiss Lightsheet Z.1 and 
analysed with ZEN 2014 SP1 software 151.  
 
 
2.9 Endocytic pathways and RNAi genome-wide screen  
 
The mode of entry of the peptides into the cell were investigated using the fluorescent 
FITC-labelled versions of A9K and G(IIKK)3I-NH2 peptides. The data with FITC-A9K 
were collected by the MSc student Joanna Henry as part of her MSc project, but under 
my supervision and experimental planning.  
 
2.9.1 Internalisation speed of FITC-G(IIKK)3I-NH2  
 
The presence of FITC attached on the N-terminal of G(IIKK)3I-NH2 allowed to directly 
track the peptide internalisation. Different concentrations, 6.25 to 100 µM, were tested 
at a 24 hrs exposure time on HCT-116 and HDFs. Two concentrations of FITC-
G(IIKK)3I-NH2, 12.5 and 25 µM, were chosen and their rate of internalisation tested on 
both HCT-116 and HDFs cells at shorter time points (15 mins to 3 hrs). Cells were fixed 
and stained in the Hoechst as previously stated. The rate of the peptide complexed with 
a nucleic acid was also tested with 75 nM of red fluorescent siGLO (Dharmacon) 
complexed to FITC-G(IIKK)3I-NH2 and transfected in both cell lines. As for the peptide 
only experiment, different time points were included (15 mins to 3 hrs) while 
DharmaFECT1 (DF1) was used as the positive control. 4/1 and 24/1 were the tested 
peptide/siRNA ratios. The complete peptide/siRNA complexing procedure could be 
found in the DNA/RNA transfection section of this chapter. 
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2.9.2 The endocytic cold assay  
 
With temperatures below 37 °C, many cellular functions, such as vesicular trafficking, 
are slowed down. It has been reported that at a temperature of 4 °C, all the endocytic 
pathways are completely blocked 152, 153. Exploiting this information, a cold assay was 
performed to evaluate the uptake of FITC-G(IIKK)3I-NH2 in a low temperature 
environment.  
 
HCT-116 cancer cells were seeded in 6 well plates (clear, flat bottom, Corning, Cat. No. 
3516) at the density of 8x105 and incubated overnight at 37 °C. The following day the 
medium was removed and the plate washed twice in cold PBS (4 °C) to block 
endocytosis. 900 µl of cold complete growth medium were added to the wells together 
with 100 µl of 12.5 µM FITC-G(IIKK)3I-NH2. Plates were then left under the hood for 
30 minutes in ice, keeping the temperature below 4 °C. 
Expired the incubation time, the medium was removed and cells were washed in cold 
PBS. Afterwards they were fixed and stained in the usual 4% paraformaldehyde and 
Hoechst 33342 (2 µg/ml) solution. To evaluate the ability of HCT-116 in restoring the 
endocytic functions, some cells instead of being fixed were moved in the incubator at 37 
°C for further 3 hrs. In addition to that, two different experimental conditions were set 
up; some cells were kept in the original medium (complete culture medium and 12.5 
µM FITC-G(IIKK)3I-NH2), while for some others the original medium was discharged 
and replaced with new warm one lacking the peptide solution. 
Controls were prepared as well; no cold solutions were used this time, and after the 
peptide addition, cells were directly placed in the incubator at 37 °C for 30 minutes or 3 
hrs. Expired the time, plates were normally fixed and stained with the 4% 
paraformaldehyde and Hoechst 33342 (2 µg/ml) solution.  
 
Images from the plates were acquired the fluorescent microscope IN Cell Analyzer 2200 
(GE Healthcare) analysed with In Cell Developer Toolbox l.9 (GE Healthcare). 
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2.9.3 Extracellular peptide acid stripping  
 
Aldehyde fixatives, such as paraformaldehyde, can produce holes in the cell surface 
allowing the passage of material in the cytoplasm during fixation 154. This might 
adversely affect the amount of peptide observed inside fixed cells. To evaluate whether 
this is the case, cells were washed with an acid solution before fixation 155. 
First either 6.25, 12.5, 25 or 50 µM FITC-G(IIKK)3I-NH2 was incubated with HCT-116 
and HDFs cells for a 24 hrs exposure. Controls cells with no peptide were prepared. 
Cells were incubated with the acid wash which was, composed of 50 mM glycine-HCl 
(CAS number: 6000-43-7, Sigma-Aldrich®), 2 M urea (CAS number: 57-13-6, Sigma-
Aldrich®) and 100 mM NaCl at a pH of 3, for 5 minutes then washed in PBS  3 times to 
return the pH to normal conditions. The sequence was repeated 3 times, then cells were 
fixed and stained with the 4% paraformaldehyde and Hoechst 33342 (2 µg/ml) solution.  
Following fixation, cells were stained using CellMask Orange (Thermo Fisher 
Scientific, Cat. No. C10045). Images were acquired using the fluorescent microscope 
(ImageXpress® Micro System, Molecular Devices) and segmentation of peptides 
analysed with the MetaXpress® Software 5.3.01 (Molecular Devices). 
 
2.9.4 Time lapse imaging  
 
Live cell imaging was performed on 6.25 and 100 µM FITC-G(IIKK)3I-NH2 in HCT-
116 cells for 18 to 24 hrs after peptide addition, acquiring a picture every 30 minutes 
using the fluorescent microscope IN Cell Analyzer 2200 (GE Healthcare) in bright field 
and fluorescent mode in 96 well plates at the density 2.5x104 in 90 µl per well. The 
following day, 10 µl of the appropriate peptide concentration were added to each well. 
Some of the wells were loaded with 10 µl of UHQ water and considered as negative 
control. The plate was then positioned in the microscope and the imaging recording 
started. At the end of the acquisitions the plates were fix and stain with 4% 
paraformaldehyde and Hoechst 33342 (2 µg/ml) solution and acquired again using 
ImageXpress® Micro System, Molecular Devices fluorescent microscope for 
segmentation analysis. 
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2.9.5 HCT-116 recovery from FITC-G(IIKK)3I-NH2 challenge 
 
HCT-116 cancer cells are sensitive to FITC-G(IIKK)3I-NH2 and depending on the 
concentration, a decrease in cellular viability is observed. The cells ability to recover 
from high peptide concentration exposure was therefore evaluated. 
Briefly, 2.5x104 cells were seeded in 90 µl per well of a 96 well plate and allowed to 
settle and grow overnight. The following day, 10 µl of the fluorescent peptide solution 
was added and the plate incubated for 30 minutes at 37 °C. The plate was then put 
overnight in the incubator. In some wells, the peptide solution was removed and new 
complete culture medium added. The following day, the plate was fixed and stained 
with the usual solution of 4% paraformaldehyde and Hoechst 33342 (2 µg/ml). Live 
bright field images were acquired using the IN Cell Analyzer 2200 (GE Healthcare) 
microscope while fixed plate was instead acquired with ImageXpress® Micro System 
fluorescent microscope. 
 
2.9.6 RNAi screen to elucidate the peptide uptake in cancer cells 
 
To evaluate the genes controlling cellular uptake of fluorescently labelled FITC-A9K a 
mini screen was performed while in the case of FITC-G(IIKK)3I-NH2 a RNAi screening 
assay was developed first, followed by a screen using more than 200 siRNAs targeting 
genes involved in endocytic pathways. 
 
2x103 HCT-116 cells were seeded in 384 well plates and were reverse transfected, using 
DF1, with 30 nM final concentration of siRNAs for 3 days and then incubated with 6.25 
µM of FITC-A9K or FITC-G(IIKK)3I-NH2 peptides for 24 hrs. Cells were fixed and 
stained with Hoechst 33342 (2 µg/ml). Cell images were acquired with the 
ImageXpress® Micro System, Molecular Devices fluorescent microscope and the 
fluorescence intensity analysed using the MetaXpress® Software 5.3.01 (Molecular 
Devices). The data obtained were subsequently analysed to calculate the robust Z score 
of each silenced gene and to quality control the data.  
 
For the mini screen on FITC-A9K, actin related protein 2/3 complex subunit 1 B 
(ARPC1B), adaptor related protein complex 2 subunit alpha 2 (AP2A2), adaptor related 
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protein complex 2 subunit beta (AP2B1), clathrin light chain A (CLTA), clathrin light 
chain B (CLTB) and clathrin heavy chain (CLTC) siRNAs were chosen as positive 
controls, due to their function in endocytosis of bio-macromolecules 156-158. Red 
fluorescent siGLO was selected as positive control for the transfection procedure, while 
5 non-targeting siRNAs (On-TARGETplus non-targeting controls #1, #2, #3, #4 (each a 
single siRNA) and the non-targeting pooled siRNA of each of the 4 single controls were 
selected as negative controls. 
For the development of the screen on FITC-G(IIKK)3I-NH2, a collection of siRNAs 
defined in a plate (assay development plate 2 (ASD2)) specifically designed for 
genome-wide RNAi screens by the Sheffield RNAi Screening Facility (SRSF) 
(http://www.rnai.group.shef.ac.uk/) was used to develop the assay. The plate contained 
~100 siRNAs, actin related protein 2 homolog (ACTR2), ADP-ribosylation factor 6 
(ARF6), caveolin 1 (CAV1), clathrin heavy chain (CLTC), dynamin 2 (DNM2), myosin 
Va (MYO5A), myosin Vb (MYO5B), myosin Vc (MYO5C) and ras-related protein 7a 
(RAB7A) which were believed to be good positive control siRNAs 157-164 and 4 non-
targeting siRNAs (On-TARGETplus non-targeting control #2, #3, #4 #5). The plates 
used for the focussed larger screen on FITC-G(IIKK)3I-NH2 fluorescent peptide were a 
specific library of Traffic-ome targeting siRNAs and were specially designed by Doctor 
Andrew Peden and Professor Elizabeth Smythe (Biomedical Science Department, 
Sheffield University). 
 
 
2.10 Graphic and statistical analyses  
 
All the images acquired and described in this chapter were ultimately processed with 
Image J to adjust brightness and contrast to the same level. Prism GraphPad was used to 
create graphs while the figures composition was made using Corel Draw. Where 
needed, Student T-test was used to test for statistical significance. The robust Z-score of 
RNAi high-content screen was calculated using Microsoft Excel. 
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3 A6K AND A9K PEPTIDES 
Short cationic peptides have been extensively studied because of their ability to kill 
bacteria through the disruption of the lipid bilayer structure 165, 166. They are defined as 
antimicrobial peptides (AMPs) and are naturally part of invertebrate and vertebrate 
innate immunity systems. Their structure and physical properties allow them to 
selectively target bacterial membranes of both Gram-negative and Gram-positive 
microbes, due to the microbial surface containing net negative charge, caused by the 
lipopolysaccharides (LPS) (Gram-negative) and to the acidic polysaccharides (Gram-
positive) 48, 167. Most of the AMPs have an amphipathic structure, which seems to be 
crucial for their antimicrobial activity 61, 168, 169. The interaction with negatively charged 
moieties is not only related with outer membrane lipids but also with other biomolecules 
such as nucleic acids and phosphorylated proteins. With the aim of creating more 
effective target antibiotics, the publications related to AMPs have substantially 
increased in recent years. Hundreds of AMPs have been isolated and characterised in 
order to better understand their mechanism of action, while many more have been de 
novo designed and synthetically produced 51.  
 
One class of de novo designed peptides are surfactant-like peptides (SLPs) having 
hydrophobic amino acids as tails and hydrophilic amino acid heads. Tails are generally 
composed of non-polar amino acid residues (G, A, V, I, L, P or F). Heads are more 
variable; they could contain positively (H, K or R) or negatively (D or E) charged 
amino acids or they could be composed of a combination of these two groups 170. The 
two amphiphilic parts can even be swapped but this rearrangement seems not to be 
particularly viable for functionality 171. It is the hydrophobic tail, with its dislike for 
water, which drives the molecular self-assembly into different nanostructures 
(nanotubes, nanofibres, nanorods, nanovescicles or membrane sheets). The hydrophilic 
head faces the aqueous phase while the tail is buried inside the core of the molecule 172. 
A6K and A9K hydrophobic tails are composed by a sequence of alanines, while the 
positive hydrophilic head in this case is a lysine 173, 174. When dissolved in aqueous 
solutions and under neutral pH conditions, A6K and A9K self-assembled into ordered 
structure, mainly through hydrophobic interactions 175. The tail length is extremely 
important for the self-assembly process as its hydrophobicity can be modulated 
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depending on the number of amino acids normally a typical tail is composed of 3 and 9 
residues. An increased hydrophobicity (due to a longer tail) involves the development of 
different aggregates because solubility, together with the Critical Aggregation 
Concentration (CAC), progressively decreases 175, 176.  
 
A6K self-assembles in long nanofibers while A9K forms short nanorods 
174. The long 
and stable nanofibres formed by A6K have lengths in excess of 1 μm and diameters 
around 8 nm while the nanorods formed by A9K have much shorter lengths, normally 
less than 100 nm and diameter around 3 nm 174, 177. Both peptides have been previously 
tested against bacteria to evaluate their antimicrobial effects 126, 177. In a paper published 
by Chen et al., A6K and A9K were successfully used against E. coli DH5α and S. 
aureus; the pair exhibited, with increasing concentrations, antibacterial effect.  
 
However, A9K is the peptide with highest efficacy among the two. A possible 
explanation of this difference can be attributed to the distinct grade of hydrophobicity 
that these peptides possess. With the increase of the hydrophobic alanine residues, the 
total molecular hydrophobicity of A9K is of course enhanced and this enables the 
peptide to have stronger self-association and aggregation tendencies compared to A6K. 
These characteristics, together with the cationicity given by the lysine, promote a better 
initial contact with the negatively charged bacterial surface via electrostatic interactions 
causing increased antimicrobial activity 178. 
However, their capability of delivering DNAs/RNAs into cells has not been investigated. 
For this reason, part of this PhD project was focused on the use of two cationic peptides 
A6K and A9K for the delivery of ODNs and siRNAs into cancer cells. 
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3.1. DNA/RNA binding abilities in vitro and cell transfection 
efficiency 
 
3.1.1 Gel electrophoresis 
 
In the last couple of decades, amphiphilic cationic peptides have been extensively 
studied as possible new vectors for gene delivery and gene silencing, especially using 
plasmid DNA 179-184. One of the main purposes of this PhD project is to use amphiphilic 
peptides as transfection vectors for DNA or RNA molecules. In order to do that, the 
peptide efficiency in binding nucleic acids was initially tested using the agarose gel 
retardation technique. Because of A6K and A9K abilities to interact with anionic 
moieties, it was hypothesised that each peptide would bind nucleic acid. Agarose gel 
electrophoresis was used to separate DNA by size (e.g. smaller nucleic acids migrate 
faster than larger molecules), based upon the electrical field moving the negatively 
charged DNA toward the positive electrode. Peptide binding to the nucleic acids would 
prevent migration towards the cathode, since the negative charges would be nullified by 
the peptides positive ones. As consequence, when the gel is visualized under UV light, 
the DNA will be immobilised in the wells and bound to the peptide. 
 
Complexes at different cationic/anionic charge ratios (0.5/1; 1/1; 2/1; 3/1 and 5/1) were 
made with FAM-labelled oligonucleotides (ODNs) according to the calculations 
explained in the Materials and Methods section “2.3.1 Peptide/ODN complex 
formation”. Figure 1 shows the wells with only peptides or ODNs, included as negative 
and positive controls (lanes 1 and 7). The concentration of only peptide was the same of 
the highest charge ratio complex; 1 µg/µl concentrated solution for A6K and 1.35 µg/µl 
concentrated solution for A9K, both corresponding to 1.63 mM.  The amount of DNA in 
the positive control was 1 µg/well, as for the other samples. Surprisingly A6K did not 
bind the DNA at any of the tested concentrations and all the nucleic materials migrated 
to the positive electrode (Figure 1 a). Contrary to this, A9K inhibited ODN migration 
through the agarose gel matrix. An appreciable different DNA intensity is observed 
inside the wells with an increase of charge ratios, followed by a weaker migration 
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through the positive electrode, as seen by the lack of lower bands in lanes 5 and 6 
(Figure 1b).  
 
 
Figure 1. ODN binding assay for peptides. Agarose gel electrophoresis with A6K (a) 
and A9K (b) complexed with FAM-ODNs. The first line on the left was loaded with 
ODNs and represents the positive control. Complexes were made at 0.5/1; 1/1; 2/1; 3/1 
and 5/1 charge ratios (from line 2 to 6 respectively). The last lane (7) of each group was 
loaded with peptides only and it is not visible with the EtBr staining. Unbound nucleic 
acids travelled unimpaired through the gel, close to the bottom of each image. Upper 
bands represent binding of peptide with nucleic acid.  
 
3.1.2 ODNs and siRNAs transfection 
 
After the preliminary results achieved with the gel retardation assay, cell transfection 
was carried out using the same ODNs, but with A9K, since A6K showed no ability to 
bind to DNA. A cancer and non-cancer cell lines were selected for study. A431, a 
human epithelial cell and HDFs, primary human dermal fibroblasts cells were 
transfected with complexes of 0.05 µg of ODNs (1.6 µM) and an increasing amount of 
peptide (0.1; 0.25; 0.5/1; 1/1; 2/1 and 3/1) ratios compared to the DNA. Transfection 
with Oligofectamine was used as positive control, while the negative control is 
represented by free ODNs mixed to culture medium and shows that, without a carrier, 
the DNA molecules cannot cross the plasma membrane. 
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Figure 2 shows an experiment to test whether A9K, in a complex with an ODN, can 
bind and translocate into cells using wide-field microscopy. Most ODNs work by acting 
in the nuclear compartment, so this experiment was designed to test whether A9K can 
locate there with its cargo. The positive control, using the commercial transfection 
reagent, Oligofectamine, reveals that when complexed with FAM-labelled ODNs is 
capable of entering the cell and locating in the nucleus. A9K can enter cells, together 
with its cargo, and the process is concentration dependent, as an increase in A9K is 
commensurate with green FAM-ODN/A9K presence. However, the complexes do not 
locate to the nucleus of the A431 cells, as compared to the transfection control using 
Oligofecatmine, suggesting that A9K is not able to cross the nuclear membrane.  
 
 
Figure 2. A9K efficiency in delivery fluorescently labelled ODNs into epithelial 
cancer cells. A431 cancer cells were transfected for 24 hrs with 0.05 µg of FAM-
labelled ODN (corresponding to 1.6 µM) and an increasing charge ratio of A9K. 
Oligofectamine (oligofect) has been used as positive control and transfection has been 
made according to the manufacturer’s protocol, while un-complexed ODNs mixed to 
the culture medium represented the negative control (control). The images show the 
progressively higher amount of ODNs transfected into cancer cells directly 
proportionate to the A9K/FAM-ODN charge ratio changes. Hoechst 33342 (2 µg/ml) 
(blue) was used as nuclear staining, FAM-labelled ODN in green. Bar = 25 µm. All 
images are scaled to the same size. 
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To confirm the presence of the fluorescent ODNs inside the cells, confocal microscopy 
was used, as thin section stacks could be used to determine a more precise location of 
the particles inside cells. A9K/nucleic acid complexes between 0.1/1 and 1/1 charge 
ratios were assessed. The images at higher resolution showed that, at the charge ratios 
considered, all the fluorescent DNA was present inside the cells, while with 1/1 some of 
the DNA material was visible also outside the cells (Figure 3). When internalised, the 
fluorescently labelled ODNs appeared like small distinctive puncta but when attached 
on the cell membranes they tended to clump together forming big aggregates.  
 
 
Figure 3. Confocal examination of the intracellular localisation of fluorescent ODN 
molecules after transfection with A9K peptide. Confocal images of A431 cancer cells 
transfected for 24 hrs with of 0.3 µg FAM-labelled (corresponding to 1 µM) and 
increased charge/ratios of A9K. Oligofectamine™ (oligofect) has been used as positive 
control and transfection has been made according to the manufacturer protocol, while 
un-complexed ODNs mixed to the culture medium represented the negative control 
(control). The images show the localisation of the fluorescent ODNs within the cellular 
boundaries according to the peptide ratio used for transfection. Hoechst 33342 (2 µg/ml) 
(blue) was used as nuclear staining. FAM-labelled ODNs in green. Bar 25 = µm. All the 
images are scaled at the same size except for 0.5/1 and 1/1 ratios where the scale bar 
measures 10 µm and the magnification is 100X. 
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The Z stacks were composed by several sections taken a few microns apart from each 
other. In this way, multiple focus planes of the cells were imaged and the exact location 
of the green fluorescent DNA could be easily determined. In Figure 4 there are some 
stacks taken from the previous figure’s 0.5/1 peptide/ODN ratio showing the 
appearance of the green puncta according to the focal plane. This proved that the DNA 
was correctly internalised into the cytoplasm. 
 
 
Figure 4. Stack analysis of sequential confocal images of fluorescent ODN 
molecules in A431 cancer cells. A431 cancer cells transfected for 24 hrs with of 0.3 µg 
FAM-labelled (corresponding to 1 µM) and 0.5/1 charge/ratio of A9K. The images show 
Z-stacks of the same group of cells acquired using confocal microscopy. The pictures 
were taken in 0.8 µm sections and display the ODNs positioned in the middle sections 
of the stack highlighted with red circles. Hoechst 33342 (2 µg/ml) (blue) was used as 
nuclear staining. FAM-labelled ODNs in green. Bar 10 = µm. All the other images are 
scaled at the same size. 
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The literature has a few examples of peptides, similar to A9K, used to penetrate cells, 
but most have chosen cancer cells to test out their effectiveness in cell transformation 
105, 122. In this study, it was also important to determine whether A9K, can enter and 
deliver a cargo of nucleic acids to a non-cancer cell type, such as fibroblasts, so that this 
could be used as a reference experiment for future use. Similar to the previous 
experiments, A9K was complexed with FAM-labelled ODNs and incubated with Human 
dermal neonatal foreskin fibroblasts at different charge ratios. Figure 5 shows 
representative images acquired using the high throughput, wide-field microscope. The 
control positive transfection reagent, Oligofectamine, shows large amounts of green 
fluorescence in cytoplasm of each cell. At lower charge ratios (0.1/1 to 0.5/1) little 
green can be seen in each of these images and it is only with higher charge ratios that 
the FAM-ODNs complexed with A9K can be observed and is mainly surrounding cells, 
forming clumps. 
 
 
Figure 5. A9K delivery of fluorescently labelled ODNs into a non-cancer cell line. 
HDFs primary cells were transfected for 24 hrs with 0.05 µg of FAM-labelled ODNs 
(corresponding to 1.6 µM) and increased charge/ratios of A9K. Oligofectamine has been 
used as positive control and transfection has been made according to the manufacturer 
protocol, while un-complexed ODNs mixed to the culture medium represented the 
negative control (control). At low ratios, the peptide has poor transfection efficiency and 
fewer green puncta can be seen, while at high ratios many fluorescent puncta are visible, 
in the form of big clumps and mainly externally localised. Hoechst 33342 (2 µg/ml) 
(blue) was used as nuclear staining. FAM-labelled ODNs in green. Bar 25 = µm. All the 
images are scaled at the same size. 
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In addition to antisense oligonucleotides, gene expression can be modulated using 
RNAi, a form of posttranscriptional RNA silencing that causes the reduction or loss of 
gene activity due to degradation by nucleases of mRNAs transcripts 185. Synthetic 
double-stranded RNA molecules (siRNAs) of 21-23 nucleotides can be used to trigger 
the RNAi pathway and selectively silence the gene expression of targeted proteins. For 
this reason, siRNA-based therapies are rising as novel approach to treat several human 
conditions, cancer included 186. Unfortunately, there are still many barriers that preclude 
the widespread of siRNA as effective therapeutics; these include toxicity towards host 
cells, activation of the immune response and off-targets effects 187, 188. Because the 
toxicity is often caused by the vectors used to deliver siRNAs into the system, many 
studies are performed to try reducing, as much as possible, their adverse effect. 
Liposomes, polymers and nanoparticles showed promising potential, but are still a long 
way off before the development of effective siRNA delivery 187.  
 
For this purpose, A9K was tested as a possible carrier and complexed with siRNA 
molecules. Transfection experiments were conducted in both cancer and non-cancer cell 
lines and A9K was tested for the delivery of siRNAs into cells. Red fluorescent non-
targeting siGLO (Dharmacon) was selected as the molecule to be transfected in the cells 
at the concentration of 75 nM. Transfection using DharmaFECT1 (DF1) was added as 
positive control while free siGLO dissolved in the culture medium was considered the 
negative control. A431 human epithelial cancer cells and HDFs, human primary 
fibroblasts were selected as the model cell lines for the experiment., Figure 6, shows 
internalisation by A9K of siGLO in the A431 cancer cells. The amount of red 
fluorescent siGLO found inside the cells correlates with the increase in A9K used for 
transfection, and for some ratios (2/1 and 3/1), the level of transfection is improved 
compared to DF1 reagent. Surprisingly, high charge/ratios did not produce big clumps 
visible outside the cells as it was noticed previously with the ODN transfection. 
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Figure 6. A9K delivery of fluorescently labelled siRNA molecules into epithelial 
cancer cells. A431 cancer cells were transfected for 24 hrs with 75 nM of siGLO, (red) 
with increasing charge/ratios of A9K. DharmaFECT1 (DF1) was used as a positive 
control, while un-complexed siGLO mixed to the culture medium represented the 
negative control (control). Images show the transfection efficiency of A9K in delivery 
siRNA molecules in cancer cells with increased ratio producing more red (siRNA) 
inside cells. Hoechst 33342 (blue) was used as nuclear staining. Bar = 25 µm. All the 
images are scaled to the same size. 
 
To confirm the presence of fluorescent siGLO located in the cell cytoplasm, confocal 
microscopy was used. Figure 7 shows high-resolution images of A431 following 
transfection with either DF1 or peptide with different ratios.  
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Figure 7. Confocal examination of the intracellular localisation of fluorescent 
siRNA molecules after transfection with A9K peptide. Single sections of confocal 
images of A431 cancer cells transfected for 24 hrs with 75 nM of siGLO, red 
fluorescent indicator and increased charge/ratios of A9K. DharmaFECT1 has been used 
as positive control. Un-complexed siGLO mixed to the culture medium represented the 
negative control (control). Images show complexes of peptide and siGLO localised in 
the cytoplasm acquired using confocal microscopy. Hoechst 33342 (2 µg/ml) (blue) was 
used as nuclear staining. Bar 25 = µm. All the images are scaled to the same size. 
 
The confocal images were taken as z stacks at 0.3 µm slices. Several multiple focal 
planes of the same group of cells could be observed in detail. Figure 8 shows the stacks 
taken for the 0.1/1 ratio with progressively appearing and disappearing of the red 
siRNA puncta according to the focal plane.  
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Figure 8. Stack analysis of sequential confocal images of fluorescent siRNA 
molecules in A431 cancer cells. Cells were transfected for 24 hrs with of 75 nM 
siGLO, (red) at 0.1/1 charge/ratio of A9K. Each image shows a 0.3 µm slice from a Z-
stacks series of the same cells acquired using the confocal microscope. The images 
display the siRNAs positioned in the centre section within the stack, confirming an 
intracellular localisation (yellow circles). Hoechst 33342 (2 µg/ml) (blue) was used as 
nuclear staining. Bar 25 = µm. All the images are scaled to the same size. 
 
When A9K was used to transfect the fibroblasts, a contrary result showed poor siGLO 
internalisation (Figure 9). The positive control DF1 showed efficient uptake, however, 
in the peptide transfection conditions, even at the highest ratio (3/1), the transfection of 
red siGLO puncta inside the cells was limited.  
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Figure 9. A9K delivery of fluorescent siRNA into fibroblasts. HDFs primary cells 
were transfected for 24 hrs with 75 nM of siGLO, (red) at increasing charge/ratios of 
A9K. DharmaFECT1 was used as positive control. Un-complexed siGLO mixed with 
medium represent the negative control (control). Images show poor efficiency of A9K 
transfection in fibroblasts with siRNA molecules. Hoechst 33342 (2 µg/ml) (blue) was 
used as nuclear staining. Bar 25 = µm. All the images are scaled at the same size. 
 
3.1.3 Evaluation of A9K transfection efficiency in a 3D cancer cellular 
model 
 
Many treatments used to induce regression in tumours fail to penetrate the centre of the 
mass and therefore are excluded during the treatment process 189. For this reason, in 
vitro models of cancers have been widely used in research to provide a more relevant 
bridge between cell lines grown in 2D and in vivo tumours 135. There are many types of 
spheroid models described over the past four decades, some of which are widely used in 
cancer research 190.  
 
To evaluate the ability of A9K to infiltrate tumours and its potential use as a vector for a 
drug or a biologic delivery, a spheroid cancer model was used. Initially the cell line 
A431, which had been reported as a good model for tumour spheroid, was tested 191. 
A431 cells were allowed to form spheroids and were transfected with the peptide 
complexed with siRNA molecules (Figure 11). However, under inspection using wide-
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field microscopy, the agglomerate did not form a single cohesive mass. In fact, the 
resultant spheroids appeared quite irregular and extremely fragile (Figure 11). Still, the 
peptide/siRNA complex did penetrate into the centre of the spheroids and appeared 
much more efficient than DF1 in doing this. A9K showed promise compared to the 
control experiment. Due to the uncertainties of the A431 spheroid morphology, another 
model was sought.  
 
There are many examples in the literature of groups using HCT-116 colon cancer cells 
to form tumour spheroids which display more compactness 192, 193. However, HCT-116 
cells have never been tested with A9K, so, prior to continuing with 3D models, the cells 
were tested in 2D for transfection with the peptide. 75 nM of siGLO red fluorescent 
siRNA were transfected in HCT-116 monolayers using both A9K and DF1. Figure 10 
shows that, for all the tested peptide concentrations, siRNA transfection is detectable. In 
particular, at higher ratios (2/1 or 3/1), siRNA transfection is superior to the positive 
control (DF1). After this initial transfection experiment, 3D spheroids were cultured 
according to the detailed procedure explained in the “2.4.3 3D spheroids” section of the 
Materials and Methods chapter.  
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Figure 10. A9K transfection of fluorescently labelled siRNA molecules into HCT-
116 cancer cells. Cells were transfected for 24 hrs with of 75 nM of siGLO, (red) at 
increasing charge/ratios of A9K. DharmaFECT1 (DF1) was used as positive control. 
Untreated siGLO was mixed to the culture medium to represent the negative control 
(control). Hoechst 33342 (2 µg/ml) (blue) was used as nuclear staining. Bar 25 = µm. 
All the images are scaled at the same size.  
Figure 11 shows images of A431 and HCT-116 3D spheroids transfected with red 
fluorescent siGLO using DF1 as positive control or A9K peptide at different charge 
ratios (2/1 or 5/1). The shape of the spheroids reveals a difference between A431 and 
HCT-116. HCT-116 shows a compact spherical mass with an average diameter of 600-
800 µM. With DF1, especially in HCT-116 spheroids, most of the red signal seemed to 
be on the surface of the spheroid. A9K, on the contrary, appeared to enter the spheroids’ 
core. Due to the nature of the microscope used to acquire these images, it was not 
possible to determine the exact location of the red puncta within the spheroids and more 
importantly, how deep the peptide effectively transfected the spheroids. 
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Figure 11. A9K delivery of fluorescently labelled siRNA molecules in tumour 
spheroids. A431 or HCT-116 3D spheroids were transfected for 24 hrs with 75 nM of 
siGLO, (red) using the A9K peptide at different ratios. DharmaFECT1 (DF1) was used 
as positive control, while un-complexed siGLO mixed to the culture medium 
represented the negative control (control). Hoechst 33342 (2 µg/ml) (blue) was used as 
nuclear staining. Bar 250 = µm. All the images are scaled at the same size. 
For this reason, images with a light-sheet fluorescence microscope were acquired. This 
type of microscopy is ideal for larger samples, such as 3D models like spheroids, and 
allows the collection of multiple stacks with the opportunity for the production of 3D 
pictures 194. In Figure 12 it is possible to appreciate 3D sagittal view images (top left 
corners) of HCT-116 spheroids transfected with DF1 (left panel) or A9K (right panel). 
To examine the penetration of siRNA molecules when transfected with DF1 or A9K, 
middle section planes were chosen from the Z-stacks as a representation of the 
spheroidal sagittal views. Moreover, the two fluorescent channels used to acquire the 
images, DAPI for the blue nuclei staining and CY3 for the red siRNAs, were further 
divided in two separate pictures in order to visualise the distribution of siGLO. When 
A9K was used as transfection agent, the red fluorescence was predominantly 
concentrated in the centre of the spheroid while when DF1 was used the siRNA 
appeared more superficially distributed (Figure 13).  
 
Figure 12 and Figure 13 show the different transfection abilities of DF1 and A9K 
peptide, suggesting that, while the commercial reagent is only able to transfect the 
surface of 3D objects, such as spheroids, the amphiphilic peptide instead gets to the core 
of the spheroid.  
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Figure 12. Light-sheet microscopy to evaluate the penetration of A9K when 
transfecting 3D cancer models. Light-sheet imaging of 3D reconstructions of HCT-
116 spheroids testing transfection ability of A9K complexed with siGLO. The left four 
panels are control HCT-116 tumour spheroids transfected with DharmaFECT1 (DF1) 
and right are the experimental A9K complexed with the siRNA (red) at 2/1 ratio. 
Hoechst 33342 (2 µg/ml) (blue) was used as nuclear staining. Bar 250 = µm. All the 
images are scaled at the same size.  
 
 
Figure 13. Orthogonal views of HCT-116 spheroids showing the location of siGLO 
siRNAs in xyz spatial coordinates. Images are the same ones used in Figure 12, DF1 
(left panel) or the A9K (right panel), and further analysed using the ZEN 2014 SP1 
(Zeiss) software. The red, green and blue lines correspond to the xyz spatial coordinates 
of a single red punctum confirming the different distribution of siGLO siRNAs when 
transfected. Hoechst 33342 (2 µg/ml) (blue). Fluorescent siGLO in red. 
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3.1.4 FITC- labelled A9K confirms the transfection abilities of the 
peptide 
 
Previous experiments evaluated the transfection ability observing the localisation of 
fluorescent DNA or RNA molecules. However, direct visualisation of the peptide once 
complexed with nucleic acid inside the cell was not achieved. Therefore, a version of 
A9K labelled with the fluorophore Fluorescein isothiocyanate (FITC) was introduced in 
the experimental plan with the aim of identifying peptide location with the nucleic acid 
once inside the cells.  
 
Cancer cells HCT-116 were transfected with different charge/ratios of FITC-A9K and 
30 nM of red fluorescent siGLO and imaged using a fluorescent microscope. Both 
negative and positive controls were as before. Figure 14 shows the yellow puncta of 
colocalising peptide/siRNA complexes in the cytoplasm in all the tested peptide ratios. 
Note, there are both separate green and red puncta in images.  
 
 
Figure 14. Subcellular co-localisation of internalised siRNA and fluorescently 
labelled A9K. HCT-116 colon cancer cells were transfected for 24 hrs with 30 nM of 
siGLO, (red) and increasing charge ratios of FITC-A9K (green). The presence of yellow 
puncta within the same subcellular compartments is an indication that green fluorescent 
peptide and red siGLO are located close together, if not directly complexed. 
DharmaFECT1 (DF1) has been used as positive control while un-complexed siGLO 
mixed to the culture medium represented the negative control (control). Hoechst 33342 
(2 µg/ml) (blue) was used as nuclear staining. Bar 25 = µm. All the images are scaled at 
the same size. 
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3.1.5 Functional siRNA transfection 
 
After trying different transfection experiments using a non-targeting siRNA (siGLO), 
which has been useful for visualisation, the efficiency of A9K release of the siRNA 
inside cells was tested experimentally. Both individual red and green puncta were seen 
from Figure 14, showing that A9K has the potential for release of the siRNAs, but there 
are other factors which could control siRNA efficiency, such as release from endocytic 
vesicles and the ability of the siRNA to be taken into the RISC machinery. This 
experiment was crucial to evaluate the effectiveness of A9K in modulating the gene 
expression. For this reason, two functional siRNAs (ECT2 and PLK1) were selected for 
transfection in A431 or HCT-116 cancer cells. If the cargo of siRNA is released, then 
the cells should undergo either apoptosis or an arrest of the cell cycle and therefore a 
substantial decrease in the cell number would be detected.  
 
The protein encoded by ECT2 (Epithelial Cell Transforming 2 Oncogene) is a Rho 
guanine nucleotide exchange factor predominantly localized in the nucleus of interphase 
cells. Rho family GTPases control many cellular functions; such as cell polarity, gene 
expression, and cell cycle progression 195. The gene is expressed very high during the 
DNA synthesis and it stays elevated during G2 and M phases, moreover ECT2 seems to 
play an important role in the DNA damage response 196. PLK1 (or Polo-Like Kinase 1) 
is a serine/threonine-protein kinase that regulates many important processes during the 
M phase, such as centrosome maturation, spindle assembly, mitotic exit and cytokinesis 
and is highly expressed during mitosis 197. Because of their roles in cell cycle 
regulation, elevated levels of these proteins are often associated with different types of 
cancer and considered validated markers for poor prognosis 198-202. Their depletion in 
cancer cells dramatically inhibits cell proliferation and induces cell apoptosis, especially 
with PLK1, which is also considered a target for anticancer drugs 136-138.  
 
Transfection of ECT2 siRNA was done on A431 cells using A9K while HCT-116 cells 
were transfected with PLK1 siRNA using FITC-A9K. PLK1 is overexpressed in 
colorectal cancers and has been validated in the SRSF as a good positive control for 
HCT-116 203, 204. A431 and HCT-116 cancer cells were transfected with 30 nM of 
siRNA and peptides at different ratios. Cells were imaged and counted using the Meta 
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Xpress® software and the graphs in Figure 15 and Figure 16 show none of the peptide 
ratios induced either ECT2 or PLK1 siRNA knock down. In the first case, when A431 
cells were treated with ECT2 siRNA (Figure 15) no significant decrease in number was 
observed.  
 
 
Figure 15. siRNA delivery and knock down efficiency of A9K on A431 cells.                 
30 nM of ECT2 siRNA were complexed with A9K and then transfected in A431 cells. 
Different ratios of peptide to ECT2 siRNA are shown on the bar-chart. The transfection 
reagent DharmaFECT1 (DF1) was used as positive control, showing a reasonable 
degree of knock down. Cells were incubated for three days with the transfection reagent 
or peptide, fixed, stained to reveal their nuclei with Hoechst 3342 (2 µg/ml) and counted 
(using nuclei as a proxy). Cell number was counted using the Meta Xpress® with the 
Multi Wavelength Scoring algorithm and the 2x objective. The results are expressed as 
a percentage normalised to the negative control (exposure to the naked ECT2 siRNA). 
The values obtained are average of different experiments ± standard error mean 
(±SEM). Statistically significant difference from the negative control was determined 
by Student’s t-test (***p<0.001). 
 
A similar outcome for PLK1 siRNA transfection on HCT-116 cells was observed 
(Figure 16), with no significant change in cell number compared to the negative control.  
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Figure 16. siRNA delivery and knock down efficiency of A9K on HCT-116 cells. 
30nM of PLK1 siRNA was complexed with A9K and then transfected in HCT-116. 
Three increasing ratios of peptide to PLK1 siRNA are showed on the graph. The 
transfection reagent DharmaFECT1 (DF1) was used as positive control, showing a 
reasonable degree of knock down. Cells were incubated for three days with the DF1 or 
peptide, fixed, stained with Hoechst 3342 (2 µg/ml) and counted (using nuclei as a 
proxy). Cell population was counted using the MetaXpress® the Multi Wavelength 
Scoring algorithm and the 2x objective. The results are expressed as a percentage 
normalised to the negative control (transfection with siGLO). The values obtained are 
the average of different experiments ± standard error mean (±SEM). Statistically 
significant difference from the negative control was determined by Student’s t-test 
(***p<0.001). 
 
The positive control experiment, using DF1, gave 20% or 35% of cell survival with 
ECT2 and PLK1 siRNA respectively. This suggested that the overall experiment 
worked but did not yield a positive result for A9K as a transfection reagent for siRNA 
functional knock down in both A431 and HCT-116 cancer cell types. 
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3.2. Toxicity and metabolic reduction caused by peptides 
exposure  
 
3.2.1 MTT assay  
 
Both A6K and A9K have been reported to have the ability to inhibit the growth of HeLa 
and human promyelocytic leukaemia HL60 cancer cells 116, 177 and it is not unusual that 
an AMP shows some anti-cancer properties 205-207. To better understand the mechanism 
of action towards cancer cells, the processes with which these peptides can induce either 
a reduction in cell proliferation or an increase in cell death were analysed. To evaluate 
the cell viability, the first assay that was performed was MTT. A cancer and a non-
cancer cell line (A431 and HDFs) were exposed to a wide range of peptides 
concentrations at different time points. 
 
The MTT assay is a rapid and easy technique, generally used to evaluate cellular 
viability. MTT is a tetrazole and is reduced into purple formazan only in living cells. 
The absorbance of this coloured solution can be quantified using a spectrophotometer 
and measuring it at a certain wavelength (normally between 500 and 600 nm). The 
reduction takes place only when NAD(P)H-dependent oxidoreductase enzymes 
(dehydrogenases) are active and therefore conversion can be directly related to the 
number of viable (living) cells, although caution has to be exercised when using direct 
biochemical assays. The resulting purple solution is spectrophotometrically quantified 
and the increase in the cell number is normally directly related to the amount of MTT 
formazan crystals formed and with a subsequent increase in the absorbance measure 140-
142. Tetrazolium dye reduction normally involves oxidoreductases of the mitochondrial 
electron transport chain, but numerous other cellular dehydrogenases, oxidases or 
peroxidases have been shown to reduce tetrazolium dyes as well 208. As discussed, MTT 
assay was performed on A431 cancer cell line and HDFs human fibroblasts after 
exposure to A6K and A9K peptides in order to investigate their possible toxicity effects 
on cells. The concentrations of used peptides in this assay were in a range between 6.25 
µM (corresponding to 3.83 mg/ml of A6K or 5.17mg/ml of A9K) and 100 µM 
(corresponding to 61.5 mg/ml of A6K or 82.72 mg/ml of A9K). The exposure time 
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varied between 24 hrs and 72 hrs. The absorbance was measured with a 
spectrophotometer at 570 nm wavelength. The results obtained from the treated cells 
were normalized to the negative control (cells treated with the UHQ water used to 
prepare the peptide solutions) and converted to a percentage, which gave a value of 
mitochondrial activity of treated samples compared to negative controls. As positive 
control, 200 µM of Na2CrO4 was used, a well-known toxic and carcinogenic compound 
209, 210. One set of wells with MTT and peptides but without cells was included to 
evaluate if A6K and A9K could interfere during the absorbance reading (data not shown, 
as the peptides did not effectively exhibit any effects alone on the assay). 
 
The complete experimental procedure is explained in the corresponding section in the 
Material Method Chapter (“2.5 MTT assay and cell counts”), but briefly, cells were 
seeded on a plate at a variable cell density, depending on the cell type and exposure 
times, and next day treated with different peptide concentrations or UHQ water and 
Na2CrO4 for the negative and positive controls, respectively. At end of the exposure 
time, the medium was removed and a fresh one containing the MTT solution (5 mg/ml 
per well) was added for 3 hrs. After that, the medium was carefully removed and 
DMSO added instead to dissolve the formazan crystals. The plate was then placed on a 
vibrating plate shaker for 15 minutes and the absorbance read at 570 nm with a spectral 
scanning multimode reader. 
 
The results obtained from the MTT assay are shown in the graphs below and revealed a 
propensity for both A6K and A9K peptides to selectively interact with the cancer cells 
and significantly inhibit their growth. The cell viability is expressed as a decrease in the 
mitochondrial activity and quantified using the MTT assay data. 
 
A6K displayed great effect against the cancer cells A431 and little reaction towards the 
human fibroblasts but not in a time dependent manner. 
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Figure 17. Assessment of A6K activity using the MTT assay performed on A431 
and HDFs for 24 hrs. The graph shows cancer cells and fibroblasts exposed to A6K 
peptide for 24 hrs followed by evaluation of the mitochondrial activity via MTT assay. 
The absorbance of formazan crystals was quantified with a spectrophotometer and read 
at 570 nm wavelength. The results are normalized to the negative control and expressed 
as a percentage. The values obtained are averages of three independent experiments ± 
standard error mean (±SEM). Na2CrO4, 200 µM has been used as positive control (data 
not showed) while water has been used as negative control (0). A statistically significant 
difference from the negative control was determined by Student’s t-test (*p<0.05; 
**p<0.01; ***p<0.001). 
 
After 24 hrs of peptide exposure (Figure 17), a significant decrease in mitochondrial 
activity correlated with the peptide concentration for A431 cells. Cell viability 
progressively dropped compared to the negative control, from the 81% of 6.25 µM to 
43% of 100 µM A6K exposure. The fibroblasts were not affected by A6K and after 24 
hrs of peptide exposure none of the tested concentration caused significant diminution 
in the cellular mitochondrial activity. 
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Figure 18. Assessment of A6K activity using the MTT assay performed on A431 
and HDFs for 48 hrs. The graph shows cancer cells and fibroblasts exposed to A6K 
peptide for 48 hrs followed by evaluation of the mitochondrial activity via MTT assay. 
The absorbance of formazan crystals was quantified with a spectrophotometer and read 
at 570 nm wavelength. The results are normalized to the negative control and expressed 
as a percentage. The values obtained are averages of three independent experiments ± 
standard error mean (±SEM). Na2CrO4, 200 µM has been used as positive control (data 
not showed) while water has been used as negative control (0). A statistically significant 
difference from the negative control was determined by Student’s t-test (*p<0.05; 
**p<0.01; ***p<0.001). 
 
After 48 hrs of peptide exposure (Figure 18) a decrease in cell viability was observed in 
a dose-dependent manner in both cell lines, but more drastically in the cancer cells.  
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Figure 19. Assessment of A6K activity using the MTT assay performed on A431 
and HDFs for 72 hrs. The graph shows cancer cells and fibroblasts exposed to A6K 
peptide for 72 hrs followed by evaluation of the mitochondrial activity via MTT assay. 
The absorbance of formazan crystals was quantified with a spectrophotometer and read 
at 570 nm wavelength. The results are normalized to the negative control and expressed 
as a percentage. The values obtained are averages of three independent experiments ± 
standard error mean (±SEM). Na2CrO4, 200 µM has been used as positive control (data 
not shown) while water has been used as negative control (0). A statistically significant 
difference from the negative control was determined by Student’s t-test (*p<0.05; 
**p<0.01; ***p<0.001). 
 
Finally, following 72 hrs exposure (Figure 19), fibroblasts did not vary in activity, 
despite a slight, non-statistical trend towards a decrease in their mitochondrial activity. 
In contrast, A431 had a reduction in mitochondrial activity of 47% compared to the 
negative control at 100 µM. 
 
Overall, the decrease in mitochondrial activity of the cancer cells, due to peptide, was 
not time dependent, an exception being for A6K at 6.25 µM. In summary, for most 
selected concentrations, on average, the mitochondrial activity dropped about 50-60% 
compared to the control. 
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Figure 20. Assessment of A9K activity using the MTT assay performed on A431 
and HDFs for 24 hrs. The graph shows cancer cells and fibroblasts exposed to A9K 
peptide for 24 hrs followed by evaluation of the mitochondrial activity via MTT assay. 
The absorbance of formazan crystals was quantified with a spectrophotometer and read 
at 570 nm wavelength. The results are normalized to the negative control and expressed 
as a percentage. The values obtained are averages of three independent experiments ± 
standard error mean (±SEM). Na2CrO4, 200 µM has been used as positive control (data 
not showed) while water has been used as negative control. Statistically significant 
difference from the negative control was determined by Student’s t-test (*p<0.05; 
**p<0.01; ***p<0.001). 
 
Replicating these experiments for A9K, after 24 hrs (Figure 20) of exposure to the 
peptide, the mitochondrial activity did not decrease in either cell lines and the values 
were always comparable with the respective negative controls. 
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Figure 21. Assessment of A9K activity using the MTT assay performed on A431 
and HDFs for 48 hrs. The graph shows cancer cells and fibroblasts exposed to A9K 
peptide for 48 hrs followed by evaluation of the mitochondrial activity via MTT assay. 
The absorbance of formazan crystals was quantified with a spectrophotometer and read 
at 570 nm wavelength. The results are normalized to the negative control and expressed 
as a percentage. The values obtained are averages of three independent experiments ± 
standard error mean (±SEM). Na2CrO4, 200 µM has been used as positive control (data 
not showed) while water has been used as negative control (0). A statistically significant 
difference from the negative control was determined by Student’s t-test (*p<0.05; 
**p<0.01; ***p<0.001). 
 
At 48 hrs exposure (Figure 22) a slightly diminution in the cell viability of A431 was 
observed, especially at intermediate concentrations (25-50 µM) where only 75% of 
mitochondrial activity was registered. Mostly ineffective, the peptide showed a 
statistically significant decrease in the fibroblast metabolic activity only at one 
experimental point: 25 µM where the mitochondrial activity decreased to 80%. 
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Figure 22. Assessment of A9K activity using the MTT assay performed on A431 
and HDFs for 72 hrs. The graph shows cancer cells and fibroblasts exposed to A9K 
peptide for 72 hrs followed by evaluation of the mitochondrial activity via MTT assay. 
The absorbance of formazan crystals was quantified with a spectrophotometer and read 
at 570 nm wavelength. The results are normalized to the negative control and expressed 
as a percentage. The values obtained are averages of three independent experiments ± 
standard error mean (±SEM). Na2CrO4, 200 µM has been used as positive control (data 
not showed) while water has been used as negative control (0). A statistically significant 
difference from the negative control was determined by Student’s t-test (*p<0.05; 
**p<0.01; ***p<0.001). 
 
The results became significant after 72 hrs exposure (Figure 22), where the 
mitochondrial activity dropped down to <50% for most peptide concentrations used 
(with the exception of the lowest dose (6.25 µM)). Fibroblasts, once again, did not show 
sensitivity towards this peptide. In all the above experiments, a positive control of cells 
treated with Na2CrO4, was used and the data is not displayed. However, as expected 
they died and the mitochondrial activity was consequently really low; 5%, 3% and 2% 
for A431 and 6.5%, 1.5% and 1% for HDFs at 24, 48 or 72 hrs, respectively.  
 
Using GraphPad, the inhibitory concentration (IC50), corresponding to the concentration 
of peptide needed to induce a mitochondrial activity inhibition of 50%, was calculated. 
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Against A431 cancer cells, A6K had an IC50 of 40, 52 and 45 µM after 24, 48 and 72 hrs 
exposures, respectively. For A9K instead the IC50 (28 µM) was calculated only for the 
72 hrs time point since in the previous ones, little variation in the mitochondria activity 
was observed. Both peptides were ineffective towards HDFs, therefore no IC50 could be 
extrapolated.  
 
3.2.2 Cell counts following exposure to A6K or A9K peptides  
 
As previously mentioned, the MTT assay is often used as an estimate of the cellular 
viability and is easy to perform with absorbance measurements and a plate 
spectrophotometer. However, monitoring, using the cell microscope, it was noticed that 
there was little variation between the experimental conditions, with the exclusion of the 
wells treated with Na2CrO4, where it was obvious all the cells were dead. This was 
observed for both peptides, A6K and A9K, so it was decided to quantify the observations 
and repeat the experiment and perform a cell count using high content microscopy and 
counting the cells based upon a nuclear stain and an algorithm to count the nuclei 
(Figure 23). 
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Figure 23. A431 cell number evaluated with high-content microscopy after 
exposure to A6K and A9K peptides. Cells were incubated with A6K (a) or A9K (b) 
peptides for one, two or three days, fixed in formaldehyde and stained with Hoechst 
3342 (2 µg/ml) to reveal the nuclei. Images were acquired using an ImageXpress® 
Micro microscope (x2 objective) and cell number was counted using the Multi 
Wavelength Scoring algorithm within the MetaXpress® software. The results are 
expressed as a percentage of the number of cells and normalized to the negative control 
at that relative time point. The values obtained are averages of different experiments ± 
standard error mean (±SEM). Na2CrO4, 200 µM has been used as positive control (data 
not showed) while water has been used as negative control (0). A statistically significant 
difference from the negative control was determined by Student’s t-test (*p<0.05; 
**p<0.01). 
 
The results from Figure 23 shows a slight, but significant change in cell number at 
longer exposures at higher doses, but the decrease did not correspond to the MTT assay.  
The remarkable differences between MTT assay and the cell counting experiments, both 
of which have been invaluable in assessing cell toxicity in other studies, shows that the 
interaction between peptides and the cancer cell lines is complex. From these 
experiments, the cells were not directly dying but the decrease in MTT activity suggests 
a possible interaction between the peptides and the cellular mitochondria, or a metabolic 
suppression in the cell.  
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3.2.3 Cell counts following exposure to FITC- A9K   
 
As already mentioned in the transfection efficiency paragraph, a fluorescent version of 
A9K, conjugated with FITC was used. This new peptide was tested to see if it had a 
similar effect on the cells compared to the non-fluorescent labelled one. Because of the 
fluorescence of the peptide, it was possible to use high-content microscopy to acquire 
images of the cancer cells when exposed to increasing concentrations of FITC-A9K. In 
Figure 24 there are images of HCT-116 cells exposed to FITC-A9K for 72 hrs. It is 
possible to observe that the amount of fluorescence associated with the cells is 
proportionally related with the peptide concentrations used in the experiment. 
 
 
Figure 24. High-content microscopy of cancer cells exposed to a fluorescent 
peptide. Images show HCT-116 cancer cells exposed for 72 hrs to FITC-A9K. The 
amount of fluorescence associated within the cells is proportional to the concentration 
of peptide used. Cells were stained with Hoechst 33342 (2 µg/ml). FITC-A9K in green.  
Bar 25 = µm. All the images are scaled at the same size. Images provided by courtesy of 
Joanna Henry, MSc in Biomedical Science, who was involved in this project for a 
period of 10 months as a part of her master degree. 
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To evaluate if the FITC labelled A9K behaved the same as its non-fluorescent version, 
cell viability was measure by counting the cells. This time HCT-116 cancer cells were 
selected, and the results are shown in Figure 25. The same range of concentrations 
(6.25-100 µM) and exposure times (24-72 hrs) were chosen. There was very little 
difference between the two peptides. 
 
 
Figure 25. HCT-116 cell number evaluated with high-content microscopy after 
exposure to FITC-A9K peptide. Cells were incubated with FITC-A9K for one, two or 
three days, fixed in formaldehyde and stained with Hoechst 33342 (2 µg/ml) to reveal 
nuclei. Cell number was counted using the MetaXpress® with the Multi Wavelength 
Scoring algorithm and 2x objective. The results are expressed as percentage of the 
number of cells and normalized to the negative control at that relative time point. The 
values obtained are averages of three replicates for each experimental point ± standard 
error mean (±SEM). Na2CrO4, 200 µM has been used as positive control (data not 
showed) while water has been used as negative control (0). A statistically significant 
difference from the negative control was determined by Student’s t-test (**p<0.01). 
Data provided by courtesy of Joanna Henry, MSc in Biomedical Science involved in 
this project for a period of 10 months as a part of her master degree. 
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3.3. Mitochondrial membranes dramatically change after both 
A6K and A9K exposure 
 
Results obtained with the cell counting experiments, especially with the MTT assay, 
showed how these two amphiphilic peptides, although clearly interacting with the cells, 
do not directly cause cell death but rather interfere with the cellular metabolism, 
possibly via a mitochondrial route. A hypothesis was tested that the peptides caused a 
dramatic effect on the mitochondrial morphology. 
 
MTT reduction mainly occurs in the mitochondria by oxidoreductases. It has also been 
reported to be used for endosomal and lysosomal vesicles 140, 141, 208, 211. To better 
elucidate the effect of peptides on mitochondria, two different dyes were used; 
MitoTracker® Red CMXRos (Thermo Fisher Scientific), a specific cell-permeant probe 
containing a mildly thiol-reactive chloromethyl moiety for labelling active mitochondria 
212, and JC-1 (Thermo Fisher Scientific), a carbocyanine with a delocalized positive 
charge. JC-1 normally exists in aqueous solution as monomers with the excitation and 
emission peak in the green. Under favourable conditions it forms J-aggregates shifting 
its emissions in the red peak 143. 
 
A431 and HCT-116 cells were exposed to A6K, A9K or FITC-A9K. Cells were 
incubated at 37 C° for 30 minutes together with 250 nM of MitoTracker® Red 
CMXRos diluted in DMEM then fixed with 4% formaldehyde and the nuclei stained 
using Hoechst 3342 (2 µg/ml).  
 
From the images in Figure 26 it is possible to observe how at normal conditions (0 µM) 
the mitochondria staining shows a network of highly interconnected long filaments. 
However, with increasing concentrations of A6K and A9K peptides, the mitochondria 
morphology starts changing and perinuclear, spherical, stained clumps are noticeable. 
This has previously been reported as an indicator of cellular stress, associated with a 
consequent reduction in metabolic activity 213, 214. 
 
  
103 
 
 
Figure 26. Mitochondrial morphology of cancer cells following peptide exposure. 
A431 cancer cells exposed for 72 hrs to A6K (a) and A9K (b) peptides and then live 
stained with MitoTracker® Red CMXRos 250 nM for 30 minutes followed by standard 
formaldehyde fixation. Images show the different morphology of mitochondria 
associated with A6K and A9K exposure. The images are presented in black and white to 
enhance mitochondrial morphology. Note, the controls contain filamentous stained 
mitochondria and as the peptide concentration increases spheroidal objects are more 
common. Hoechst 33342 (2 µg/ml) was used as nuclear staining. Bar 25 = µm. All the 
images are scaled at the same size. 
 
Figure 27 shows the resulting images of the mitochondria from HCT-116 cells 
challenged with the FITC-A9K peptide. It is possible to observe a similar pattern 
compared to A431 cells treated with either A6K or A9K peptides. 
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Figure 27. Mitochondrial morphology of cancer cells following fluorescent peptide 
exposure. HCT-116 cancer cells exposed for 48 hrs to FITC-A9K peptide and then live 
stained with MitoTracker® Red CMXRos 250 nM for 30 minutes followed by standard 
formaldehyde fixation. Images show the different morphology of mitochondria 
associated with FITC-A9K exposure. The images are presented in black and white to 
enhance the mitochondrial morphology. Hoechst 33342 (2 µg/ml) was used as nuclear 
staining. Bar 25 = µm. All the images are scaled at the same size. Data provided by 
courtesy of Joanna Henry, MSc in Biomedical Science involved in this project for a 
period of 10 months as a part of her master’s degree. 
 
The second dye we used on mitochondria is JC-1. As previously mentioned, this 
specific dye could fluoresce differently according to the variations of the mitochondrial 
membrane potential (Δψm) shifting from green to red green 215. The different spectrum 
of excitation and emission is based on its aggregation status inside the mitochondria. 
Due to its cationicity, JC-1 easily interacts with the highly negative mitochondrial 
membranes (- 140 mV). When the membranes are polarised (high Δψm), it accumulates 
in the organelles yielding a red coloured emission (~590 nm), and vice versa, with 
membranes depolarisation, normally associated with unhealthy mitochondria (low 
Δψm), JC-1 stays in low concentrations and in monomers yielding to a green fluorescent 
emission (~529 nm).  
 
A431 cancer cells were exposed to A6K or A9K (6.25 – 100 µM) for 24 or 48 hrs. 
Following peptide exposure, the cells were incubated at 37 °C for 20 minutes together 
with 2.0 µg/ml of JC-1 diluted in growth medium, then washed and live imaged under 
the fluorescent microscope. 
An increased number of green depolarized mitochondria, compared to the respective 
controls, was observed for each peptide and was dose and time dependent.  
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Figure 28. Mitochondrial membrane potential (Δψm) status of cancer cells 
following peptide exposure. JC-1 staining on A431 cells exposed to different 
concentrations of A6K peptide (a) for 24 hrs (top) or 48 hrs (bottom) or A9K peptide (b) 
for 24 hrs (top) or 48 hrs (bottom). Cells were incubated with 2.0 µg/mL of JC-1 diluted 
in growth medium for 20 minutes and then live imaged. Images show the effect of A6K 
and A9K peptides on mitochondrial polarisation status. Due to the dual-colour 
properties of the dye JC-1, healthy mitochondria appear red, while unhealthy 
depolarised ones appeared green. Bar 25 = µm. All the images are scaled at the same 
size.  
 
The amount of green and red mitochondria in each experimental condition was 
quantified using the MetaXpress® and an algorithm specifically customised to count the 
different coloured mitochondria was used. The results from the A6K experiments are 
presented in Figure 29a and Figure 30, while the results for A9K peptide are shown in 
Figure 29b and Figure 31. 
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Figure 29. Quantitative analyses of ΔΨm variation following peptide exposure.    
The graphs show the dose response of the peptide over time and reveal the number of 
green mitochondria after exposure to different concentrations of A6K (a) or A9K (b). 
The results are expressed as a percentage of the number of green mitochondria 
normalized to the negative control at that relative time point. The values obtained are 
averages of independent experiments ± standard error mean (±SEM). A statistically 
significant difference from the negative control was determined by Student’s t-test 
(*p<0.05; **p<0.01; ***p<0.001). 
 
For A6K the number of green stained mitochondria increased according to the 
concentration of peptide. In standard conditions, the number of green mitochondria 
present within cells is about 20% of the total. At 6.25 µM the population of green 
mitochondria did not vary significantly, when compared to the control, but at 25 µM 
and especially at 100 µM the difference was significant. An increase of the green 
reporter, was not only dose, but time dependent and, after 48 hrs exposure to 25 and 100 
µM of A6K peptide, the percentage of green mitochondria rose to 23% and 43%, 
respectively ( Figure 29 a).  
A9K exposure followed the same pattern as A6K, showing an increase in membrane 
depolarisation directly related to the amount of peptide dispensed. From the quantitative 
analysis on the number of green mitochondria (Figure 29 b), it emerged that the A431 
cells were sensitive to the A9K peptide in a dose and time dependent manner. After 24 
hrs exposure, the only peptide concentration that did not cause a substantial change in 
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mitochondrial number was 6.25 µM. After 48 hrs of peptide exposure at all the 
concentrations tested the cells showed a significant augmentation in green mitochondria 
 
 
Figure 30. Quantitative analyses of ΔΨm variation caused by A6K exposure.              
The graphs show the total number of mitochondria counted in A431 cells after exposure 
to different concentrations of A6K at 24 (a) or 48 hrs (b) time points. Mitochondria were 
counted using MetaXpress® and a specifically designed algorithm that was able to 
count and separate green mitochondria from red ones. The results are expressed as a 
percentage ratio of mitochondria separated by colour. The values obtained are averages 
of independent experiments ± standard error mean (±SEM). 
 
A green/red mitochondrial ratio was also calculated (Figure 30 and Figure 31) in order 
to evaluate the real impact of both peptides on the JC-1 colour shift, according to the 
mitochondrial membrane potential status (Δψm). Figure 30 shows the green/red 
mitochondrial ratios after 24 or 48 hrs A6K exposure. In the 24 hrs control cells, 80% of 
mitochondria were red and 20% were green. When the peptide was added this ratio 
changed slightly. With 6.25 µM no variation was observed. Almost identical results 
were obtained after 48 hrs exposure. 
 
With A9K, equivalent results were obtained at 6.25 and 25 µM for both time points, but 
at 100 µM the ratio of green/red mitochondria changed more than the A6K experiment 
(Figure 31).  
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Figure 31. Quantitative analyses of ΔΨm variation caused by A9K exposure.              
The graphs show the total number of mitochondria counted in A431 cells after exposure 
to different concentrations of A9K at 24 (a) or 48 hrs (b) time points. Mitochondria were 
counted using MetaXpress® and a specifically designed algorithm that was able to 
count and separate green mitochondria from red ones. The results are expressed as a 
percentage ratio of mitochondria separated by colour. The values obtained are averages 
of independent experiments ± standard error mean (±SEM). 
 
 
3.4. Images acquisition and analysis 
 
The images presented in this chapter were collected using the ImageXpress® Micro 
System wide-field fluorescent microscope with 20x objective lenses and further 
analysed using the MetaXpress® 5.0.0.20 software. Confocal images presented in the 
section “3.1.2 ODNs and siRNAs transfection” were acquired using the Nikon A1+, 
confocal microscope with 60 and 100x objectives lenses and analysed using the NIS 
Element software. Light-sheet imaging of 3D spheroids and their orthogonal views 
showed in the “3.1.3 Evaluation of A9K transfection efficiency in a 3D cancer cellular 
model” section was made with the Zeiss Lightsheet Z.1 microscope with 2x objectives 
lenses and further analysed with the ZEN 2014 SP1 (Zeiss) software. Brightness and 
contrast were ultimately adjusted for all the images to the same level by using Image J. 
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4 G(IIKK)3I-NH2 PEPTIDE 
Antimicrobial peptides (AMPs) have a wide spectrum of activity including pathogens 
such as bacteria, fungi, some viruses and even cancer cells 105, 216. Amongst the AMPs, 
the alpha-helical ones are certainly the most studied; the amphibian Magainin 60, the bee 
venom component Mellitin 59 and the human LL-37 13 are just few examples of this 
large class. Like for the β-sheet peptides, the α-helical ones share the same very 
important features; a net positive charge (+2 to +9), a considerable quantity of 
hydrophobic residues (≥ 30%), a well-defined amphipathicity and a general small size 
(normally 6-50 aa long) 43, 45. The analysis of natural α-helical AMP amino acidic 
sequences revealed that there is little positional conservation of individual residues but 
some exceptions are observed: position 1, for example is occupied by a Glycine in 70% 
of the cases and a lysine in position 8 is seen in 50% of cases 168. Most of the α-helical 
AMPs do not have a defined structure in aqueous solutions but assume proper folding 
once in contact with a membranous environment 50. This structure propensity is critical 
for antimicrobial activity and lowers the cytotoxicity towards mammalian host cells 48.  
 
G(IIKK)3I-NH2 is an alpha helical molecule, part of the novel class of synthetic short 
cationic peptides G(IIKK)nI-NH2 (n = 1-4) containing the simple repeated sequence 
IIKK, enabling the ratio of hydrophobic isoleucines (I) to cationic lysines (K) remaining 
equal. Like other α-helical peptides, it remains unfolded in aqueous solution due to 
significant intermolecular hydrogen bonding between the peptide backbone and the 
solvent, but can adopt the typical α-helical folding structure in appropriate conditions. 
Previous works revealed how, amongst the series, G(IIKK)nI-NH2, G(IIKK)3I-NH2 was 
the peptide showing the most promising results; great antibacterial activity against both 
Gram-positive (B. subtilis 168) and Gram-negative (E. coli DH5 α) but at the same time 
low cytotoxicity towards mammalian host 117.  A recent publication showed G(IIKK)3I-
NH2 cancer cell selectivity with a possible cytostatic effect against HeLa and 
promyelocytic leukaemia HL60 118. Therefore, G(IIKK)3I-NH2 was selected as the 
object of study in this PhD project in order to further evaluate its efficiency in targeting 
cancer cells and investigate the possibility for its use as a vector for gene delivery. 
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4.1 In vitro cell transfection efficiency with DNA or RNA 
 
The first set of experiments with G(IIKK)3I-NH2 and its fluorescent version FITC-
G(IIKK)3I-NH2 were planned to evaluate the binding ability towards negatively charged 
DNA or RNA molecules and, more importantly, their transfection efficiency in different 
cellular models. All the images were collected using the ImageXpress® Micro System 
wide-field fluorescent microscope with 20x objective lenses. Following acquisition, the 
images were further analysed using the MetaXpress® 5.0.0.20. Brightness and contrast 
were ultimately adjusted for all the images to the same level by using Image J. 
 
4.1.1 ODNs and siRNAs transfection 
 
DNA transfection efficiency was evaluated on A431 and HDFs. Complexes made with 
0.05 µg (1.6 µM) of FAM labelled oligonucleotides (ODNs) and increasing ratios of 
G(IIKK)3I-NH2 (0.1; 0.25; 0.5/1; 1/1; 2/1 and 3/1) were transfected into cell monolayers 
according to the procedure explained in the Materials and Methods section. Transfection 
with Oligofectamine was used as positive control, while the addition to the cells of un-
complexed ODNs, used as negative control. Without an adequate transfection reagent, 
the DNA molecules were not able to cross the plasma membrane. 
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Figure 32. G(IIKK)3I-NH2 efficiency in delivering fluorescently labelled ODNs into 
epithelial cancer cells. A431 cancer cells were transfected for 24 hrs with 0.05 µg of 
FAM-labelled ODNs (corresponding to 1.6 µM) and increased charge/ratios of 
G(IIKK)3I-NH2. Oligofectamine (oligofect) was used as positive control and 
transfection was performed according to the manufacturer’s protocol. Un-complexed 
ODNs mixed to the culture medium represented the negative control (control). The 
images show fluorescent ODN molecules transfected into cancer cells proportionated to 
the G(IIKK)3I-NH2 / FAM-ODN charge ratio changes. Hoechst 33342 (2 µg/ml) (blue) 
was used as nuclear staining. FAM-labelled ODN in green. Bar = 25 µm. All images are 
scaled to the same size. 
 
Figure 32 shows a similar result to A9K, as G(IIKK)3I-NH2 can bind DNA molecules 
and carry them inside cells. Most cells contain several green puncta in each image and 
the amount of fluorescent DNA seemed to be consistent with increasing peptide ratios, 
especially at the 3/1 ratio. Unlike A9K (Figure 2 in Chapter 3) where high ratios had the 
tendency in producing clumps, with G(IIKK)3I-NH2 this phenomenon was not 
observed. Nevertheless, when G(IIKK)3I-NH2 transfection efficiency is compared with 
the Oligofectamine transfection control, it is possible to observe that none of the 
peptide/ODN complexes are located in the nuclei. This suggests that this peptide, like 
A9K, is not able to efficiently cross the nuclear membrane.  
 
As previously assessed with A9K, (Figure 5 in Chapter 3), it was important to determine 
the peptide efficiency in transfecting different cell lines, including non-cancer cell types 
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in order to evaluate possible selectivity toward a specific cellular type, G(IIKK)3I-NH2 
was complexed with FAM-labelled ODNs and transfected in primary cultures of HDFs. 
In Figure 33 only few green puncta can be observed, even at the highest peptide ratio, 
suggesting that almost none of the FAM-ODN complexed with G(IIKK)3I-NH2 crossed 
the fibroblasts’ plasma membrane. Contrary to this, the positive control showed highly 
transfected cells with green fluorescence mainly visible in the cytoplasmic environment. 
 
 
Figure 33. G(IIKK)3I-NH2 efficiency in delivery of fluorescently labelled ODNs 
into a non-cancer cell line. HDFs were transfected for 24 hrs with 0.05 µg of FAM-
ODNs (corresponding to 1.6 µM) and increasing charge/ratios of G(IIKK)3I-NH2. 
Oligofectamine was used as positive control (oligofect), while un-complexed ODNs 
mixed to the culture medium represented the negative control (control). The images 
show the transfection rate of G(IIKK)3I-NH2 in a normal (not-cancer) cell line: the 
peptide showed poor transfection efficiency at every tested ratio and very few green 
puncta can be seen in the cells. Hoechst 33342 (2 µg/ml) (blue) was used as nuclear 
staining. FAM-labelled ODNs in green. Bar = 25 µm. All the images are scaled at the 
same size. 
 
ODNs mainly work in the nucleus, and so to test if a cytoplasmic functioning molecule 
could be used in conjunction with G(IIKK)3I-NH2, siRNAs were tested. The ability of 
G(IIKK)3I-NH2 transfection in both cancer and non-cancer cell lines was evaluated. 
siGLO red fluorescent indicator (Dharmacon) was chosen as siRNA molecule to be 
transfected into cells. Experiments were conducted on A431 and HCT-116, both cancer 
cell lines and HDFs as normal, not cancerous cells. Transfection using DharmaFECT1 
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(DF1), commercial reagent, was considered as positive control while the addition of un-
complexed siGLO molecules to the cells was considered as negative control.  
In Figure 34 there are representative images of A431 cells transfected with 75 nM of 
siGLO with progressively higher ratios of G(IIKK)3I-NH2. The amount of red 
fluorescent siRNA molecules localised in the cells showed that the alpha helical peptide 
can transfect cells well, when compared to the positive control. Moreover, the 
internalisation of peptide/siRNA complexes does not depend on the charge ratios and all 
the tested concentrations show compatible levels of transfection. 
 
 
Figure 34. G(IIKK)3I-NH2 efficiency in delivery of fluorescently labelled siRNA 
molecules into epithelial cancer cells. A431 cancer cells were transfected for 24 hrs 
with 75 nM of siGLO, red fluorescent indicator (Dharmacon) and increased 
charge/ratios of G(IIKK)3I-NH2. DharmaFECT1 was used as positive control (DF1), 
while un-complexed siGLO mixed to the culture medium represented the negative 
control (control). The amount of fluorescent siRNA (red) is consistent in all the peptide 
/ siGLO ratios and when compared to DF1, the transfection efficiency of G(IIKK)3I-
NH2 appears greater. Hoechst 33342 (2 µg/ml) (blue) was used as nuclear staining. Bar 
= 25 µm. All the images are scaled at the same size. 
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A similar outcome to the A431 experiment is observed for the experiment conducted on 
HCT-116 colon cancer cells (Figure 35), with the vast majority of cells showing many 
red puncta, indicating that a reasonable amount of siRNA had been internalised. Again, 
the siRNA transfection ability does not seem to be related to the peptide ratios. 
Moreover, for this cell line the transfection efficiencies of peptide and DF1 could be 
comparable. This result was also important in determining the peptide ability in 
transfecting colon cancer cells prior use to for 3D cancer models (see the section 4.1.4 
Evaluation of G(IIKK)3I-NH2 transfection efficiency in a 3D cancer cellular model  of 
this chapter). 
 
 
Figure 35. G(IIKK)3I-NH2 efficiency in delivery of fluorescently labelled siRNA 
molecules into colon cancer cells. HCT-116 cells were transfected for 24 hrs with 75 
nM of siGLO, (red) and increased charge/ratios of G(IIKK)3I-NH2. DharmaFECT1 was 
used as positive control (DF1), while un-complexed siGLO mixed to the culture 
medium represented the negative control (control). The amount of fluorescent siRNA 
(red) is consistent in all the peptide and DF1 experiments. Hoechst 33342 (2 µg/ml) 
(blue) was used as the nuclear staining. Bar = 25 µm. All the images are scaled at the 
same size. 
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Figure 36. G(IIKK)3I-NH2 efficiency in delivery of fluorescently labelled siRNA 
molecules into a non-cancer cell line. HDFs primary cells were transfected for 24 hrs 
with of 75 nM of siGLO (red) with increasing charge/ratios of G(IIKK)3I-NH2. 
DharmaFECT1 was used as positive control (DF1) and un-complexed siGLO mixed to 
the culture medium represented the negative control (control). Images show the poor 
efficiency of G(IIKK)3I-NH2 in transfecting fibroblasts with siRNA molecules, 
especially when compared to the commercial transfection reagent DF1. Hoechst 33342 
(2 µg/ml) (blue) was used as nuclear staining. Bar = 25 µm. All the images are scaled at 
the same size. 
 
When testing normal, non-cancerous cells, with G(IIKK)3I-NH2 used to transfect the 
fibroblasts the results showed a poor siRNA internalisation, with red staining probably 
in between cells (Figure 36). For every tested peptide ratio, there were few, if any, red 
puncta, compared to the positive control, where there was an efficient rate of 
transfection.  
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4.1.2 Cell selectivity of G(IIKK)3I-NH2 in a co-cultured system  
 
The experiments described in the previous sections showed how G(IIKK)3I-NH2 has a 
preference in transfecting cancer cells, compared to normal ones. To further evaluate the 
peptide ability in targeting and transfecting cancer cells, a co-culture system was 
prepared, in which HCT-116 colon cancer cells and HDFs primary fibroblasts were 
seeded together in a 96 well plate. The two cell lines were simultaneously transfected 
with 50 nM of siGLO using the commercial DF1 or 3 different ratios of peptide. Un-
complexed siRNA molecules were added to the cell medium to represent the negative 
control. Images were acquired using the IN Cell Analyzer 2200 microscope with 40x 
objective. The results are shown in Figure 37, in which images were acquired using the 
bright field mode to better visualise the cell boundaries and consequently discriminate 
the cell types (HCT-116 or HDFs). DAPI (blue) and CY3 (red) channels were used 
instead to image the cell nuclei and the siGLO puncta, respectively. Fibroblasts could be 
easily identified due to their elongated shape, their larger nuclei and the presence of 
more cytoplasm. The colon cancer cells instead appeared clustered in colonies with 
small amount of cytoplasm and generally with a rounder morphology. Because this 
experiment was performed with the intent of evaluate the transfection efficiency of the 
alpha-helical peptide when compared to DF1, the distribution of the red fluorescent 
siGLO was carefully estimated. The merged images of bright field and fluorescent 
filters enabled the distinguishing of the siRNA molecules localisation within the two 
cell lines. When the transfection was made using DF1, an even distribution of red 
siGLO among both cells types (HCT-116 and HDFs) was observed while, when the 
G(IIKK)3I-NH2 was used as complexing agent, the fluorescent siRNA was mainly 
associated with HCT-116 cells. The outcome of this experiment confirmed that 
G(IIKK)3I-NH2 has a peculiar selectivity for cancer cells even when cultured together 
with other cell types.  
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Figure 37. G(IIKK)3I-NH2 delivery of fluorescently labelled siRNA molecules into 
a co-cultured system. HCT-116 cancer cells and HDFs primary were cells co-cultured 
together and simultaneously transfected for 24 hrs with 50 nM of siGLO (red) and 
increasing charge/ratios of G(IIKK)3I-NH2. DharmaFECT1 was used as positive control 
(DF1), while un-complexed siGLO (red) mixed to the culture medium represented the 
negative control (control). Images were acquired in bright field or fluorescent modes. 
The black arrows indicate the fibroblasts while the last column of images represents a 
magnification of the cells in the black squares. Hoechst 33342 (2 µg/ml) (blue) was 
used as nuclear staining. Bar = 25 µm. All the images are scaled at the same size. 
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4.1.3 A study of FITC labelled G(IIKK)3I-NH2 to determine co-
localisation  
 
A version of G(IIKK)3I-NH2, labelled with the FITC was synthesised with the aim of 
visualising the peptide with siRNA once internalised by the cells.  
 
Both HCT-116 and HDFs cells were transfected independently with 50 nM of red 
siGLO using the fluorescent FITC-G(IIKK)3I-NH2 and following the same procedure 
applied to the other transfection experiments. Figure 38 shows the results achieved; 
similarly to the non-labelled version of the peptide, FITC-G(IIKK)3I-NH2 preferably 
targeted and transfected mainly HCT-116 cells, while DF1 was not so selective and 
equally amounts of red fluorescent puncta (siGLO) were observed in both cell types. 
Because of FITC-G(IIKK)3I-NH2 fluorescence, it was finally possible to observe the 
presence of both peptide and siRNA molecules in the transfected cells. This remarkable 
feature unequivocally confirmed the peptide ability in binding and transfecting siRNA 
molecules into cells. Moreover, the peptide/siRNA complexes, when co-localised in the 
same cellular compartment, appeared as yellow puncta, as consequence of the 
fluorescent green and red signals overlapping. The presence of few red puncta also 
suggested that, once the complexes are internalised, the peptide can release its cargoes 
allowing the modulation of gene expression mediated by the RNAi pathway. To better 
visualise fluorescence of the peptide in the co-localised complexes, a higher ratio (24/1) 
was used. At this ratio, even in some HDFs few yellow puncta could be observed.  
 
It is important to underline that the cells, following the transfection procedure, did not 
show any toxicity signs, even at the highest used ratio 24/1 (1.2 μM of peptide 
complexed with 50 nM of siRNA). This because the concentrations of peptide 
employed for transfection were always below the toxic range identified with the cell 
counting assay and showed in Figure 45 (IC50 60 μM). 
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Figure 38. Subcellular co-localisation of internalised siRNA molecules and 
fluorescently labelled G(IIKK)3I-NH2. HCT-116 colon cancer cells and HDFs 
primary cells were transfected for 24 hrs with 50 nM of siGLO (red) and two different 
charge/ratios of FITC-G(IIKK)3I-NH2 (green). In the images it is noticeable that there is 
an overlap of the red and green fluorescent signals, indicating co-localisation. 
DharmaFECT1 was used as positive control (DF1), while un-complexed siGLO mixed 
to the culture medium represented the negative control (control). Hoechst 33342 (2 
µg/ml) (blue) was used as nuclear stain. Bar = 25 µm. All the images are scaled at the 
same size. 
 
4.1.4 Evaluation of G(IIKK)3I-NH2 transfection efficiency in a 3D 
cancer cellular model  
 
The siRNA transfection efficiency of G(IIKK)3I-NH2 was evaluated in a 3D culture 
system, making it more relevant than 2D 134. Generally, one of the most important 
qualities that a cancer treatment should have is a good level of tumour penetration. Cells 
situated in the centre of solid tumours are normally hypoxic and, as evidence suggests, 
not only are they resistant to radiation treatment, but they possess regenerative 
properties, even after intense chemotherapy 217. Therefore, if a cancer therapy is unable 
to reach all the cells in a solid tumour, treatment efficacy is jeopardised 189.  
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To evaluate the ability of G(IIKK)3I-NH2 to penetrate solid tumours, and its possible 
role as a carrier for drug or gene delivery, 3D spheroids of A431 were initially tested. 
Previously the cell line had been transfected with siRNA molecules (Figure 34). 3D 
spheroids were generated using ultra-low attachment well plates. Unfortunately, despite 
reports that A431 were a good spheroid model, the preliminary observation under the 
wide-field microscope revealed that the these spheroids were extremely fragile, with 
irregular shapes 191. HCT-116 cells were selected for experimentation and 3D spheroids 
were created 192, 193. 
 
Images of spheroids were acquired using the ImageXpress® Micro System wide-field 
fluorescent microscope and the Zeiss Lightsheet Z.1 microscope with 2x objectives 
lenses. Following acquisition, wide-field and light-sheet images were further analysed 
using the MetaXpress® 5.0.0.20 and the ZEN 2014 SP1 (Zeiss) software, respectively. 
Brightness and contrast were ultimately adjusted for all images to the same level using 
Image J. In Figure 39 it is possible to observe images of several spheroids from both 
cell lines transfected with 75 nM of red siGLO using DharmaFECT1 or different 
peptide ratios (2/1 or 5/1). Un-complexed siGLO was mixed with the culture medium 
and directly exposed to the cells representing the negative control. A431 spheroids were 
asymmetrical and differently sized, while HCT-116 spheroids were compact, spherical 
and with an average size of 600-800 µM. 
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Figure 39. G(IIKK)3I-NH2 efficiency in delivery of fluorescently labelled siRNA 
molecules into 3D cancer models. A431 or HCT-116 3D spheroids transfected for 24 
hrs with 75 nM of siGLO, red fluorescent indicator (Dharmacon) using G(IIKK)3I-NH2 
peptide at different ratios. DharmFECT1 transfection was used as positive control 
(DF1), while un-complexed siGLO (red) mixed to the culture medium represented the 
negative control (control). Transfection performed using the G(IIKK)3I-NH2 appears 
more successful in deeply penetrating the central cores of the spheroids. Hoechst 33342 
(2 µg/ml) (blue) was used as nuclear staining. Bar = 250 µm. All the images are scaled 
at the same size. 
 
The main visible difference between transfections made with DF1 or with G(IIKK)3I-
NH2 was the distribution of the red fluorescent siRNA molecules. When DF1 was used, 
the vast majority of red signal was located on the outer layer of the spheroidal mass and 
very little could be detected in the middle part. When the peptide was used, most of the 
fluorescent siRNAs were concentrated in the centre of the spheroids. Unfortunately, 
these images do not clarify the exact location of the red puncta due to the lack three-
dimensionality.  
 
To obtain better quality images in 3D, light-sheet-based fluorescence microscopy 
(LSFM) was used. This innovative technique allows not only to penetrate deep into the 
specimen with high imaging speed and ultra-low intensity light excitation, but also to 
acquire multiple stacks of the same sample, creating, with a dedicated software, 
exhaustive three-dimensional reconstructions 194.  
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Figure 40. Light-sheet microscopy to evaluate the penetration of G(IIKK)3I-NH2 in 
3D cancer models. Light-sheet images of HCT-116 spheroids transfected for 24 hrs 
with 75 nM of siGLO using DharmaFECT1 (DF1) (a) or G(IIKK)3I-NH2 at 2/1 ratio 
(b). The first image on top left corners in the left panels are 3D reconstructions showing 
the complete spheroids shape, while the others, in the same panel, represent sagittal 
views with combined or separated DAPI (blue nuclei) and CY3 (red siRNA) channels 
showing the difference distribution of the red fluorescent siRNA within the spheroid 
body. In the right panels, orthogonal views of the same spheroids show the location of 
the red siGLO in xyz planes. Hoechst 33342 (2 µg/ml) (blue) was used as nuclear 
staining. Bar = 250 µm. All the images are scaled at the same size. 
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Figure 40 shows, not only the 3D reconstruction of HCT-116 spheroids (top left corner, 
left side panels), but the distribution of the fluorescent siRNA molecules. The ZEN 
2014 SP1 (Zeiss) software was used to create the 3D reconstructions and the spheroid 
orthogonal views with distinct xyz planes where the blue, red and green lines display 
the localisation of single red spots in the xyz spatial distribution. In the sagittal and 
orthogonal planes it is possible to observe the localisation of the fluorescent siRNA 
molecules. These image sets clearly show DF1 was unable to deeply transfect the 
spheroid, with the siGLO exclusively concentrated on the outer surface, while the 
peptide was able to reach deep into the spheroid where many red puncta are centrally 
located.  
 
4.1.5 Functional siRNAs transfection 
 
All the transfection experiments described in the previous sections used a non-targeting 
siRNA (siGLO), which has been really useful for visualisation purposes, but does not 
tell us anything about the efficiency of G(IIKK)3I-NH2 in releasing siRNA molecules to 
functionally knock down gene expression once internalized into the cellular 
environment. Therefore, to evaluate the effectiveness of the peptide in modulating gene 
expression through RNAi, two functional siRNAs were selected as cargoes. ECT2 
(Epithelial Cell Transforming 2 oncogene) and PLK1 (Polo-Like Kinase 1), which both 
can decrease cellular growth, were selected for transfection in A431 and HCT-116 
cancer cells. If the cargo of siRNA is correctly released and incorporated into the RISC 
machinery, then the cells should undergo either apoptosis or an arrest of the cell cycle 
and therefore a substantial decrease in the cell number would be detected.  
ECT2 siRNA was transfected in A431 cells using G(IIKK)3I-NH2 while PLK1 was used 
on HCT-116 using the fluorescently labelled peptide FITC-G(IIKK)3I-NH2. ECT2 is a 
protein largely localised in the nucleus of interphasic cells and it is responsible, among 
many things, for cell cycle progression and cytokinesis. Over-expression of ECT2 is 
believed to potentiate tumorigenesis via activating small GTPases such as Rho, Rac and 
Ras and elevated levels are often found in several types of human tumours 218, 219. 
Moreover, the knock down of ECT2 via RNAi should provoke a decrease of the cellular 
population 220.  
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30 nM of siRNA together with peptides at different ratios were added to a plate and left 
to complex for 30 minutes. Afterwards, cells diluted in media lacking antibiotics were 
added and left incubate to for three days. Transfection using DharmaFECT1 (DF1) was 
used as positive control while un-complexed siRNAs diluted in the culture medium or 
transfection using the non-targeting red fluorescent siGLO were considered the negative 
control. MetaXpress® software was used to count the number of cells in each well and 
data normalised to the relative negative controls.  
 
 
Figure 41. siRNA delivery and knock down efficiency of G(IIKK)3I-NH2 on A431 
cells. 30 nM of ECT2 siRNA were complexed with G(IIKK)3I-NH2 and then transfected 
in A431 cells. To allow a complete knock down of ECT2 via RNAi the cells were left in 
the transfection medium (DF1 or peptide) for a total of 72 hrs, then fixed in 
formaldehyde and stained with Hoechst 3342 (2 µg/ml) to visualise the nuclei. Cell 
number was evaluated through nuclei counting using MetaXpress with the Multi 
Wavelength Scoring algorithm and the 2x objective. The results are expressed as a 
percentage and normalised to the negative control (exposure to the naked ECT2 
siRNA). Different ratios of peptide to ECT2 siRNA are shown on the bar-chart. The 
transfection reagent DharmaFECT1 (DF1) was used as positive control, showing a 
reasonable degree of knock down. With the exception of 0.5/1, the other peptide ratios 
showed a significant decrease in cell number consistent with a successful gene knock 
down. The values obtained are the average of different experiments ± standard error 
mean (±SEM). Statistically significant difference from the negative control was 
determined by Student’s t-test (*p<0.05; **p<0.01; ***p<0.001). 
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The number of A431 cells in each experimental condition were imaged and counted. 
The data were then normalised to the negative control (cells exposed to un-complexed 
ECT2 siRNA) and represented as a percentage. Transfection using DF1 was considered 
as the positive control. From Figure 41, DF1 was effective in transfecting the siRNA 
and a significant reduction in cell number was observed (75% less cells counted than 
the negative control). Furthermore, G(IIKK)3I-NH2 could reduce the cell number in the 
assay and successfully deliver the siRNA molecules in ratios from 1/1 to 5/1 and could 
transfect and release enough siRNA inside the cells to significantly reduce the cell 
number to ~50%. There was an exception to this, where for the lowest ratio (0.5/1) only 
a 10% reduction was observed. 
 
To test if this effect could be seen on other cells, HCT-116 were tested. The graph in 
Figure 42 shows the data collected from the transfection of PLK1 siRNA using DF1 or 
FITC-G(IIKK)3-NH2 on HCT-116 colon cancer cells. The Polo-like kinase proteins 
family are critically essential for the cell cycle homeostasis, controlling centriole 
duplication, mitosis, cytokinesis and the DNA damage response 221, and any variations 
occurring in their expression could lead to tumorigenic events. PLK1, as part of this 
family, is crucial to maintaining the normal mitosis and when overexpressed is often 
used as a prognostic marker for several human cancers 222. For this reason, PLK1 
inhibition is sometimes a target for cancer therapies and new drugs have been developed 
showing encouraging results in early-phase clinical trials, such as volasertib (BI 6727) 
in patients with acute myeloid leukaemia (AML) 223. When PLK1 is knocked-down in 
cancer cells using RNAi a significant reduction in the cell number population is 
observed, with an increasing rate of cells arrested in G2/M phase and evidence of many 
apoptotic nuclei 137.  
 
The data obtained with the transfection experiment is expressed in graphic form in 
Figure 42. The negative control, from which all the data was normalised, was 
represented with the non-functional red fluorescent siGLO. DF1 was used as positive 
control as per usual and it significantly decreased the cell population by 65%. FITC- 
G(IIKK)3-NH2 transfection efficiency was even more successful, and at every ratio 
tested the number of cells dramatically dropped down to more than 80% of the control.  
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Figure 42. siRNA delivery and knock down efficiency of FITC-G(IIKK)3I-NH2 on 
HCT-116 cells. 30 nM of PLK1 siRNA were complexed with FITC-G(IIKK)3I-NH2 
and then transfected in HCT-116 cells. To allow a complete knock-down of PLK1 via 
RNAi, the cells were left in the transfection medium (DF1 or peptide) for a total of 72 
hrs, then fixed in formaldehyde and stained with Hoechst 3342 (2 µg/ml) to visualise 
the nuclei. Cell number was evaluated with nuclei counting using MetaXpress with 
Multi Wavelength Scoring algorithm and 2x objective. The results are expressed as 
percentage normalised to the negative control (transfection with siGLO). Different 
ratios of peptide to PLK1 siRNA are shown on the bar chart. All the tested peptide 
ratios showed a significant variation in cell population consistent with a successful gene 
knock-down. The transfection using DharmaFECT1 (DF1) was considered as a positive 
control and showed a reasonable degree of knock-down. The values obtained are the 
average of different experiments ± standard error mean (±SEM). Statistically significant 
difference from the negative control was determined by Student’s t-test (***p<0.001). 
To visually compare the differences between the peptide and DF1 transfections, images 
of each tested condition were acquired with the wide-field microscope and the 20x 
objective (Figure 43). Some cells were exposed to the highest FITC-G(IIKK)3-NH2 
concentration used to form complexes with siRNA (300 nM in the 10/1 ratio). This was 
important to ensure that this amount of peptide did not compromise the cell viability but 
could be safely used for transfection purposes. Cells following peptide exposure were 
counted and compared to the negative control. The results confirmed the absence of 
toxicity (103%) of cells counted compared to the negative control, data not showed). 
Transfection of PLK1 siRNA causes apoptosis in cancer cells 137 and the cellular 
phenotypes observed after both DF1 and FITC-G(IIKK)3I-NH2 transfections were 
compatible with apoptotic events. Interestingly, the presence of the fluorescent peptide 
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is visible when the highest ratio (10/1 ratio) was used. This is noticeable not only with 
siGLO (yellow puncta) but also in PLK1 siRNA transfection. 
 
 
Figure 43. Knock down efficiency of DF1 and FITC-G(IIKK)3I-NH2 on colon 
cancer cells. 30 nM of PLK1 or red fluorescent siGLO were complexed with three 
different ratios of FITC-G(IIKK)3I-NH2 (green) and then transfected in HCT-116 cells. 
DharmaFECT1 (DF1) was used as positive control. In the first image in the top left 
corner are cells exposed to 300 nM of peptide (maximum peptide concentration used in 
the experiment). PLK1 knock down using RNAi causes apoptotic events in cells whose 
phenotype can be recognised in the images of PLK1 transfection using both DF1 and 
the peptide, confirming the data of the decrease in cell number shown in the graph in 
Figure 42. Hoechst 33342 (2 µg/ml) (blue) was used as nuclear staining. Bar = 25 µm. 
All the images are scaled at the same size.  
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These preliminary results suggest that G(IIKK)3I-NH2 could be used as possible vector 
for transfection, especially after the promising data obtained with functional siRNAs 
experiments.  
 
 
4.2 Toxicity and phalloidin staining 
 
Previous published works showed that G(IIKK)3I-NH2 is quite effective in inhibiting 
cancer cell growth (IC50 values for HeLa and HL 60 being respectively 15 and 25 µM) 
but at the same time well tolerated by normal mammalian cells (fibroblasts were only 
slightly affected by the peptide exposure for concentrations up to 100 µM) 117, 118.  
The inhibitory effects of G(IIKK)3I-NH2 and FITC-G(IIKK)3I-NH2 were analysed on 
HCT-116 and HDFs cell lines. A range of concentrations was used (from 6.25 to 100 
µM) for 24, 48 or 72 hrs of exposure time. Both peptides were compared, as it was 
important to establish if the relation between peptide and cells was somehow changing 
due to the presence of the fluorophore FITC. Moreover, the location of FITC-
G(IIKK)3I-NH2, could be tracked in both HCT-116 and HDFs using Alexa Fluor® 568 
Phalloidin, a dye that binds actin filaments in the cytoplasm, allowing cellular shape to 
be defined 37. 
 
4.2.1 Cell counting assay as evaluation of peptide toxic effect 
 
Cells were seeded and treated with peptides and fixed in formaldehyde, stained with 
Hoechst 3342 (2 µg/ml) and the nuclei of each experimental point counted and 
normalised to the relative negative control (untreated cells). The assessment of possible 
cellular toxicity was evaluated using MetaXpress software and the dedicated algorithm 
able to recognize cellular nuclei when stained with Dapi (or Hoechst). Na2CrO4, a 
potent toxic and carcinogenic compound 209, 210 was used as positive control and caused 
a significant decrease in cell number on both cell lines and at every time point (Table 3).  
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Table 3. HCT-116 and HDFs cell number evaluated with high-content microscopy 
after exposure to sodium chromate (Na2CrO4). The results are expressed as a 
percentage and normalized to the negative control at that relative time point. 
Cell counting after 200 μM of Na2CrO4 exposure (%) 
 
 HCT-116 HDFs 
24 hrs 20 26 
48 hrs 2 21 
72hrs 2 15 
 
 
Figure 44. HCT-116 and HDFs cell number evaluated with high-content 
microscopy after exposure to G(IIKK)3I-NH2. HCT-116 (a) or HDFs (b) cells were 
incubated for one, two or three days with increasing concentrations of G(IIKK)3I-NH2, 
fixed in formaldehyde and stain with Hoechst 3342 (2 µg/ml) to reveal the nuclei. Cell 
number was evaluated with nuclei staining analysis using the MetaXpress with the 
Multi Wavelength Scoring algorithm and 2x objective. The results are expressed as a 
percentage of number of cells and normalized to the negative control at that relative 
time point. The values obtained are averages of three independent experiments ± 
standard error mean (±SEM). Na2CrO4, 200 µM has been used as positive control (data 
showed in Table 3) while water has been used as negative control (0). Statistically 
significant difference from the negative control was determined by Student’s t-test 
(*p<0.05; **p<0.01; ***p<0.001). 
 
Figure 44 represents the relative cell numbers for HCT-116 (a) and HDFs (b) to 
untreated samples. For the fibroblasts G(IIKK)3I-NH2 did not have an inhibitory effect 
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on the cellular growth at any of the tested concentrations and exposure times, while the 
colon cancer cells showed sensitivity towards the peptide.  
 
The exposure to FITC-G(IIKK)3I-NH2 gave slightly different results; while the cancer 
cells responded in a comparable way to the unlabelled one, the fibroblasts appeared to 
be more sensitive to this new peptide, especially at the highest concentration (100 µM). 
Figure 45 shows the results obtained after the cell counting. The overall toxicity 
observed for HCT-116 is perfectly comparable with the data of Figure 44. For example, 
100 µM of FITC-G(IIKK)3I-NH2 caused a decrease in cell number of 84%, which is the 
same as the non-fluorescent peptide. On fibroblasts the same concentration caused a 
reduction of 63% while with the G(IIKK)3I-NH2 it was only 13%. 
 
 
Figure 45. HCT-116 and HDFs cell number evaluated with high-content 
microscopy after exposure to FITC-G(IIKK)3I-NH2. HCT-116 or HDFs cells were 
incubated for one day with increasing concentrations of FITC-G(IIKK)3I-NH2, fixed in 
formaldehyde and stained with Hoechst 3342 (2 µg/ml) to reveal the nuclei. Cell 
number was evaluated with nuclei staining analysis using the MetaXpress with the 
Multi Wavelength Scoring algorithm and 2x objective. The results are expressed as a 
percentage of number of cells and normalized to the negative control at that relative 
time point. The values obtained are averages of three independent experiments ± 
standard error mean (±SEM). Na2CrO4, 200 µM has been used as positive control (data 
not showed) while water has been used as negative control (0). Statistically significant 
difference from the negative control was determined by Student’s t-test (*p<0.05; 
**p<0.01; ***p<0.001). 
  
131 
 
Using GraphPad, the inhibitory concentration (IC50), corresponding to the concentration 
of peptide needed to induce cellular growth inhibition of 50%, was calculated. Against 
HCT-116 colon cancer cells, G(IIKK)3I-NH2 had an IC50 of 56, 50 and 43 µM after 24, 
48 and 72 hrs exposure, respectively. The peptide proved ineffective towards HDFs in 
the range of tested concentrations and no IC50 could be extrapolated. The IC50 of FITC-
G(IIKK)3I-NH2 after 24 hrs exposure was 60 µM for the colon cancer cells and 
therefore perfectly comparable with the non-fluorescent peptide at the same conditions. 
FITC-G(IIKK)3I-NH2 induced toxicity also in fibroblasts and the correspondent IC50 
was 86 µM. 
 
It is important to underline that despite showing a certain level of toxicity, both 
G(IIKK)3I-NH2 and FITC-G(IIKK)3I-NH2 were perfectly safe to use in gene delivery 
experiments. This is because the highest concentrations used for transfection of either 
ODN and siRNA were always several folds below the peptides IC50 values. For 
example, the range of G(IIKK)3I-NH2 used in ODNs transfection experiments varied 
between 160 nM and 4.8 μM while for siRNA transfection the range was even lower; 
between 25 nM to 375 nM. For siRNA transfection using FITC-G(IIKK)3I-NH2 the 
concentration range was between 30 nM and 1.2 μM. Moreover, when functional 
siRNAs were transfected into cells only small amounts of peptides were employed and 
the maximum concentrations used were 150 and 300 nM for G(IIKK)3I-NH2 and FITC-
G(IIKK)3I-NH2, respectively. 
 
4.2.2 Phalloidin staining to enhance the cellular boundaries 
 
To have a more precise subcellular localisation of the peptide within the cells, Alexa 
Fluor® 568 Phalloidin was used; a fluorescent dye which allows one to distinguish the 
cell shape and enhances its morphology. Phalloidin is a natural toxin that belongs to the 
class of phallotoxins, found in the death cap mushroom species Amanita phalloides. It 
naturally binds filamentous-actin (F-actin) and prevents its depolymerisation, ultimately 
causing cell death. Because of its affinity for F-actin, phalloidin, conjugated with 
various fluorophores, is widely used in imaging applications to selectively fluorescently 
label actin 36, 37, 224, 225.  
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Both HCT-116 and HDFs were exposed for 24 hrs to various concentrations of FITC-
G(IIKK)3I-NH2. Once fixed in formaldehyde they were stained with Hoechst 3342 (2 
µg/ml) to enhance the nuclei and with 150 nM of Alexa Fluor® 568 Phalloidin, which 
gave a bright red fluorescence to the actin filaments. Images were acquired using the 
ImageXpress® Micro System wide-field fluorescent microscope with 20x objective 
lenses. Following acquisition, the images were further analysed using MetaXpress® 
5.0.0.20 software. Brightness and contrast were ultimately adjusted for all the images to 
the same level by using Image J. To avoid confluency, which would have decreased the 
imaging quality of the cellular boundaries and structures, cells were seeded at low 
density. In this way, it was possible to capture only one or a few single cells per field 
with well-defined borders.  
 
Figure 46 shows images of HCT-116 or HDFs after Alexa Fluor® 568 Phalloidin 
staining. Interestingly, it was observed with mitotic cells that most of the FITC 
fluorescence was outside, surrounding the plasma membrane and the peptide was not 
internalised (yellow circled cells in 12.5 and 25 µM pictures). It has been shown that 
during the early mitotic phases, endocytosis is inhibited 226. Therefore, this evidence 
may suggest the possibility of an active mechanism being involved in peptide uptake. 
Current understanding suggests the mechanism of internalisation is through rapid 
binding to cancer cell membranes and the subsequent membrane permeabilization 118. 
The fibroblasts, in contrast, showed localised FITC-G(IIKK)3I-NH2 sometimes on the 
plasma membrane and occasionally internalised. This is true especially at higher 
concentrations of peptide (25-50 µM). 
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Figure 46. HCT-116 and HDFs phalloidin staining evaluated with high-content 
microscopy after exposure to FITC-G(IIKK)3I-NH2. HCT-116 (a) or HDFs (b) cells 
were incubated for one day with increasing concentrations of FITC-G(IIKK)3I-NH2 
(green) and stained with Hoechst 3342 (2 µg/ml) (blue) and 150 nM of Alexa Fluor® 
568 Phalloidin (red). The yellow circles show cells in mitosis with peptide molecules 
surrounding the plasma membranes. The control is represented by untreated cells.      
Bar = 25 µm. All the images are scaled at the same size. 
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50 µM of FITC-G(IIKK)3I-NH2 changed both cell shape and nuclear morphology in 
both cell lines (Figure 47). The peptide concentrated to the nuclear area and the F-actin 
filaments appeared condensed and damaged. The nuclear Hoechst stain was intense and 
nuclei were smaller, suggesting the cells were possibly dying via apoptosis 227. The 
toxic effect caused by 50 µM of peptide could be related to the reduced seeded cell 
number used to perform the experiment and the consequent higher peptide/cell ratio 228. 
 
 
Figure 47. HCT-116 and HDFs cells exposed to 50 µM of FITC-G(IIKK)3I-NH2. 
HCT-116 or HDFs cells were incubated for one day with 50 µM of FITC-G(IIKK)3I-
NH2 (green) and stained with Hoechst 3342 (2 µg/ml) (blue) and 150 nM of Alexa 
Fluor® 568 Phalloidin (red). In these images, the three fluorescent channels were 
separated to show the destruction of cellular structures and the peptide distribution.   
Bar = 25 µm. All the images are scaled at the same size.  
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4.3 Electron microscopy explores the effects and interaction of 
FITC-G(IIKK)3I-NH2 with cancer cells    
 
To understand in more detail what is happening at the subcellular level higher resolution 
of imaging of HCT-116 cancer cells exposed to FITC-G(IIKK)3-NH2 would be better. A 
scanning electron microscope (SEM) and a transmission electron microscope (TEM) 
were used to understand more about membrane morphology and localisation of the 
peptide. With these two techniques it is possible to acquire images using a focused 
electron beam as “light source” which, having lower wavelength, allows one to get 
resolutions a thousand times better than a standard light microscope.  
 
SEM provides information regarding the surface morphology and composition of a 
specimen, normally scanning the top 1 µm and without destroying the sample in the 
process, with a resolution in the order of nanometres 229, 230. TEM works with an 
electron beam at high energy, which travels across a column where a vacuum is created 
and hits an ultra-thin specimen section (usually less than 100 nm). When they hit the 
sample, the electrons can be scattered and consequently disappear from the beam, or 
stay un-scattered. At the end of the microscope there is a fluorescent screen able to 
capture the un-scattered electrons. From the screen, images of the various areas of the 
sample can be created, and depending on their density they will appear as different 
shades of darkness 231. With this microscope it is possible to acquire extremely detailed 
structures, even in the order of few ångström. 
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4.3.1 SEM technique is a reliable instrument for studying cell 
membranes 
 
HCT-116 were exposed for 24 hrs to 0, 0.3, 6.25 or 100 µM of FITC-G(IIKK)3I-NH2 
then fixed in glutaraldehyde and dried in ethanol according to the protocol described in 
the Materials and Methods chapter. Once ready, the samples were mounted onto a pin-
stub and examined using the Philips XL-20 Scanning Electron Microscope at 15 kV. 
With this type of microscope, it was possible to observe any changes to the morphology 
of the membranes due to the peptide exposure. 
 
Figure 48 shows lower magnification images of untreated HCT-116 cells or exposed to 
FITC-G(IIKK)3I-NH2, to get a feeling for obvious differences between the 
concentrations. In normal healthy cells, the membranes are covered in thin actin plasma 
membrane protrusive structures called filopodia which are essentials for the cells to 
sense the nearby environment and have a crucial role in cell migration, adhesion, 
morphogenesis, endocytosis and phagocytosis. Cells were treated with different peptide 
concentrations: 0.3 µM (300 nM) the highest concentration used in the functional 
siRNA transfection experiments (Figure 43); 6.25 µM which gave only little toxicity to 
the cells (Figure 45) and 100 µM which drastically decreased the cell population (Figure 
45). Phenotypic changes of treated cells compared to the untreated sample were 
recorded. Figure 48 (a) shows images at 500X while (b) shows images at much higher 
magnification (2000X). Modifications were observed in cells treated with 0.3 or 6.25 
µM, while with 100 µM cells, not only were they reduced in number but also were 
completely modified in their membrane structure. In the control or 0.3, 6.25 µM sample 
cells appeared healthy and with their membranes enriched with many filopodia but cells 
exposed to 100 µM had their filamentous protrusions completely damaged and the 
membranes showed signs of deterioration. 
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Figure 48. SEM images showing the morphology of cancer cells following exposure 
to FITC-G(IIKK)3I-NH2. HCT-116 cancer were cells exposed for 24 hrs to different 
concentrations of FITC-G(IIKK)3I-NH2 and imaged using the SEM microscopy with. 
500X (a) or 2000X (b) of magnification. Untreated cells are the control. At 0.3 µM 
(highest concentration used for transfection experiments) and 6.25 µM cells kept their 
typical morphological structure and the membranes stayed covered in filopodia, 
protruding structures containing actin filaments essential for cellular adhesion and 
motility. At 100 µM, cell number is dramatically decreased and the morphology of the 
cells radically changed with a complete loss of filopodia and the cells had a sponge-like 
or porous phenotype. Bars = 50 µm for (a) and 10 µm for (b).  
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Progressively higher magnification images (Figure 49) of untreated control (a) and 100 
µM treated (b) cells were taken at 5000X, 10000X and 20000X. The difference between 
treated and untreated cells is impressive: the plasma membrane projections which 
usually cover the cells’ surface as numerous hair-like structures in (a) images are 
completely disappeared in (b) images, where the cells present an obvious “spongy” 
looking phenotype. It is unclear if the destruction of filopodia is a direct effect of the 
peptide interaction with the cell membranes or if it is an indirect consequence of the 
internalisation mechanism.  
 
 
Figure 49. Higher magnification SEM images showing changes in the plasma 
membrane morphology of cancer cells following exposure to FITC-G(IIKK)3I-
NH2. HCT-116 cancer were cells exposed for 24 hrs to 0 µM (a) or 100 µM (b) of 
FITC-G(IIKK)3I-NH2peptide and imaged using the SEM microscopy at progressively 
higher magnifications (5000X, 10000X, 20000X, top to bottom). Untreated cells were 
considered as control. Images show the differences in the membranes’ morphology of 
HCT-116 when treated with high concentration of peptide. Compared to normal healthy 
cells, the membranes of cells exposed to FITC-G(IIKK)3I-NH2lost all their filamentous 
protrusion and with the 20000X magnification it is even possible to observe in the 
cellular membrane structures similar to pores. Bars = 5 µm 2 µm and 1 µm, top to 
bottom. 
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4.3.1 Cellular localisation of FITC-G(IIKK)3I-NH2 in cancer cells using 
TEM  
 
Transmission Electron Microscopy (TEM) can be used to obtain high resolution images 
of biological internal structures such as mitochondria, endosomes or nuclei. TEM is 
several orders of magnitude better than from an optical or fluorescent microscope 231. 
 
To investigate the fate of internalised peptide molecules in cancer cells, TEM was used 
on cellular samples previously exposed to the peptide. HCT-116 cancer cells were 
therefore exposed to 6.25 µM of FITC-G(IIKK)3-NH2 peptide for 3 or 24 hrs, then fixed 
and embedded in resin. Ultra-thin sections of 85 nm thickness were cut using an 
ultramicrotome and mounted on an FEI Tecnai Transmission Electron Microscope at an 
accelerating voltage of 80 kV. To be able to localise the peptide in the samples with the 
transmission electron microscope, an antibody anti-FITC conjugated with 10 nm gold 
nanoparticles was used. Gold nanoparticles, due to their high electron density, can 
indeed be easily detected using TEM and visualised as dark spherical dots inside the 
cells. Gold nanoparticles are used in molecular cell imaging techniques and more 
recently in several cancer nanotechnology disciplines (molecular diagnosis and targeted 
therapy)  232-234.  
 
Despite my efforts, it was impossible to immunolabel the samples using the technique 
suggested by the manufacturer. The pre-and post-embedding protocols (pre-embedding 
protocol; post-embedding protocol), which describe how to incubate the samples with 
the antibody before or after the resin embedding, were both tested but the results yielded 
nothing, always with images without gold nanoparticles.  
For this reason, it was decided to directly combine the antibody with FITC-G(IIKK)3I-
NH2 and then administer to living cells. The rationale was that, if the peptide acted as a 
carrier for siRNA molecules then it could transport the antibody inside the cells. The 
antibody could be visualised using gold nanoparticles with TEM. Samples incubated 
with only the antibody were considered as negative controls. 
The images in Figure 50 show the result of 3 hrs incubation with the peptide. Panel (a) 
is for reference, where the cells were fixed and stained with Hoechst. The peptide 
location is represented with a green fluorescent signal, visible around the nuclei (A). In 
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B, there is an image of an untreated control cell (both antibody and peptide absent) and 
in C details of the plasma membrane where several filopodia are visible. Figure 50 (b) 
shows a cell exposed to a solution of anti-FITC antibodies labelled with gold 
nanoparticles (D-E). The absence of spherical black dots in the image suggests that the 
antibody was unable to cross the plasma membrane. Finally, (c) displays a series of 
images of a cell exposed to a solution of peptide and antibody (F-I). The yellow circles 
show gold nanoparticles visible as dark, electron dense spheres. These are found in 
large vesicles (red panel) or on the cell membranes (blue and green panels).  
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Figure 50. TEM images of cancer cells following 3 hrs exposure to FITC-
G(IIKK)3I-NH2 and anti-FITC antibody conjugated with 10 nm Au nanoparticles. 
HCT-116 cancer cells were exposed for 3 hours to 6.25 µM of FITC-G(IIKK)3I-
NH2complexed with a mouse monoclonal antibody anti-FITC conjugated with 10 nm 
Au nanoparticles (1/100 dilution) and then imaged using TEM. The antibody was used 
to label the peptide and localise it inside the cells. (a, A) Fluorescent image showing the 
presence of few peptide molecules internalised into the cells after 3 hours of peptide 
exposure (bar 25 µm). (a, B-C) TEM images of a control cell (not exposed to peptide or 
antibody) and a detail of its membrane. (b, D-E) TEM images of a cell exposed to the 
mouse antibody, showing no Au nanoparticles. (c, F-I) TEM sections showing cells 
exposed to FITC-G(IIKK)3I-NH2and anti-FITC antibody conjugated with 10 nm Au 
nanoparticles. Several Au nanoparticles (yellow circles) are visible in vesicles or in 
proximity to the plasma membrane. In the fluorescent image: Hoechst 33342 (2 µg/ml) 
(blue) was used as nuclear staining. FITC-G(IIKK)3I-NH2in green. Bars = 0.2, 0.5, 1 or 
2 µm. 
 
To determine if a longer exposure could reveal more particles, a 24-hour peptide 
incubation was applied (Figure 51). In panel (a) a series of control images can be 
observed; a live bright field image taken with the IN Cell Analyzer 2200 microscope 
and 10x objective with many cells displaying green fluorescence, as indication of 
correct peptide uptake, an untreated cell with a detailed zoom on its membrane and a 
picture showing a control cell membrane with 2 endocytic budding vesicles. In (b) the 
other control samples consist of a cell treated with antibody only. In the blue and red 
panel are detailed images of the cell membrane full of actin protrusion (filopodia), and 
an exosome (blue panel). In (c), a cell exposed to the peptide/antibody complexes shows 
several endocytic compartments full of gold nanoparticles (yellow circles). Some are 
more superficial (blue panel) and possibly represent early endosomes, some more are 
internally localised (red panel) which might be late endosomes. Finally, in (d) there is 
another cell exposed to peptide/antibody complexes, but in this case the cellular health 
is compromised and the membrane structures are falling apart. Many gold nanoparticles 
could be detected (yellow circles) in really big vesicles and it is possible that due to the 
massive peptide/antibody uptake, the cell is irreversibly damaged and it is dying.  
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Figure 51. TEM images of cancer cells following 24 hrs exposure to FITC-
G(IIKK)3I-NH2 and anti-FITC antibody conjugated with 10 nm Au nanoparticles. 
HCT-116 cancer cells were exposed for 24 hours to 6.25 µM of FITC-G(IIKK)3I-
NH2complexed with a mouse monoclonal antibody anti-FITC conjugated with 10 nm 
Au nanoparticles (1/100 dilution) and then imaged using TEM. The antibody was used 
to label the peptide and localise it inside the cells. (a, A) Live fluorescent bright field 
image showing the presence of many peptide molecules (green) internalised into the 
cells after 24 hours of peptide exposure (bar 100 µm). (a, B-C) TEM images of a control 
cell (not exposed to peptide or antibody), and details of its membrane. (a, D) a cell 
membrane of an untreated cell showing the invaginations typical of an endocytic 
process. (b E) TEM images of a cell exposed to the mouse antibody, which doesn’t have 
Au nanoparticles; (b, F) details of an exosome; (b, G) cell membrane full of actin 
protrusions (filopodia). (c, H-J) TEM sections of a cell exposed to FITC-G(IIKK)3I-
NH2and anti-FITC antibody conjugated with 10 nm Au nanoparticles showing several 
Au nanoparticles (yellow circles) included in a big endocytic compartment, possibly 
endosomes. (d, K-M) Another cell exposed to peptide/antibody complexes with many 
internalised Au nanoparticles (yellow circles); the cell is severely damaged and the 
membrane is falling apart. Bars = 0.2, 0.5, or 1 µm. 
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4.4 Studies to evaluate the involvement of endocytosis in 
peptide uptake 
 
Endocytosis involves a portion of the membrane being invaginated, encapsulating 
integral proteins, plasma membrane lipids and extracellular fluid. During this process, a 
membrane-bounded vesicle called an endosome is formed. The engulfment of material 
is not energy free and to work requires ATP and is considered an active process. Recent 
evidence suggests that endocytosis not only is involved in the internalisation of 
extracellular molecules but also plays a key role in mitosis, antigen presentation and cell 
migration processes 235, 236. The specific mechanisms through which cargoes are 
recruited and internalised by the cell membranes are still partially unclear. The 
endocytic uptake can follow different routes depending on the nature of the internalised 
molecules; phagocytosis or macropinocytosis (which involve the engulfment of big 
particles or large volume fractions and extracellular fluid, respectively) and receptor-
mediated endocytosis. Of this latter category, the most studied is certainly the clathrin 
mediated endocytosis (CME). Other types of clathrin-independent endocytosis include 
the caveolin-1 mediated endocytosis and a few others which can all go under the main 
group of clathrin and caveolin independent endocytosis 237. 
 
Experiments described in the previous sections revealed evidence regarding the 
possibility of an active mechanism being involved in the internalisation of the peptides. 
This includes mitotic cells that did not uptake FITC-G(IIKK)3-NH2 (Figure 46) and 
TEM images showing gold nanoparticles (conjugated to an antibody specific against 
FITC (Figure 50 and Figure 51) encapsulated in vesicular compartments. To better 
investigate this phenomenon, several new experiments were performed: internalisation 
speed of peptide molecules, cold assay analysis, acid stripping to remove molecules not 
covalently bound from the surface of the cellular plasma membrane and time-lapse 
videos. The results are presented in the sections below. 
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4.4.1 Internalisation speed of FITC-G(IIKK)3I-NH2 
 
An evaluation of the internalisation time of FITC-G(IIKK)3-NH2 was conducted on both 
HCT-116 cancer cells and HDFs primary fibroblasts in order to obtain an estimate of 
how much time was needed by FITC-G(IIKK)3-NH2 to be sufficiently concentrated 
inside the cells to give a visible fluorescent signal. Two concentrations of peptide (12.5 
and 25 µM) were added to the cells, which were then fixed in formaldehyde and stained 
with Hoechst at various time points (from 15 minutes up to 3 hours). The speed with 
which siRNA molecules were transfected and internalised was also evaluated. 50 nM of 
red fluorescent siGLO was transfected using two peptide ratios (4/1 and 24/1, 
corresponding to 200 or 1200 nM of peptide, respectively) and DharmaFECT1 (DF1) 
used as the positive control.  
 
Figure 52 presents images of HCT-116 cells showing FITC labelled peptide appearing 
after 30 minutes at both concentrations tested. With time the amount of peptide 
increases. The cells exposed to 25 µM peptide concentration after 3 hrs all showed some 
fluorescence. When complexed with siRNA, the peptide required more time to be 
detected; for the 4/1 ratio, no complexes were visible after 30 minutes and even after 
one hour only a few red fluorescent siRNAs could be localised inside the cells. With a 
6-fold increase in ratio, (24/1) fluorescence could be detected after 30 minutes, and the 
agglomerates appeared yellow, due to the co-localisation of green peptide and red 
siRNA. Compared to FITC-G(IIKK)3I-NH2, DF1 has a higher internalisation speed and 
some red molecules appeared already after 15 minutes. 
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Figure 52. FITC-G(IIKK)3I-NH2 internalisation evaluated on cancer cells at 
different time points. HCT-116 were exposed to two concentrations FITC-G(IIKK)3I-
NH2 (12 and 25 µM) and fixed after specific time points to evaluate uptake by the cells. 
50 nM of siGLO red fluorescent indicator (Dharmacon) was transfected using 2 peptide 
ratios for the same purpose. DharmaFECT1 (DF1) was used instead as positive control 
and transfection was performed according to the manufacturer’s protocol. The presence 
of peptide localised inside the cells is first detectable after 30 minutes while for 
peptide/siRNA complexes, unless a really high peptide ratio is used (24/1) a minimum 
of an hour is required. DF1 internalisation is faster and red puncta are visible already 
after 15 minutes. Hoechst 33342 (2 µg/ml) (blue) was used as nuclear staining. 
Fluorescent siGLO in red. FITC-G(IIKK)3I-NH2 in green Bar = 25 µm. All the images 
are scaled at the same size. 
 
Figure 53 shows images of HCT-116 exposed for 24 hrs to FITC-G(IIKK)3-NH2 at 
concentrations of 6.25-100 µM. The quantity of peptide internalised by the cells is 
concentration dependent: at 100 µM the signal from the fluorophore inside the cells is 
so high, that, at the same exposure time used to acquire all images, all the cells are 
completely saturated in the green channel. A reduction in cell population was also 
observed at this concentration. Noticeable in the 12.5 and 50 µM pictures are cells in 
mitosis with the peptide surrounding the plasma membrane (yellow circles). 
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Figure 53. HCT-116 cells exposed for 24 hrs to FITC-G(IIKK)3I-NH2. The cells 
were exposed to progressively higher concentrations of the fluorescent peptide. Images 
show a clear correlation between the concentration used and the amount of fluorescence 
detected in the cells. At 100 µM, the amount of peptide internalised is so high that the 
green channel is saturated. In the yellow circles cells are in mitosis. Hoechst 33342 (2 
µg/ml) (blue) was used as nuclear staining. FITC-G(IIKK)3I-NH2in green Bar = 25 µm. 
All the images are scaled at the same size. 
 
Figure 54 shows the internalisation performed of FITC-G(IIKK)3I-NH2 on HDFs. No 
fluorescence is visible in the cells, even after 3 hours of exposure. With the higher 
peptide ratio (24/1), a few puncta are visible after 30 minutes as yellow puncta. With 
DF1 internalisation was comparable to the one experienced in HCT-116 cells and red 
fluorescence starts to be visible even after 15 minutes. 
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Figure 54. FITC-G(IIKK)3I-NH2internalisation evaluated on fibroblasts at 
different time points. HDFs primary cells were exposed to two concentrations of 
FITC-G(IIKK)3I-NH2 (12 and 25 µM) and fixed after specific time points to evaluate 
uptake by the cells. 50 nM of siGLO red fluorescent indicator (Dharmacon) was 
transfected using 2 peptide ratios. DharmaFECT1 (DF1) was used as a positive control 
and transfection was performed according to the manufacturer’s protocol. The presence 
of peptide localised inside the cells cannot be detected at any of the time points selected. 
For the peptide/siRNA complexes unless a really high peptide ratio is used, a minimum 
of an hour is required to observe red fluorescent puncta. With the24/1 ratio, the presence 
of yellow puncta as an indication of peptide and siRNA molecule co-localisation is 
noticeable after 3 hours. DF1 internalisation can be observed after 15 minutes. Hoechst 
33342 (2 µg/ml) (blue) was used as nuclear staining. Fluorescent siGLO in red. FITC-
G(IIKK)3I-NH2 in green Bar = 25 µm. All the images are scaled at the same size. 
 
Lastly, in Figure 55, fibroblasts were exposed for 24 hrs to the fluorescent peptide. The 
peptide localised to the cells in a dose-dependent fashion. 100 µM of peptide had an 
inhibitory effect on the cellular growth. The morphology of the HDF cells in Figure 55 
changed with an increase in diameter and the fibroblasts were saturated with the peptide 
which was located within the nuclei.  
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Figure 55. HDFs exposed for 24 hrs to FITC-G(IIKK)3I-NH2. HDFs were exposed 
to progressively higher concentrations of the fluorescent peptide. Images show a clear 
correlation between the concentration used and the amount of fluorescence detected in 
the cells. At the concentration of 100 µM, the amount of peptide internalised caused the 
saturation of the cells in the green channel. Moreover, at this concentration a reduction 
in cell number was observed as well. Hoechst 33342 (2 µg/ml) (blue) was used as 
nuclear staining. FITC-G(IIKK)3I-NH2 in green Bar = 25 µm. All the images are scaled 
at the same size. 
 
Overall, the results obtained on both cancer cells and fibroblasts showed different 
internalisation between the two cell lines. With the cancer cells, the uptake is quick and 
the peptide is visible inside cells in a time window between 15 and 30 minutes, whilst at 
the same range of concentrations in fibroblasts, none of the fluorescent FITC-G(IIKK)3-
NH2, could be detected, even after 3 hours of incubation (Figure 52 and Figure 54). If 
the incubation time is prolonged to at least 24 hrs, HCT-116 and HDFs equally showed 
internalised molecules and 100 µM induced almost the same level of toxicity in both 
cell lines (Figure 53 and Figure 55).  
 
 
 
 
  
149 
 
4.4.2 Peptide internalisation using the cold assay to reduce endocytosis  
 
Endocytosis is a dynamic and energy-dependent process which is strictly influenced by 
the cell temperature: several studies have shown how, by decreasing temperature, the 
internalisation of molecules via endocytic pathways is strongly inhibited 152, 153, 238. 
 
To strengthen the hypothesis of endocytosis being involved in peptide uptake, the cold 
assay was performed on HCT-116 cells. Cells were initially washed with cold PBS and 
subsequently exposed to a solution composed by 12.5 µM of FITC-G(IIKK)3I-NH2 and 
cold medium. Three different plates were prepared and each of them was kept at 4 °C 
for 30 minutes. At 4 °C all the endocytic pathways are blocked. If endocytosis was 
involved in the FITC-G(IIKK)3I-NH2 uptake, no peptide would be detectable inside the 
cells. After 30 minutes, one of the plates was rapidly fixed in formaldehyde, while the 
other two were first moved to 37 °C for 3 hours and then fixed. In one of the two 
remaining plates, the original medium was discharged and substituted with new warm 
media prior to being moved to 37 °C, while in the other the same medium was kept till 
the end. Control plates, where cells were directly exposed to 12.5 µM of FITC-
G(IIKK)3I-NH2 for 30 minutes or 3 hours and at 37 °C were also prepared. All the 
plates were then imaged using the wide field fluorescent microscope and quantitative 
analysis of the internalised peptide performed. Figure 56 (a) shows images of cells 
acquired after fixation, while (b) shows the graph obtained from the quantitative 
analysis of FITC green fluorescence intensity. Images were acquired using the IN CELL 
Analyzer microscope with 20x objective. Brightness and contrast were ultimately 
adjusted for all the images to the same level by using Image J. The quantitative analysis 
was performed using the In Cell Developer Toolbox l.9 software. 
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Figure 56. The peptide uptake is blocked in a cold environment. A cold assay was 
performed to evaluate the peptide uptake efficiency in cancer cells under cold 
conditions; (a) HCT-116 cancer cells were exposed to 12.5 µM of FITC-G(IIKK)3I-NH2 
for 3 hours (control), or for 30 minutes in a cold environment directly following fixation 
(cold+fix). Some cells were subsequently incubated for 3 hours at 37 °C keeping the 
same medium (kept medium) or replacing the medium with a fresh one but lacking 
peptide (changed medium). The graph in (b) shows the quantitative analysis performed 
to evaluate the level of FITC intensity observed in the experimental conditions and 
normalised by the controls (cells incubated for 30 minutes or 3 hrs at 37°C). Because 
cells can auto-fluoresce in the green, cells without peptide were included (data not 
showed) in the experimental set-up and their values were subtracted from each 
experimental condition in order to have only the effective value of FITC intensity. The 
values obtained are averages of independent experiments ± standard error mean 
(±SEM). The images complemented by the graph show that the peptide is not 
internalised by the cells unless a warm environment is provided, suggesting that the 
internalisation occurs mainly via an active process that requires energy to function.    
Bar = 25 µm. All the images are scaled at the same size. 
 
With both images and quantitative analysis, it was found that, depending on the 
experimental conditions, the amount of green fluorescent intensity of FITC-G(IIKK)3-
NH2 detected inside the cells was quite different. Cells kept in cold conditions and then 
immediately fixed showed very little peptide internalisation, but if the temperature was 
restored to normal conditions at 37 °C for 3 hrs, cells were again able to uptake the 
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peptide. However, if before moving the cells in the 37 °C incubator the medium was 
replaced with a new one lacking peptide, the level of fluorescence detected inside the 
cells was low. This proved not only that cells require a warm environment (and 
therefore energy) to uptake FITC-G(IIKK)3-NH2, but also that in cold conditions and in 
the absence of internalisation, the peptide probably does not stick onto the cellular 
membranes. If the medium is replaced, most of FITC-G(IIKK)3-NH2 is also washed 
away. Due to the auto-fluorescence that cells have in the green channel an extra 
experimental condition was created: untreated cells were seeded in a few wells and kept 
in an incubator (37°C) for 30 minutes or 3 hours then fixed and stained as usual. Their 
green fluorescence intensity was measured and used as background level to be 
subtracted from all the other data. 
  
4.4.3 Acid stripping to remove covalently bound molecules from the 
membranes 
 
It was important to estimate the effective amount of peptide internalised in cells to 
evaluate any crucial differences between cancer and not cancer cell lines. Some of the 
peptide could have been attached to the cell membranes without being internalised. 
Moreover, the fixation used formaldehyde, which can permeabilize cell membranes, 
meaning that the translocation inside the cells of materials attached on the outer surface 
may be a source for misinterpreting our observations 154.  
 
To discard both problems and evaluate if any of FITC-G(IIKK)3I-NH2 was attached on 
the membranes of both HCT-116 and HDFs cell lines, a series of washes with an acidic 
solution was performed prior to fixation. This potent acid stripping, with a pH of 3, 
allows the removal of any molecules, not covalently bound, from the plasma membrane 
reducing the chances of misinterpreted results 155. Cells were initially incubated for 24 
hrs with increasing concentrations of peptide followed by acid stripping, fixation with 
formaldehyde and staining with Hoechst and Cell Mask Orange to stain nuclei and 
plasma membranes, respectively. Images were then acquired with the ImageXpress® 
Micro System wide-field fluorescent microscope with a 20x objective. Following 
acquisition, the images were further analysed using the MetaXpress® 5.0.0.20. 
Brightness and contrast were ultimately adjusted for all the images to the same level by 
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using Image J. Quantitative analyses of the total peptide fluorescence intensity were 
performed to evaluate any differences between washed and unwashed cells.  
 
Cells were exposed for 24 hrs to a range of peptide concentrations (6.25 – 50 µM). The 
concentration 100 µM was excluded, due to its severe toxic effect (Figure 45). The 
quantitative analysis showed in Figure 57 represents the total FITC intensity detected in 
HCT-116 or HDFs after peptide exposure. As it is possible to observe there is a 
difference in the amount of green fluorescence between unwashed cells and cells 
washed with the acidic solution. This was particularly evident for the fibroblasts, where 
the FITC average intensity drastically dropped at all the tested concentrations after acid 
wash, especially at 50 µM. In HCT-116, there was generally little or no variation. The 
total green fluorescence intensity observed in HDFs was smaller compared to HCT-116, 
but because fibroblasts are much bigger cells when compared to HCT-116, in an equal 
surface area they occupy more space. As a consequence, the number of cells counted in 
a well is much lower compared to the cancer cells. Therefore, when the data are 
represented as average intensity per cell, the values appeared to be higher for the 
fibroblasts than the colon cancer cells. 
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Figure 57. Quantitative analysis of FITC average intensity per cell in unwashed 
and washed cells. HCT-116 cancer cells (a) or fibroblasts (b) were exposed to different 
concentrations of FITC-G(IIKK)3I-NH2 for 24 hours with or without an acid wash prior 
fixation (pH 3). The values obtained were divided by the total amount of cells counted 
in each experimental condition. Cells washed with this acidic buffer showed a 
significant decrease in the FITC intensity compared to the unwashed cells. This is 
particularly true for fibroblasts, where in all the tested concentrations (and especially at 
50 µM) a drastic reduction in green fluorescence was observed. This data suggests that 
some of the peptide is located on the cellular membranes and gets internalised only after 
fixation. This is true especially for HDFs where the effective internalisation of FITC-
G(IIKK)3I-NH2 is quite limited. The values obtained are averages of independent 
experiments ± standard error mean (±SEM). Statistically significant differences between 
normal cells and cells treated with the acid buffer were determined by Student’s t-test 
(*p<0.05; **p<0.01; ***p<0.001). 
 
The images in Figure 58 show the results obtained with acid washes and cellular 
staining. The peptide distribution inside varied between cancer cells and fibroblasts; in 
the first case the vast majority of fluorescence was centrally located in the same cellular 
area near the nucleus (Figure 58 a) while in the second (Figure 58 b) the distribution 
was more randomised and did not follow a precise pattern. In Figure 58 (c) there are 
zoomed in images of HCT-116 cells exposed to 50 µM of FITC-G(IIKK)3I-NH2. The 
white circles highlight two cells in mitosis where the vast majority of the fluorescent 
peptide is located on the membranes. To facilitate the observation of the peptide’s 
distribution, the red and blue channels, representing the plasma membranes and nuclei 
staining, were removed from the second and third images respectively.  
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Figure 58.  Acid wash removal of non-covalently bound peptide molecules from the 
cell membrane. HCT-116 cancer cells (a) and HDFs primary cells (b) were exposed to 
several concentrations of FITC-G(IIKK)3I-NH2 for 24 hours and washed prior fixation 
with an acid buffer (pH 3). The acid stripping removes non-covalently bound material 
from the cellular membranes, and in this instance, could be used to evaluate the 
effective amount of peptide internalised prior to fixation. (c) HCT-116 cells exposed to 
50 µM of fluorescent peptide. The white circles show cells in mitotic phase with the 
peptide (green) mostly externally surrounding the membrane. The plasma membrane 
(red) or the nuclei (blue) channels are removed in the second and third images 
respectively, showing peptide distribution external to the cells. Endocytosis is normally 
supressed under mitotic events, therefore the presence of peptide outside these cells 
suggests that an active mechanism could be involved in its uptake. Hoechst 33342 (2 
µg/ml) and Cell Mask Orange (0.1X of working solution) were used as nuclear and 
plasma membranes staining, respectively. Bar = 25 µm. All the images are scaled at the 
same size.  
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4.4.4 Time-lapse videos to show live internalisation of FITC-G(IIKK)3I-
NH2 
 
To observe the peptide directly being taken up by living cells, time-lapse videos of 
HCT-116 were recorded using the IN Cell Analyzer microscope in both fluorescence 
and bright field mode with a 40x objective. Brightness and contrast were ultimately 
adjusted for all the images to the same level by using Image J. HCT-116 cells were 
exposed to a toxic (100 µM) and a non-toxic (6.25 µM) concentration of FITC-
G(IIKK)3I-NH2 and imaged every 30 minutes, for a total time of 24 hrs. Two separate 
movies were produced; the first one between 0 and 18 hrs of peptide exposure and the 
second one between 18 and 24 hrs. Cells with no peptide were filmed, as a control of 
normal cellular behaviour. In Figure 59 it is possible to observe cell movements and 
their morphological changes in response to the peptide internalisation. Control cells had 
heterogenous shape and morphology, showing lamellipodia, motility, migrating through 
the well plate surface and interacting with each other. Some underwent mitosis while 
some others died via apoptosis. In contrast, cells exposed to 6.25 µM of FITC-
G(IIKK)3I-NH2 dramatically changed their morphology due to peptide internalisation. 
From the images in Figure 59 (a), it is possible to observe that as soon as the cells 
increased their peptide cargo, they suddenly stopped moving, adopting a round 
morphology and staying still for hours in the same area of the well. However, this 
behaviour was not homogenous and only some cells seemed to be affected in this 
drastic way. It appeared that the cells, which were still behaving normally, were lacking 
green fluorescence, however it is not clear whether those cells internalised any peptide. 
The cells exposed to 100 µM on the other side, were completely filled by FITC-
G(IIKK)3I-NH2 in the space of only a few minutes and completely stopped moving. The 
amount of peptide internalised was so high that the green fluorescence signal became 
saturated. Due to the saturation issues, a second set of images (Figure 59 b) were 
acquired in bright field mode. In this way, it was possible to improve imaging of cell 
movements and morphologies. A similar scenario to the first movie was observed, 
where cells with no peptide moved freely, dividing and increasing in number, while 
cells exposed to 6.25 µM of FITC-G(IIKK)3I-NH2 had mostly changed their 
morphology, adopting a more circular shape and reducing their migration speed. Cells 
treated with the highest peptide concentration were completely stationary. The images 
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shown in Figure 59 a-b revealed that the peptide had mostly a cytostatic effect, 
inhibiting the cell proliferation. This was particularly evident in the cells exposed to 100 
µM, where the cell number did not vary between the first and the last image of each 
movie. The results obtained with these live videos are extremely important because they 
added valuable information about the cell physiology and morphology in presence of 
FITC-G(IIKK)3I-NH2, which was not possible to acquire with the standard fixed 
fluorescent pictures. 
 
Interestingly, the peptide distribution pattern appeared different from live and fixed 
images. Figure 60 shows cells prior and after fixation at the end of the movies’ periods 
(18th or 24th hour). In live images it is possible to observe some cells showing green 
fluorescence, while when the cells were fixed all of them appeared with a certain 
amount of internalised peptide. This effect could be caused by the membranes 
permeabilization by formaldehyde, already discussed in the previous paragraph, or a 
different sensitivity between the microscope modes. 
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Figure 59. Live time-lapse imaging showing peptide uptake in cancer cells.           
HCT-116 cancer cells were exposed for 24 hrs to 0, 6.25 and 100 µM of FITC-
G(IIKK)3I-NH2 and recorded continuously for 18 hours (a) or between the 18th and 
24th hours (b). The presence of peptide changed the morphology of the cells and altered 
their motility, especially at the 100 µM where cells were completely immobile. In (a) 
the 100 µM of peptide caused the saturation in the GFP channel, therefore in (b) only 
bright field mode was use. Bar = 25 µm. All the images are scaled at the same size.  
 
   
158 
 
 
Interestingly, the peptide distribution pattern appeared different from live and fixed 
images. Figure 60 shows cells prior and after fixation at the end of the movies periods 
(18th or 24th hour). In live images it possible to observe some cells showing green 
fluorescence, while when the cells were fixed all of them appeared with a certain 
amount of internalised peptide. This effect could be caused by the membranes 
permeabilization by formaldehyde, already discussed in the previous paragraph, or a 
different sensitivity between the microscope modes. 
 
 
Figure 60. Differences in bright field and fluorescence acquisitions. Images of HCT-
116 cells at the 18th and 24th hours before (bright field) and after formaldehyde fixation 
(fluorescence) showing the distribution pattern of the peptide. In the bright field images, 
only the cells with alterations in the cellular shape (enhanced circularity) have green 
fluorescent peptide, while in the fluorescent images all the cells have some of it. Bar = 
25 µm. All the images are scaled at the same size. 
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4.4.5 Cancer cells can recover from peptide uptake under favourable 
conditions 
 
From the cell counting results and images of cells exposed to FITC-G(IIKK)3-NH2 it 
clearly appeared that 100 µM of peptide had a strong cytostatic effect on cells, 
especially HCT-116 (Figure 45 and Figure 53) causing a drastic decrease in the cell 
population growth. Even the time-lapse video showed how in very little time all the 
cells were completely saturated by the peptide and unable to move (Figure 59). 
It is still unclear if the cells could pump out the peptide once internalised, but studies 
conducted on nanoparticles, for example, proved that it is not uncommon that cells use 
exocytosis as a mechanism to remove nanoparticles from the cytoplasm. When this 
happens, it is normally via vesicles or non-vesicle secretions 239-241.  
 
In the experiment illustrated below, HCT-116 cancer cells were exposed to 100 µM of 
FITC-G(IIKK)3I-NH2 for 30 minutes and then left overnight in the incubator at 37 °C 
with or without media changes. In this way, it was possible to evaluate the cellular 
efficiency to recover from the peptide retention and investigate if the cancer cells were 
able to excrete the peptide. Unexposed cells were added as negative control. Afterwards 
cells were fixed with formaldehyde and stained with Hoechst. Images were acquired 
with the ImageXpress® Micro System wide-field fluorescent microscope or IN CELL 
Analyzer (bright field mode) with 2x or 20x objective lenses. Brightness and contrast of 
all the images were ultimately adjusted to the same level by using Image J. The cell 
counting analyses were performed with MetaXpress and the dedicated algorithm able to 
recognize cellular nuclei stained with Hoechst.  
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Figure 61. Cancer cells can recover from FITC-G(IIKK)3I-NH2uptake.                         
(a) HCT-116 cancer cells were exposed to 100 µM of fluorescent peptide for 30 minutes 
(bright field) and then incubated overnight keeping the same medium (kept medium) or 
changing the medium with to a fresh one but lacking peptide (changed medium). The 
next day, cells were fixed and stained and images acquired at 10 or 100 ms exposure 
time for GFP (green) channel. Cells that had the medium changed contained less 
peptide and could be imaged at high exposure time (100 ms) without saturating the 
signal. The cell number was evaluated (b) with nuclei staining analysis using the 
MetaXpress with the Multi Wavelength Scoring algorithm and 2x objective. According 
to the results obtained, cells could recover from the peptide exposure and increased in 
number in the space of a few hours. The results are expressed as a percentage of number 
of cells and normalized to the negative controls at that relative time point. The values 
obtained are averages of independent experiments ± standard error mean (±SEM). 
Water has been used as negative control (0). Bar = 25 µm. All the images are scaled at 
the same size. 
 
Figure 61 (a) shows images of live cells (top panels) after 30 minutes of peptide 
exposure (bright field mode) or fixed cells (second and third panels) after overnight 
incubation with or without changing the medium (kept and changed medium). It is 
possible to observe from the bright field/FITC channel merged image that there is a 
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substantial FITC fluorescence inside the cells after 30 minutes and their morphology 
has already started to change. After an overnight treatment with the peptide, a low 
exposure time was necessary (10 ms). Nuclei appeared small and brightly stained. 
However, cells which had the peptide removed through washing could be imaged with a 
longer exposure time, with the total amount of peptide localised in the cells reduced 
compared to the cells where the medium was retained.  
 
This data suggests that cells were able to secrete the peptide and when the peptide was 
removed from the media this became apparent. To evaluate any differences between the 
two experiments, cells were counted (Figure 61 b). Interestingly, a difference was 
observed and the cells with lower concentration of peptide in the media doubled their 
population compared to the ones which were exposed overnight.  
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5 IN VIVO STUDIES ON DANIO RERIO 
EMBRYOS 
 
5.1 Zebrafish is a valuable animal model to study human 
genetics and diseases. 
 
In vivo studies are necessary to fully understand the mechanism of action of drugs, the 
onset of diseases or the spread of cancer. A model organism should present important 
features such as short generation time, high fecundity, complete sequenced genome, 
metabolism comparable with humans or disease models similar to humans. Danio rerio 
(or zebrafish), a tropical cyprinid fish native to the floodplains of North Eastern India 
and Bangladesh, is extensively used in biomedical research. It is especially useful for 
genetic and developmental studies, particularly after 2013 when its genome was 
completely sequenced. Comparisons between human and zebrafish sequences showed 
that 71% of human genes have at least one obvious zebrafish orthologue and that in 
total we share up to 82% of disease-associated targets, together with a large number of 
drug metabolism pathways 242. 
It is George Streisinger with his pioneering work started in the late 1960s, who 
transformed this little tropical fish into a leading model organism. Streisinger has 
certainly a place amongst the principal creators of the modern era of molecular genetics 
especially for his pivotal study published in 1981 where for the first time he produced 
clones of homozygous diploid zebrafish 243. Since then, the number of studies involving 
zebrafish exponentially increased, counting >20,000 publications 244. There are many 
advantages of using zebrafish in research laboratories. First, zebrafish are small, robust, 
cheap to maintain (compared to mice) and capable of producing hundreds of offspring 
in short periods of time. Female spawning is influenced by photoperiod and takes place 
within approximately an hour of exposure to light after darkness, while for many other 
fish species this happens only during the night 245. Its growth rate is fast, (blood 
circulation begins after only 24 hrs) and since fertilization occurs outside the mother’s 
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body, it is easy to study early embryonic development. Moreover, the optical clarity 
during embryogenesis allows us to observe the internal structures during development 
with light microscopes 146. For example, haematopoiesis, cardiac and vasculature 
diseases are among the most studied subjects in zebrafish embryos. Haematopoiesis is 
conserved through vertebrate evolution and there are 80 homologues of mammalian 
genes involved in this process isolated so far in zebrafish 246-249. As vertebrates, 
zebrafish have similar physiology, organs and tissues as humans, apart from differences 
due to adaptation to aquatic life. Recently, zebrafish embryos have been used for 
toxicology screening and as part of the drug discovery process 242, 250, 251. 
 
The behaviour of A9K and FITC-G(IIKK)3I-NH2 peptides was evaluated in zebrafish 
embryos and the results regarding their toxicity will be detailed in the following 
sections of this chapter. This represents the first study where zebrafish embryos have 
been injected to test the toxicity of cationic amphiphilic peptides. 
 
 
5.2 Danio rerio embryos and their employment in toxicology.  
 
Zebrafish embryos have been often used as model to evaluate the toxicity of chemical 
compounds and biocides released in the aquatic environment. Initially, the acute fish 
toxicity test (AFT) 252, following the Organisation for Economic Co-operation and 
Development (OECD) guidelines was the chosen assay for aquatic vertebrate toxicity. 
The assessed endpoint was fish death, so as to reduce the distress and suffering of the 
animals OECD decided to develop an alternative test called Fish Embryo Acute 
Toxicity (FET), where embryos are used instead of juvenile or adult animals 253. The 
usage of embryos is preferred because, according to the EU Directive 2016/63/EU, in 
the earliest life-stages (0-5 days post fertilisation), until the beginning of independent 
feeding, embryos aren’t considered as protected and do not fall under animal 
experimentation regulations. Usually in the FET the chemical compounds which needs 
to be tested are directly dissolved in the medium. The embryos are monitored for 96 
hours and any changes from the standard embryonic development are carefully recorded 
254. Due to the high concentration of peptide needed in the fish tank for oral 
administration, and the route of administration of peptide, if it were to be used as a 
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cancer treatment for Humans, the peptides were directly microinjected into the single 
cell egg stage. Microinjection also avoided the chorion, a natural barrier of 1.5-2.5 𝜇m 
thickness, which can potentially restrict the uptake of compounds especially if carrying 
a charge 255, 256.  
 
 
5.3 The first 5 days of zebrafish embryogenesis. 
 
During the monitoring phase of microinjected embryos three distinct checkpoints were 
established. The first checkpoint was at 5 hours post fertilisation. At this developmental 
stage, embryos are normally at late blastula stage and approaching gastrulation (5.25 hrs 
post fertilization).  During this check point unfertilised eggs were removed to reduce the 
risk of infection and to minimize the chance of other embryos dying overnight. 
 
Following blastula stage, gastrulation begins with epiboly. During epiboly, complex co-
ordination of cell movements establishes three different layers: the enveloping layer 
(EVL), an epithelial monolayer which will exclusively contribute to form the periderm, 
a protective outer surface; the yolk syncytial layer (YSL) an associated layer of 
cytoplasm and nuclei on top of the yolk which are critical for mesoderm and endoderm 
induction and the deep cell layer (DEL), a multilayer of cells of fairly uniform 
thickness. DEL will eventually give rise to epiblast and hypoblast which will 
consecutively form the 3 germ layers (ectoderm, mesoderm, and endoderm) 146, 257, 258.  
 
Gastrulation normally lasts for 5 hours and is one of the most important phases of 
embryogenesis; during this stage, epiboly completes and in addition other important 
morphogenetic cellular movements called involution, convergence and extension occur 
defining the primary germ layers and the embryonic axis (anterior-posterior and dorsal-
ventral) 259. By this stage, an organ-and tissue-level fate map is available giving lineage 
tracing of undifferentiated precursor cells which are crucial for determining how 
haematopoietic, and blood vessel lineages arise in developing embryos 247, 260. If the 
peptides induce toxicity in the embryos, signs of cellular degeneration were could be 
recorded at this stage, during the first planned check-point. 
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If an embryo manages to complete gastrulation, then the segmentation stage will 
commence. Somites, together with a wonderful variety of morphogenetic movements 
occur; rudimental organs are becoming visible, the tail is budding, the notochord 
develops in an apical-posterior sequence and the embryo begins to elongate. During this 
phase, the neural tube closes and a rudimental brain starts to develop together with 
primordial eyes. Segmentation lasts from 10.30 to 24 hrs post fertilization (hpf) and by 
completion, most cell lineages are morphologically differentiated and first body 
movements are observed 146, 258. The end of the first day post fertilisation (1 dpf) is 
another critical point for the embryos’ development, therefore the survival rate 
following the peptides microinjection was once again recorded (second checkpoint); the 
number of alive and dead embryos were counted and coagulated eggs discharged from 
the Petri dishes. 
 
The following phase is called pharyngula and it lasts for the whole second day of post 
fertilisation (24 to 48 hrs). At this stage, the neuronal system becomes more complex 
with formation of primordial nerves. The fins begin to form and pigment cells to 
differentiate. By 24 hpf, the heart begins to beat and the blood can circulate through a 
closed set of channels by 26 hpf. Aortic arches appear together with the carotid and 
caudal arteries, the anterior cardinal and caudal veins. First signs of marked behavioural 
development appear together with tactile sensitivity and rhythmic bouts of swimming 
146.  
 
The third day there is the hatching phase. At this stage embryos, emerge from the 
protective chorion. This process can happen anytime up to 5 dpf and does not inhibit 
embryonic development by this stage. After the end of the third day, zebrafish embryos 
can be arbitrarily called “larvae”, whether they have hatched or not. During this stage, 
embryos keep growing and the morphogenesis of many organs is complete and slows 
down considerably, with the exception of the gut and its associated organs which will 
complete development by the fifth day 260-262.  
 
Quite noticeable is the rapid development of the pectoral fins, the jaws, and the gills. At 
the end of the hatching phase the mouth is wide open and it protrudes anteriorly just 
beyond the eye. The pectoral fins continue to expand and extending posteriorly over 
most of the length of yolk which is, vice versa, decreasing in size. At the third day, 
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since the majority of the organs have completed their morphogenesis, the survival rate 
of the injected larvae was checked (third checkpoint), highlighting any abnormalities 
and defects from normal development. 
 
The most important changes happening in the next days (4 and 5 dpf) are the inflation 
of the swim bladder and the continued anterior-dorsal protrusion of the mouth. The yolk 
sac is reduced and the gut tube drops more ventrally. Early larvae begin to swim 
actively, followed by jaw, fins and eye movements. By day five these physiological 
changes produce rapid cascade of responses such as respiration and exogenous feeding 
146. Before the end of the fifth day, due to legal requirements, embryos were sacrificed 
in bleach following prior anaesthetization with Tricaine (40 mg/l).  
 
 
5.4 Microinjections of A9K peptide in zebrafish embryos  
 
Zebrafish were raised in the Bateson Centre aquaria and fed Artemia nauplii. Zebrafish 
adult animals were kept on a constant 14 hours on 10 hours off light cycle at 28 °C. 
Embryos were obtained only by natural spawning of adult wild type animals as 
described in the zebrafish book 258. All the experiments performed on animals were 
approved by the local ethical review committee and performed under the Home Office 
project license 40/3708. At least 50 embryos per concentration were injected and 
several un-injected embryos were kept as controls. One-cell stage embryos were 
injected with 150 – 4000 pg (0.15 – 4 ng) of A9K peptide (corresponding to 180 μM – 5 
mM) within 20 minutes after they were laid and according to the procedure described in 
“2.8.3 Peptides and siGLO microinjections” section of the Materials and Method 
chapter. Briefly, the embryos were lined up against a microscope slide in a petri dish 
and injected using a needle mounted on a microinjector. The needle was broken with a 
pair of sharp tweezers and the injection volume calibrated, using a stage micrometer, to 
deliver 0.5 nl of liquid per drop (diameter 0.1 mm) 148, 149. After completing a line of 
injections, eggs were moved in a clean Petri dish filled with E3 medium and kept in an 
incubator at 28 ˚C. At the established check-points the number of embryos was recorded 
using a Leica MZ16 stereomicroscope.  
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Figure 62 graphically represents the ratio of dead and surviving embryos at one or three 
day post-fertilisation (1 or 3 dpf) The ratio was calculated considering as 100% the total 
number of injected embryos per each concentration (or un-injected for the control) and 
then divided between dead and survived embryos at each time point. According to the 
literature, for studies involving zebrafish embryos and microinjections in one cell-stage 
eggs to allow identification of variability, the recommend number of embryos per 
treatment is 40-60 256. Therefore at least a full microscope slide line of embryos, which 
roughly corresponds to 50 eggs, was injected per concentration. 
5 hpf embryos were checked but no differences were observed when compared to the 
initial microinjected eggs number (0 hpf) (data not represented).  
 
 
Figure 62. Microinjection of A9K induces dose-dependent toxicity in wild type 
zebrafish embryos. Zebrafish embryos at one-cell stage were injected with increasing 
amounts of A9K peptide and the number of surviving embryos recorded at 1 day post 
fertilisation (a) or 3 days post fertilisation (b). The graphs show a decrease in embryo 
viability consistent with the increasing volume of peptide injected with the most severe 
effects found with 4000 pg of peptide injected. No major differences can be observed 
between the two check-points. Several batches were used for the injections and for each 
of them, few embryos were kept as un-injected controls. An average of 50 eggs per 
concentration were injected in order to ensure sufficient sample size to detect 
variability. Statistically significant difference from the negative control was determined 
by Student’s t-test (*p<0.05; **p<0.01). 
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A visible decrease in the survival rate could be observed at higher peptide 
concentrations (1000 – 4000 pg) while at the lower doses (150, 300 ng) the survival rate 
is comparable to control levels. The trend is peptide dose-dependent. Embryos were 
scored as dead either if the tissues were no longer transparent and had become opaque, 
suggesting embryonic death, or if they were no longer moving and the heart had stopped 
beating. The survival rate of un-injected control embryos was constant around 90% 
between the checkpoints.  
At 1 dpf the survival rate of embryos injected with the lowest doses (150, 300 pg) 
matched the control and were recorded at 85-88%, respectively; at intermediate doses 
(400, 500 pg) the survival rate was instead at 71-74% respectively, while at high doses 
(1000 – 4000 pg) it drastically dropped from the 61% of 1000 pg to 28% of 4000 pg.  
The number of surviving embryos counted at 3 dpf did not significantly change from 
previous observations. Again, the lower doses (150, 300 pg) matched the control with 
83% and 87% respectively; with intermediate doses (400, 500 pg) the surviving rate 
was 70% while at higher doses (1000 – 4000 pg) the surviving rate was stationary from 
56% for 1000 pg to 24% for 4000 pg. 
 
Using GraphPad, the lethal concentration (LC50), equivalent to the concentration of 
peptide needed to kill 50% of the embryos, was calculated. In 1 or 3 dpf embryos the 
LC50 were respectively 1700 and 1400 ng corresponding to 2 and 1.7 mM. 
 
Images were acquired using a Leica M165 FC stereomicroscope to evaluate changes in 
the embryos phenotypes at the 1 and 3 dpf check-points. In Figure 63 it is possible to 
observe embryos at 1 dpf, during the pharyngula stage. At this phase, a normal embryo 
should have already several somites, rudimental organs, budded tail, primordial 
neuronal system and eye primordia (image A). From the images, it is possible to 
correlate the increased level of A9K toxicity with an increment of developmental 
abnormalities detected in embryos exposed to high level of peptide (1000 – 4000 pg, 
images F-I). The embryos showed different levels of tissue degradation, defects in the 
notochord formation, lack of tail budding, yolk sack oedemas and a general reduced 
development of both head and somites.  
 
 
  
169 
 
 
Figure 63. Morphological changes in 1 dpf embryos injected with A9K.             
Embryos following microinjections with A9K were imaged at 1 dpf and their 
phenotypes compared to an un-injected wild-type embryo (image A). At 150 – 500 pg 
of injected concentrations (images B-E), embryos did not present abnormalities and 
their development could be considered as normal. On the other side, embryos 
microinjected with higher doses of peptide (1000 – 4000 pg; images F-I), not only 
experience a reduced survival rate but showed several abnormalities as well, included 
notochord malformations (nm), general darkening tissue coagulation (dt), head 
suppression (hs) and failed tail budding (fb) (red acronyms and arrows). Bars = 500 µm. 
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Figure 64. Morphological changes in 3 dpf embryos injected with A9K.             
Embryos following microinjections with A9K were imaged at 3 dpf and their 
phenotypes compared to un-injected wild-type embryo (image A). At 150 – 500 pg of 
injected concentrations (images B-E), embryos did not show morphological changes 
abnormalities and their development could be considered as normal. Embryos 
microinjected with higher doses of peptide (1000 – 4000 pg; images F-I), experienced a 
significant decreased in the survival rate and showed severe abnormalities: notochord 
malformations (nm), yolk sack oedemas (ye), pericardial oedemas (pe), tail 
malformation (tm) (red acronyms and arrows). Embryos were kept still during image 
acquisition using, Tricaine (40 mg/l) in E3 medium.  Bars = 500 µm. 
 
Embryos at 3 dpf are in the hatching phase and it is normal to observe at this stage some 
embryos swimming around the Petri dish while others still enclosed in their chorions. 
During this step, the embryos have complete blood circulation and a more complex 
nervous system, most of the organs morphologically defined and noticeable eyes 260-262. 
From the images in Figure 64 it is possible to observe, at low and intermediate 
concentrations (150 – 500 pg), embryo development appears normal but at higher 
concentrations (1000 – 4000 pg) major defects are again visible. Pericardial and yolk 
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sack oedemas are the most prominent, followed by notochord or tail malformations and 
a general reduced brain development. With such severe abnormalities, it is unlikely that 
these embryos would complete embryogenesis and embryos were sacrificed. 
  
 
5.5 Microinjections of FITC-G(IIKK)3I-NH2 peptide in 
zebrafish embryos  
 
Using the same procedure described for A9K peptide, the toxicity of FITC-G(IIKK)3I-
NH2 was evaluated by performing microinjections in zebrafish embryos at one cell-
stage. The number of embryos was recorded using a Leica MZ16 stereomicroscope. 
Due to the high level of toxicity, the range of concentrations was extended to a larger 
interval, starting from 6.25 pg (10x higher than in cell transfection experiments) to 4 ng, 
corresponding to 3 μM – 2 mM. Indeed, all the concentrations with the exclusion of 
6.25 pg, significantly reduced the number of embryos counted already after the 5 hours 
post fertilisation (hpf) check-point. Many embryos showed embryonic death and were 
therefore removed from the Petri dishes and scored as dead. The lowest (6.25 – 50 pg) 
and the highest (2000 – 4000 pg) concentrations, from the 5 hpf observations, are 
graphically represented in Figure 65. It is possible to notice the viability is decreased by 
50% for all the concentrations, with the exclusion of the control, 6.25 pg and 2 ng.   
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Figure 65. FITC-G(IIKK)3I-NH2 microinjection induces toxicity by 5 hpf in wild 
type zebrafish embryos. Zebrafish embryos at one-cell stage were injected with 
increasing amounts of FITC-G(IIKK)3I-NH2 peptide and the number of surviving 
embryos recoded after counted 5 hours post fertilisation. The graph shows a decrease in 
the embryo viability consistent with the increasing volume of peptide injected. Several 
batches were used for the injections and for each of them, few embryos were kept as un-
injected controls. An average of 80-100 eggs per concentration were injected to ensure 
sufficient sample size to detect variability.  
 
FITC-G(IIKK)3I-NH2 showed, in both check-points (1 and 3 dpf), severe levels of 
toxicity at every tested concentration (Figure 66). For instance, at the 1 dpf check-point, 
between 1000 and 4000 pg, almost every embryo was scored as dead and at lower 
concentrations (12.5 pg to 500 pg) the survival rate was always found below 40%. The 
only recorded data above 50% was 6.25 pg, where 59% of the embryos were counted as 
still alive. At the 3 dpf check-point the survival rate of the injected embryos decreased 
even more, and the recorded viability was always below 50%. Even at 6.25 pg, the 
lowest injected concentration, the final count of alive embryos was only 44%.  
 
These results showed a progressively decrease in the number of embryos scored as 
alive. This trend had already started at the very first check-point (5 hpf), where the 
survival rate per each tested concentration drastically dropped to 50% compared to the 
initial number of injected embryos. However, the decrease in the embryos’ viability was 
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found to be more drastic between the first and the second check-points (5 hpf and 1 dpf) 
than later on, suggesting that the toxicity induced by the peptide is more severe in the 
first phases of embryogenesis (from gastrulation to the segmentation stage).  
On the contrary, the survival rates observed in the un-injected embryos (controls) were 
always high (84% and 83% at 1 or 3 dpf, respectively). These percentages are in the 
range of what considered a standard value of viability for healthy wild type zebrafish 
embryos during their developmental stage and could confirm that the decreased in 
viability observed in the injected embryos was exclusively induced by FITC-G(IIKK)3I-
NH2  
 
 
Figure 66. FITC-G(IIKK)3I-NH2 microinjections induce severe toxicity in wild type 
zebrafish embryos. Zebrafish embryos at one-cell stage were injected with increasing 
amounts of FITC-G(IIKK)3I-NH2 peptide and the number of survived embryos was 
recorded at 1 day post fertilisation (a) or 3 days post fertilisation (b). Both graphs show 
a drastic decrease in embryo viability at every concentraion tested. No major differences 
can be observed between the two check-points. Several batches have been used for the 
experiment and for each of them, few embryos were kept as un-injected controls. An 
average of 80-100 eggs per concentration were injected to ensure sufficient sample size 
to detect variability.  
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Using GraphPad, the lethal concentration (LC50), equivalent to the concentration of 
peptide needed to kill 50% of the embryos, was calculated. In 1 or 3 dpf embryos the 
LC50 were respectively 7 and 2 pg corresponding to 3,5 and 1 µM.  
 
 
5.6 Injections of siRNAs alone or complexed with FITC-
G(IIKK)3I-NH2  
 
Complexes of FITC-G(IIKK)3I-NH2 and red fluorescent non-targeting siRNA molecules 
(siGLO from Dharmacon) at different ratios were also injected into the zebrafish 
oocytes. The purpose was to observe if there was a reduction in peptide toxicity, due to 
the complexation with the siRNA molecules. The hypothesis tested would be if FITC-
G(IIKK)3I-NH2 could bind to the siRNA it might be less prone to interact with any of 
negatively charged cellular material found in the embryo. As consequence, the harmful 
effect caused by the peptide could potentially decrease. 
 
5.6.1 Microinjections of siGLO to estimate the siRNA toxic threshold 
 
Initially, prior to complexation with FITC-G(IIKK)3I-NH2 peptide, siGLO on its own 
was tested, to evaluate any eventual toxicity towards zebrafish embryos. 
In the literature, there are several studies showing the effect of siRNAs to modulate 
gene expression on fish, however the results are controversial. Although in some 
published reports there are successful results about the effectiveness of siRNAs in gene 
silencing, the general outcome indicates that the current methodology of RNA 
interference is not a useful technique for investigating gene function, especially during 
the early stages of zebrafish development, where the effects observed might be entirely 
nonspecific 263-267. To modulate gene silencing and expression in early stage 
development embryos, synthetic morpholino antisense oligonucleotides (MOs), are 
normally used 268, 269. MOs are often injected at the concentration of 3 ng/embryo and 
more in general never above the concentration of 5 ng/embryo, since it would have an 
adverse effect on embryonic development. In contrast, injections of 100 pg or more of 
siRNA or DNA would kill most of the embryos 265, 269. 
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For this reason, a range of siRNA concentrations between 20 pg and 80 pg per embryo 
was tested. siGLO red fluorescent siRNA is a non-functional siRNA and designed to be 
passive when transfected into the cells, and is normally used as positive control in 
transfection experiments. Since this siRNA has no targeting function, in these 
experiments its main purpose is to make complexes with the peptide and possibly 
reduce its negative effect on the embryos viability.   
In Figure 67 it is possible to observe zebrafish embryos at 3 dpf microinjected with 
increasing amounts of siGLO red fluorescent siRNA. Images were acquired using a 
Zeiss Axio Zoom.V16 fluorescence stereomicroscope. Brightness and contrast were 
ultimately adjusted to the same level using Image J. The intensity in red fluorescence is 
directly related to the increased concentrations of siGLO injected in the embryos. The 
fluorescent siGLO was mainly localised in the yolk and partially in the brain and neural 
tube, but very little in the rest of the embryo (see arrows in Figure 67).  
 
 
Figure 67. Microinjections of fluorescent siRNA in zebrafish embryos.                        
One cell stage zebrafish embryos were injected with siGLO red fluorescent siRNA 
(Dharmacon) and imaged at 3 dpf. The images, acquired using the same exposure time, 
show progressively higher red fluorescence intensity comparable with the increased 
concentrations of fluorescent siRNA injected. The siGLO is predominantly located in 
the yolk sac, (y) brain (b) and neuronal tube (nt); see yellow acronyms and arrows.    
Bar = 500 µm. All the images are scaled at the same size. 
 
At 1 or 3 dpf the viability was recorded using a Leica MZ16 stereomicroscope and the 
results can be observed in the graph in Figure 68. High concentrations of siGLO (60, 80 
pg) caused acute toxicity in zebrafish embryos with a reduction of at least 50% of the 
survival rate, when compared to the un-injected controls. On the contrary, 40 and 20 pg 
caused very little toxicity comparable to the controls. For this reason, 20 pg was the 
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concentration chosen for the subsequent experiments of microinjections using siRNA 
and peptide complexes.  
 
Using GraphPad, the lethal concentration (LC50), equivalent to the concentration of 
peptide needed to kill 50% of the embryos, was calculated. In 1 or 3 dpf embryos the 
LC50 were respectively 73 and 56 pg. 
 
 
Figure 68. Microinjection of fluorescent siRNA induces dose-dependent toxicity in 
wild type zebrafish embryos. Zebrafish embryos at one-cell stage were injected with 
increasing amount of siGLO, red fluorescent indicator (Dharmacon) and the number of 
surviving embryos recorded at 1 day post fertilisation (a) or 3 days post fertilisation (b). 
The graphs show a decrase in embryo viabiliy compatible with the increased injected 
volume.  Several batches have been used for each experiment and some embryos were 
kept as un-injected controls. An average of 80-100 eggs per concentration were injected 
in order to ensure sufficient sample size to detect variability.  
 
5.6.2 Microinjections of FITC-G(IIKK)3I-NH2 and siGLO complexes  
 
Complexes at two different ratios (1/1 or 4/1) were made according to the complexation 
method described in the Materials and Method Chapter for transfection experiments. 20 
or 80 pg of fluorescent peptide were therefore mixed with 20 pg of siGLO in order to 
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have 1/1 or 4/1 ratios per embryo, respectively. Figure 69 and Figure 70 show images of 
embryos injected with the complex and imaged at 1 or 3 days post fertilisation. The 
images were acquired using a Zeiss Axio Zoom.V16 fluorescence stereomicroscope. 
Brightness and contrast were ultimately adjusted to the same level by using Image J. In 
embryos at 1dpf the distribution of both siGLO and peptide is uniform in the whole 
organism and no real difference in terms of fluorescent intensity can be observed 
between the two ratios (Figure 69). 
 
 
Figure 69. Microinjections of FITC-G(IIKK)3I-NH2 and fluorescent siRNA 
complexes in zebrafish embryos. One cell stage zebrafish embryos were injected with 
FITC-G(IIKK)3I-NH2 and siGLO red fluorescent siRNA (Dharmacon) complexes and 
imaged at 1 dpf. Red and green channels were separated to better visualize the 
distribution of peptide and siRNA in the organisms. No differences in fluorescent 
intensity can be observed between the ratios. Bar = 75 µm. All the images are scaled at 
the same size. 
 
In 3 dpf embryos (Figure 70), both siGLO and peptide mostly accumulated in the yolk 
sack and a significant difference in green fluorescence intensity is appreciable between 
the two ratios. The presence of both red and green fluorescence confirms succesful 
injections of peptide/siRNA complexes. 
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Figure 70. Microinjections of FITC-G(IIKK)3I-NH2 and fluorescent siRNA 
complexes in zebrafish embryos. One-cell stage zebrafish embryos were injected with 
FITC-G(IIKK)3I-NH2 and siGLO red fluorescent siRNA (Dharmacon) complexes and 
imaged at 3 dpf. Red and green channels were separated to better visualize the 
distribution of peptide and siRNA in the organisms. A difference in fluorescent intensity 
can be observed between the ratios. Bar = 500 µm. All the images are scaled at the same 
size. 
 
The toxicity of the complexes injected into the embryos was carefully evaluated and any 
variations between these data and the ones regarding the un-complexed peptide 
microinjections (Figure 66) recorded. Since 20 pg of siRNA do not have a toxic effect 
on zebrafish embryos (Figure 68), any significant decrease observed in the survival rate 
could be related to the peptide. Graphs in Figure 71 show the toxicity results obtained 
after scoring the rate of dead and alive embryos at 1 or 3 dpf check-points. In both 
ratios, the overall toxicity does not reach 50% and it is stable between 1 and 3 days. 
These results, when compared to Figure 66, show a substantial difference and the 
complexes of peptide/siRNA appear less toxic than peptide only. For example, 20 pg of 
FITC-G(IIKK)3I-NH2 when complexed to siGLO, caused a decrease in embryo viability 
of 40% in both, day 1 and day 3, while a similar concentration of un-complexed peptide 
(25 pg) caused the death of 70% of embryos at 1 dpf and 76% by the third day. With the 
higher amount used in the 4/1 ratio, the difference between the complexed and un-
complexed peptides was even more significant; 80 pg of FITC-G(IIKK)3I-NH2 
complexed with siGLO gave a decrease in the survival rate of 34 and 35% in 1 dpf and 
3 dpf embryos, respectively. The closest concentration of un-complexed peptide instead 
(62.5 pg) had a severe impact on the embryos’ surviving rate; 1 dpf embryos showed a 
mortality of 81% which, by day 3, increased to 88%. 
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Figure 71. Microinjections of FITC-G(IIKK)3I-NH2 peptide complexed with siRNA 
have a reduced toxic effect in wild type zebrafish embryos. Zebrafish embryos at 
one-cell stage were injected with peptide and siGLO, red fluorescent indicator 
(Dharmacon) complexes. The amount of siRNA chosen was 20 pg per embryo while 
peptide ratios were made at 1/1 or 4/1 corresponding to 20 or 80 pg of the fluorescent 
peptide. The number of suriviving embryos was recorded at 1 day post fertilisation (a) 
or 3 days post fertilisation (b). The graphs show a stable decrease in embryo viability of 
40% compared to the un-injected controls. Several batches have been used for the 
experiment and for each of them, few embryos were kept as un-injected controls. An 
average of 50 embryos were injected per concentration to ensure sufficient sample size 
to detect variability. Statistically significant difference from the negative control was 
determined by Student’s t-test (*p<0.05; **p<0.01). 
 
In Figure 72, the graphs show data collected after the first check-point (5 hpf) for both 
experiments (siGLO and peptide/siRNA complexes). A small reduction in survival rate 
is observed for siGLO microinjections when compared to the graphs in Figure 68; at 
high concentrations (60, 80 pg) the survival rate is already down to 60 and 50%, 
respectively, while at 40 pg is 93% and with 20 pg all the embryos were all still alive. 
Complexes peptide/siRNA showed lower toxicity compared to the data represented in 
Figure 65. For example, while 25 pg of peptide decreased the survival rate of 48%, 20 
pg of the same peptide when complexed with siGLO gave a reduction of only 24%. 
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Figure 72. Microinjections of fluorescent siRNA alone or complexed with FITC-
G(IIKK)3I-NH2 peptide induce toxicity by 5 hpf in wild type zebrafish embryos. 
Zebrafish embryos at one-cell stage were injected with siGLO, red fluorescent indicator 
(Dharmacon) only (a) or complexed with FITC-G(IIKK)3I-NH2 peptide at 1/1 or 4/1 
ratios (b). The number of surviving embryos was recorded at 5 hpf. The graphs show 
little variation in the survival rate of embryos injected with 20 or 40 pg of siRNA when 
compared to the control.  A more severe effect is caused by 60 and especially 80 pg 
where a mortality rate near 50% is observed. The peptide complexed with the siRNA 
had a small effect with the mortality rate around 20-25%. Several batches have been 
used for the experiment and for each of them, few embryos were kept as un-injected 
controls. An average of 50-100 eggs per concentration were injected to ensure sufficient 
sample size to detect variability. Statistically significant difference from the negative 
control was determined by Student’s t-test (*p<0.05). 
 
 
5.7 In vivo caudal injections of FITC-G(IIKK)3I-NH2 peptide 
to evaluate the peptide distribution across the animal 
 
The last section of this chapter explains the results obtained after injecting 4 days post 
fertilisation (4 dpf) larvae in their caudal vein with the peptide FITC-G(IIKK)3I-NH2 or 
just the fluorophore FITC, as control. The purpose of this experiment is to observe the 
behaviour and localisation of the peptide once injected directly in the bloodstream of an 
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animal. It is important to understand how the peptide behaves in the circulation in vivo 
since the peptide could be potentially used to target tumours inside a living organism, 
therefore, it is crucial to have good understanding of its fate in a complex animal 
environment. Caudal injections allow the rapid delivery of soluble compounds directly 
in the bloodstream of the fish and are used as a standard procedure in bacteriological 
studies, where embryos are inoculated with bacteria strains to induce a systemic 
infection 150, 270.   
 
The complete procedure is explained in the correspondent section in Material & Method 
chapter (“2.8.3 Peptides and siGLO microinjections”) but briefly, zebrafish embryos at 
4 dpf were anaesthetized with Tricaine (40 mg/l) and mounted on a Petri dish in 3% 
low-melting point agarose. The agarose solution was made using E3 media, heated until 
dissolved and kept at 37 °C to avoid solidification. Tricaine (40 mg/l) was also added to 
the solution to guarantee continued embryos anaesthetisation during the injections 
procedure. Once mounted, and before the complete solidification of the agarose, 
embryos were positioned laterally to allow a complete view and access to the caudal 
vein with their tail pointing towards the needle tip. The TG(kdrl:HRAS-mCherry) 
transgenic zebrafish line was used to visualize the blood vessels under a fluorescent 
microscope 147. Both FITC and FITC-G(IIKK)3I-NH2 were injected in the embryos at 
the concentration of 25 pg/nl. Once injected, the embryos were quickly checked under a 
Leica M165 FC fluorescent stereo microscope to evaluate injection efficiency.  
Two of the correctly injected embryos per compound were taken from the Petri dish and 
mounted in a glass capillary tube (Transferpettor caps, DE-M, 50 µl, green) with 3% 
low-melting point agarose specific for Light Sheet Fluorescence Microscopy (LSFM) 
151. Images were acquired with the Zeiss Lightsheet Z.1 and further analysed with ZEN 
2014 SP1 software. LSFM is becoming more and more popular as a method to image 
early embryonic development especially for species like Danio rerio, Drosophila 
melanogaster and Caenorhabditis elegans, because allows live imaging at low light 
exposures, reducing photo-bleaching and photo-toxicity 271, 272.  
 
The vascular network in zebrafish embryos can be easily studied to understand 
pathways that are potentially important for pathological conditions, such as vascular 
permeability for instance, which is a major cause of morbidity and mortality in humans 
247, 273, 274. There are a few studies showing how large molecules (>10 KDa) are 
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normally retained in the vasculature once injected while small molecules, on the 
contrary, may rapidly leak out 275, 276. Both, FITC with a weight of 389 Da and FITC-
G(IIKK)3I-NH2  with a weight of 2024 Da were not retained in the vasculature system, 
but instead of leaking out directly from the injection point (caudal vein) they travelled 
in the bloodstream, to the head vasculature and leaked out at the aortic arches which 
will provide circulation to the future gills or at the choroid plexus, a polarised epithelial-
based structure localized in the brain ventricle (Figure 73 and Figure 74) 277. 
 
 
Figure 73. Light sheet images of FITC and FITC-G(IIKK)3I-NH2 caudal injections 
in 4 dpf larvae. 4 dpf larvae were anesthetized with Tricaine (40 mg/l), mounted in 3% 
low-melting point agarose and injected with 25 pg/nl of FITC fluorophore or FITC-
G(IIKK)3I-NH2 peptide. Injections were made in a caudal vein and the distribution of 
the FITC and peptide in the bloodstream immediately observed using Light Sheet 
Fluorescence Microscopy (LSFM). Due to their small size, the two molecules were not 
retained by the vasculature and leaked from the circulation through the aortic arches 
connected with the gills and at the choroid plexus. The transgenic fish strain used for 
this experiment is TG(kdrl:HRAS-mCherry) with membrane localised red fluorescent 
blood vessels.  Bar = 50 µM. All the images are scaled at the same size. 
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The rest of the larval bodies were clear from FITC fluorescence, as it is possible to 
observe from the trunk view in Figure 74. In Figure 74 it is possible to observe also a 
magnification of the dorsal vessel showing FITC fluorophore leaking out from the 
choroid plexus endothelium. 
 
 
Figure 74. Light sheet images of a zebrafish head, trunk and detailed dorsal vessel 
after FITC caudal injections in 4 dpf larvae. 4dpf larvae were anesthetized with 
Tricaine (40 mg/l), mounted in 3% low-melting point agarose and injected with 25 pg/nl 
of FITC fluorophore. Injections were made in a caudal vein and the distribution of the 
FITC in the bloodstream observed using Light Sheet Fluorescence Microscopy (LSFM. 
Due to its small size, the fluorophore is not retained by the vasculature but instead 
leaked out from the fish system. There are only two leakage points; the aortic arches and 
a big vessel located on the dorsal side of the head, possibly the choroid plexus (CP). 
The rest of the body (trunk view) is clear. The fish strain used for this experiment is 
TG(kdrl:HRAS-mCherry) with red fluorescent blood vessels. Bar = 50 µM.                  
All the images are scaled at the same size. 
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6 RNAI SCREENS TO IDENTIFY 
ENDOCYTIC PATHWAYS INVOLVED IN 
PEPTIDE CELLULAR UPTAKE 
RNA-mediated interference (RNAi) is an important cellular process found in almost 
every eukaryotic organism, which post transcriptionally regulates gene expression. 
Endogenously expressed or transfected small RNA molecules target and degrade 
endogenous mRNA transcripts and, as result, a reduction of gene activity is observed 
185. In animals, the phenomenon was firstly discovered in 1993 by Ambros and co-
workers in the nematode Caenorhabditis elegans with lin-4 miRNA, an endogenous 
regulator of genes that control developmental timing 278.  
Many types of small RNAs (between 20-30 nt) have been discovered and can be all 
generally divided into three main categories; short interfering RNAs (siRNAs), which 
are completely synthetic, microRNA (miRNAs) and piwi interacting RNAs (piRNAs), 
the latter two which are found endogenous 279, 280. siRNAs and miRNAs derive from 
double stranded precursors, while piRNAs are mainly found in the germline and 
originate from single stranded precursors. Moreover both miRNAs and siRNAs are 
recognized by Argonaute (Ago) proteins while piRNAs bind to members of the Piwi 
family 279. siRNAs are recognized by the protein Dicer (Dicer-2 in Drosophila) and are 
~ 21 nt duplexes 281. The RNAs duplex is then incorporated in the RISC complex bound 
to Ago2, a protein member of the Argonaute family. The passenger strand is discharged 
while the RISC complex becomes functional. Target mRNA decay is activity dependent 
upon Ago2, which has a slicer function 279, 282. siRNAs (~ 21 nt length) duplexes are 
mainly synthetically produced and use to directly transfect cells 133, 185.  
Since the discovery of RNAi, the technology moved forward on a more global scale and 
today many siRNA libraries are commercially available on the market. With nearly 
complete genome coverage for several species, human included, it is possible to pursue 
large-scale functional genomic screens and identify therapeutic targets or elucidate 
specific biomolecular pathways using a different approach compared to classical genetic 
screens 283, 284. The main advantages are that the sequences of identified genes are easily 
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retrieved, and can be knocked down. Unfortunately, there are some disadvantages, such 
as the possibility of off targets effects (OTEs) which would produce false 
negative/positive results and more importantly proteins with long half-lives that hardly 
would be affected by the knocking down activity of RNAi 285, 286. However, with new 
algorithms for rules of target design and additional chemistries to improve siRNA 
efficacy, recent research has abated some of the worries regarding OTEs. 
 
High-content screening (HCS) is a recent technique developed in the late 90’s that 
combine automated fluorescent microscopy with image analysis. With this technology, 
it is possible to collect quantitative data from complex biological systems. The pairing 
of HCS with RNAi allowed to perform either genome-scaled or focussed library cell-
based screens to a wide variety of cell types, mammalian included 287. High-content 
genome-wide screens are successfully applied in preclinical drug discovery or in cell 
biology to identify molecular targets involved in signal transduction, cell cycle, 
organelles morphology, protein localisation and/or function and responses to pathogens 
288. Thanks to the major progress achieved in microscopy it is now possible to finely 
image structures and identify molecular compartments of cells. HCS is based on the 
microscope’s ability to acquire multiple high-quality functional and morphometric 
images of individual cells and contemporary analyse all the phenotypic variations in 
accordance to the administration of specific compounds 289. 
 
Using a siRNA library for endocytosis-related genes, one high-content genome screen 
and a mini-validation screen were performed on HCT-116 cancer cells as an approach 
to identify the pathway(s) involved in FITC-G(IIKK)3I-NH2 and FITC-A9K cellular 
uptake. The complete methodology is explained in section “2.9.6 RNAi screen to 
elucidate the peptide uptake in cancer cells” of Chapter 2, Materials and methods but 
briefly, HCT-116 cancer cells were transfected with 30 nM of siRNAs using the reverse 
transfection method 139 and after 3 days of incubation, 6.25 μM of  fluorescent peptide 
was added for other 24 hrs. Cells were then fixed and stained with the standard solution 
of 4% formaldehyde and Hoechst (2 μg/ml) and imaged using the ImageXpress® Micro 
System fluorescent microscope. Quantitative analyses of the variations in fluorescence 
intensity between transfected cells were performed using MetaXpress® 5.0.0.20 
software. Brightness and contrast were adjusted for all images to the same level by 
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using Image J. The FITC-A9K mini-screen was performed by the student Joanna Henry, 
as part of her MSc final project. 
 
 
6.1 Assay development screening for FITC-G(IIKK)3I-NH2 
 
Prior to conducting the high-content screen, assay development screening was 
performed. The parameters of the assay were identified from this approach, establishing 
the correct experimental conditions for a successful screen. The primary parameters that 
needed to be established were, seeded cell number, the amount of DharmaFECT1 (DF1, 
Dharmacon) used for reverse transfection, the assay window and in this specific case the 
correct peptide concentration to be added to the cells. More importantly relevant genes 
have to be identified as possible “hits” if knocked down using RNAi 285.  
 
Few experiments were conducted to evaluate the suitable initial seeding cell number for 
HCT-116, which was then established to be 2x103 cells per well (384 well plate format). 
A reduced cell number could in fact not only increase the cells sensitivity towards DF1 
but also give misleading results such as increased sensitivity to either DF1 or peptide 
exposure. On the other side, an elevated cell number could equally compromise the 
screen outcome; if the cells reach confluence, and in the case of cancer cells, start to 
overgrow, it is more difficult to perform a correct analysis afterwards. Cells on the plate 
need to be individually identified by using pre-defined algorithms, but when over-
confluent, the software would struggle to recognise individual boundaries between cells 
and would end up producing ambiguous results, i.e. undercounting cells or peptide. 
 
In the same way, the amount of DF1 is critical, too much of it and cells would die but 
too little and the transfection efficiency would decrease. For HCT-116 the chosen 
volume was 0.05 µl per well (total medium volume in each well was set at 25 µl). Cells 
were left with the transfection medium for the duration of 3 days. In this way, plenty of 
time was given for the gene-silencing process. Finally, the selected concentration of 
peptides was 6.25 µM, enough to give a good fluorescent signal but without inducing 
extreme toxicity (see Figure 45, Chapter 4). 
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For this assay, a siRNA library called assay development plate 2 (ASD2), specifically 
designed for genome-wide RNAi screens was used. See Table 6 at the end of this 
chapter for the complete list of genes. The library created by the Sheffield RNAi 
Screening Facility, SRSF (http://www.rnai.group.shef.ac.uk/) was predominantly 
composed of a selection of siRNAs which knock down kinases involved in many 
cellular functions. Few other siRNAs were specific for genes related with endocytic 
pathways and therefore chosen as possible “hits”. Literature was scanned and the 
selected siRNAs were Actin related protein 2 homolog (ACTR2), ADP-ribosylation 
factor 6 (ARF6), caveolin 1 (CAV1), clathrin heavy chain (CLTC), dynamin 2 
(DNM2), myosin Va (MYO5A), myosin Vb (MYO5B), myosin Vc (MYO5C) and ras-
related protein 7a (RAB7A) (see Table 4 for genes IDs and functions). Cells were 
transfected with four non-targeting siRNAs and then exposed to the peptide. They 
represented the negative controls and the standard phenotype to be compared with. The 
images collected from the possible “hits” were confronted with the negative controls in 
search of variations in the phenotypes and quantitatively analysed according on the 
amount and distribution of the fluorescent peptide across the cells compartments. 
 
Table 4. List of the genes for which siRNAs were selected in the assay development 
screening as possible “hits” for FITC-G(IIKK)3I-NH2 peptide. Gene name, NCBI's 
database gene ID and gene function are provided.  
Gene ID Function 
ACTR2 10097 
ATP-binding component of the Arp2/3 complex which is involved 
in regulation of actin polymerization 157 
ARF6 382 
GTP-binding protein involved in protein trafficking that regulates 
endocytic recycling and cytoskeleton remodelling 159 
CAV1 857 Scaffolding protein within caveolar membranes 160 
 
CLTC 
 
1213 
Clathrin heavy chain protein is one of the components of a 
polyhedral structure of coated pits and vesicles which entrap 
specific macromolecules during receptor-mediated endocytosis 158 
DNM2 1785 
GTP-binding protein associated with microtubules and implicated 
in endocytosis and cell motility 161 
MYO5A 
MYO5B 
MYO5C 
4644 
4645 
55930 
Class of actin-based motor proteins involved in cargoes transport 
endocytic vesicular trafficking and endosomes recycling in 
neuronal and epithelial cells 162, 163 
RAB7A 7879 
Key regulator in endo-lysosomal trafficking and in the early-to-
late endosomal maturation 164 
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ACTR2 gene encodes for Actin Related Protein 2 Homolog, a component of the Arp2/3 
complex 157. Arf 6 (ADP-ribosylation factor 6) is a GTP-binding protein with a variety 
of cellular functions including membrane trafficking, modulation of actin cytoskeleton, 
endosomal recycling, cell migration and cell polarity. Arf 6 may also contribute to the 
membrane recruitment of AP-2 159.  
 
Caveolin 1 (Cav 1), together with Caveolin 2 and 3 (Cav 2- 3) are structural proteins 
required for the formation of caveolae, flasks-shaped plasma membrane invaginations 
implicated in endocytosis, cholesterol and lipid metabolism and cellular signalling. Cav 
1 and Cav 2 are expressed in many tissues but especially in endothelial cells, 
adipocytes, fibroblasts and smooth-muscle cells while Cav 3 is uniquely expressed in 
skeletal and cardiac muscle 160. Moreover, there have been controversial evidence 
implying that Cav 1 can be both a tumour suppressor and an oncogene, depending on 
the tissue where it is expressed. However, few studies proved that the overexpression of 
Cav 1 is associated with several cancers and it is responsible for tumour invasion, drug 
resistance and a general indicator of poor prognosis 290.  Specifically, colorectal tumours 
and human colon cancer cell lines, HCT-116 included, have been shown to frequently 
abnormally express Cav 1 291, 292. 
 
Dynamin 2 (DNM2) is a large GTP-ase involved in the endocytosis. In mammals, there 
are three dynamin genes (DNM 1-2-3) which share 80% of homology but are expressed 
in different tissue; Dynamin 1 is highly expressed in neurons, Dynamin 2 is 
ubiquitously expressed while Dynamin 3 is found in brain (in low levels), testis and in 
some other tissues. Dynamins are localised at sites of endocytosis on the plasma 
membrane. Their principal role is the membrane fission, mainly associated with 
clathrin-mediated endocytosis events; dynamins self-assemble into helical polymers at 
the bottom of budding vesicles and via GTP hydrolysis-dependent activity promote the 
membrane detachment to generate a free endocytic vesicle 161. 
Myosin Vs (myo V) is a family of cytoskeletal motor proteins that transport cargoes 
(secretory and endocytic vesicles, mRNA, lipids and proteins) along actin filaments. In 
humans, there are three classes of myosin Vs (Va, Vb and Vc) which are associated to 
specific sets of membrane trafficking events and share about 50% of amino acidic 
sequence. They are organised in different domains: a globular head containing a highly 
conserved motor domain responsible for generating movement via an actin-activated 
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ATPase; an extended α-helical neck region adjacent to the head which regulates the 
activity of the head domain and a tail which contains the binding sites that link myosin 
Vs to their cargoes. Myo Va is most abundant in brain tissue and melanocytes, while 
myo Vb and myo Vc are mainly expressed in epithelial cells 162. Moreover, myo Vb is 
associated with the endosomes recycling 163. 
Ras-related protein 7a is a protein encoded by RAB7A gene. It has been called Rab 7a 
to distinguish it from Rab 7b, a protein involved in the regulation of membrane 
trafficking from late endosomes to the trans-Golgi network (TGN) 293. Rab 7a is a small 
GTPase of the Rab family ubiquitously expressed and mainly associated with late 
endosomal structures and lysosomal compartments. It controls vesicle trafficking from 
late endosomes to degradative compartments. Rab 7a is also required in growth-factors 
transport or in specialised endosomal membrane trafficking such as melanosomes, 
pathogen-induced phagosomes and autophagosomes 164.  
 
Four non-targeting siRNAs (On-TARGETplus non-targeting control #2, #3, #4 #5) 
were chosen instead as negative controls.  
 
To establish whether the negative controls did not cause any adverse effects, or the 
siRNAs selected to target the endocytic pathway, a series of experiments were 
performed. Cell counting analyses presented in Figure 75 shows that the transfections 
made with the non-targeting siRNAs did not interfere with the cell viability (Figure 75 
a), while depending on the functional siRNA, a variation in cell number could be 
observed (Figure 75 b). A decrease in the cellular growth was encountered with 
ACTR2, CAV1 and MYO5B genes knock down where the number of cells counted 
were 25%, 47% and 36% compared to the negative controls average, respectively. 
Knock down of ARF6 and MYO5A, MYO5C and RAB7A decreased the cell number to 
63%, 60%, 78% and 70%, respectively. Knock downs of CLTC and DNM2 instead did 
not affect the cell population. 
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Figure 75. HCT-116 cell number evaluated with high-content microscopy after 
RNAi and FITC-G(IIKK)3I-NH2 exposure. Cells were transfected with (a) non-
targeting siRNAs; (b) endocytosis-related siRNAs for three days, exposed to the peptide 
for another day then fixed in formaldehyde and stained with Hoechst 3342 (2 µg/ml) to 
reveal the nuclei. Images were acquired using ImageXpress® Micro microscope and the 
cell number was counted using the Multi Wavelength Scoring algorithm within the 
MetaXpress® software. The results are expressed as a percentage of number of cells 
normalized to the negative control (mean of the 4 non-targeting siRNAs). The values 
obtained are averages of independent experiments ± standard error mean (±SEM). 
Statistically significant differences from the negative control were determined by 
Student’s t-test (*p<0.05; **p<0.01; ***p<0.001). 
 
Knock down effects and correlation with variation in the cell population were made 
with the rest of the plate; the siRNAs that caused a reduction in cell number of 95% or 
more were plotted in the graph showed in Figure 76. All the knock down genes were 
kinases involved in biological functions linked to metabolism, cell signalling, 
proliferation, inflammatory response, differentiation and apoptosis. Therefore, their 
cellular depletion should generally induce a significant decrease of the cell number. 
Moreover, upregulation of these kinases has been observed also in numerous types of 
cancer. 
 
  
191 
 
 
Figure 76. Bottom 5% of HCT-116 cells number count evaluated with high-content 
microscopy after kinases knock down via RNAi and FITC-G(IIKK)3I-NH2 
exposure. Cells were transfected with siRNAs for three days, exposed to the peptide for 
another extra day, then fixed in formaldehyde and stain with Hoechst 3342 (2 µg/ml) to 
reveal the nuclei. Images were acquired using ImageXpress® Micro microscope and 
cell number was counted using the Multi Wavelength Scoring algorithm within the 
MetaXpress® software. The results are expressed as a percentage of number of cells 
normalized to the negative control (mean of the 4 non-targeting siRNAs). The values 
obtained are averages of independent experiments ± standard error mean (±SEM). 
Statistically significant differences from the negative control were determined by 
Student’s t-test (***p<0.001). 
 
The evaluation of the amount of internalised peptide per cell revealed interesting results; 
the knock down of ARF6 significantly increased the peptide concentrations while with 
the exclusion of ACTR2 and RAB7A which were not significant, for all the others an 
important decrease in peptide uptake was observed (Figure 77). ARF6 regulates the 
endosomal-membrane traffic and it is essential for the endosomal recycling to the 
plasma membrane in both clathrin-dependent and -independent pathways 159. The 
important observation of increased peptide concentration when Arf 6 is knock down 
could suggest that not only the peptide is internalised via endocytosis but also that, in 
normal conditions, it is recycled back to the cell surface.   
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Figure 77. Variation in the fluorescence intensity evaluated with high-content 
microscopy in HCT-116 cancer cells after RNAi and FITC-G(IIKK)3I-NH2 
exposure. Cells were transfected with siRNAs for three days, exposed to the peptide for 
another extra day then fixed in formaldehyde. A quantitative analysis of the green FITC 
fluorescence (a) was performed. The results are expressed as a percentage of FITC 
Integrated Intensity and normalised to the negative control (mean of the 4 non-targeting 
siRNAs). The values obtained are averages of independent experiments ± standard error 
mean (±SEM). Statistically significant differences between non-targeting and targeting 
siRNA transfections were determined by Student’s t-test (*p<0.05; **p<0.01). In (b) 
images showing the distinct levels of FITC intensity related to the different genes knock 
down. Hoechst 33342 (2 µg/ml) (blue) was used as nuclear staining. Bar = 25 µm. All 
the images are scaled at the same size. 
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6.2 High-content genome screen on FITC-G(IIKK)3I-NH2 
 
For the high content screen on the fluorescent peptide FITC-G(IIKK)3I-NH2 a designed 
library called Traffic-ome was used (genes selected by Prof Elizabeth Smythe and Dr. 
Andrew Peden); a plate with more than 200 siRNAs targeting the gene expression of 
genes involved in endocytic pathways. See Table 7 at the end of this chapter for the 
complete list of genes. The experimental procedure was the same adopted for the assay 
development and explained in the previous section.  
Once fixed, the cell number was counted and the FITC fluorescence intensity quantified 
using MetaXpress®. The data were subsequently normalized using the robust z-score 
method (Z = (Xi-median)/MAD) which uses median and median absolute deviation 
(MAD) instead of mean and standard deviation. The median absolute deviation is 
defined as MAD = median (|Xi - median (Xi…n)|) and corresponds to the median of the 
absolute deviation from the median of the data points Xi to Xn. It is less sensitive to 
outliers than the standard deviation therefore more preferable to use in RNAi screens 294, 
295. The possible “hits” were identified in the outliers scoring ≥ - 3.5 or + 3.5 z-scores. 
 
The identified hits were 31; Rin 1, Use 1, Rin 2 and Copa knock downs gave Z-scores 
very high compared to the rest of the distribution (Figure 78 a). Images of the 
correspondent cells (Figure 78 b) show how the fluorescence intensity of the peptide is 
much higher compared to the negative control cells (transfected with non-targeting 
siRNAs); especially in the case of Rin1, where the peptide completely saturated the cell 
cytoplasm. The predictive interactions between them could be observed in Figure 79 
The representation was built using STRING 10.5 database (https://string-db.org/). 
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Figure 78. Z-scores distribution and string map of putative hits genes. The robust 
Z-score method was used to normalise the data obtained from independent replicates. In 
(a) there is the graphical representation of the RNAi screen output with the distribution 
of Z-scores across the whole library. In (b) there are images of cells in which Rin 1, Use 
1, Rin 2 and Copa were knocked down. The level of green FITC fluorescence intensity 
were much higher compared to the control (non-targeting siRNAs). Hoechst 33342 (2 
µg/ml) (blue) was used as nuclear staining. Bar = 25 µm. All the images are scaled at 
the same size. 
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Figure 79. Schematic representation interactions between the hits found in the 
screen. String 10.5 was used to create the hit interaction map. The majority of the genes 
found as hits are interconnected with each other forming an intricated net which could 
be divided in two main clusters; one related to the vesicles trafficking to and from the 
Golgi network and one associated with the early endosome and vesicles recycling. The 
lines were created according to text mining (yellow), experiment results (pink) or online 
databases (blue). 
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The hits can be divided in two big interconnected clusters; one related with endocytic 
recycling pathways and the other regarding vesicles transport between secretory 
compartments but mainly associated with the Golgi network. Excluded from these 
groups there are only three genes; IP6K3 which encodes for the Inositol hexaphosphate 
kinase 3, a protein that regulates inositol phosphate-stimulated vesicle formation and 
trafficking 296; ADAM10 that encodes for a sheddase, metallopeptidase which cleaves 
membrane proteins at the cellular surface 297 and WASF3 that encodes for Wiskott-
Aldrich syndrome protein family member 3, a protein that plays a crucial role in actin 
polymerization through the activation of the actin-related protein (Arp) 2/3 complex and 
it is required for filopodia formation and cell motility 298. 
 
Associated with the recycling pathways cluster there are Rin 1, Rin 2, and Rin 3 which 
have all been found with high z-scores. These proteins are Guanine Nucleotide 
Exchange Factors (GEFs) for Rab proteins and are involved in many biological 
functions including cell growth, differentiation and endocytosis receptor mediated 299. 
Several components of the Rab family, the largest group of Ras superfamily of 
monomeric G proteins generally involved in vesicle trafficking were found as hits: Rab 
5b, Rab GEF1, Rab 4a, Rab 4b and Rab 11FIP5 specifically involved in the kinetics of 
membrane trafficking in the early endocytic pathway, and in the regulation of both rapid 
and slow endocytic recycling 300-303. Interestingly, Arf 6, involved in many biological 
functions including membrane trafficking and endosomal recycling, was already 
identified as a hit from the pilot screen, performed prior to the main one. ARFIP2 a 
gene that encodes for ADP Ribosylation factor interacting protein 2 (or Arfapti-2) 
involved in mediating cross-talk between Rac (a member of the Rho family) and Arf 1 
or Arf 6 was found with a positive z-score as well 159. 
 
The majority of hits fell in another big cluster which contains proteins more generally 
involved in vesicular trafficking, especially to and from the Golgi Network. The hits Bet 
1-like, Gosr 1, Snap 25, Syntaxins 6, 12, 16 and 19, Use 1, Vtib and Ykt 6 are all 
Soluble N-ethylmaleimide-sensitive factor attachment protein (SNAP) receptors 
(SNAREs), involved in targeting and fusion of Golgi-ER derived anterograde, 
retrograde and and intra-Golgi vesicles transport 304-311. The Syntaxin binding protein 
(or Munc 18-1) encoded by STXBP1 gene was considered a hit; this protein is an 
essential exocytotic vesicle trafficking protein which strongly interacts with Syntaxins. 
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In the same cluster there is also the N-ethylmaleimide-sensitive factor (NSF), homo-
hexameric ATPase indispensable for numerous intracellular fusion processes 312, and 
Coatomer subunit α, part of a cytosolic protein complex (coatomer) required for 
membrane trafficking of coated vesicles in the Golgi-ER (ER) retrograde transport 313. 
 
Other few hits genes were related to the clathrin-dependent endocytosis, including 
AP2A2, AP2B1, DAB2 and DNM3. The presence of these hits gave positive 
confirmation that the RNAi screen effectively worked.  Adaptor related protein complex 
2 subunit alpha 2 and adaptor related protein complex 2 subunit beta are components of 
the adaptor protein complex 2, involved in cargo selection 156. Disabled homolog 2 is an 
endocytic adaptor protein implicated in clathrin-mediated endocytosis and cargo 
trafficking in eukaryotes 314 while Dynamin 3 is a large GTP-ase associated with 
microtubules and involved in membrane fission events mainly associated with clathrin-
mediated endocytosis 315.  
 
Valosin-containing protein (VCP), instead, also known as ATPases associated with 
diverse cellular activities (AAA+) or ATPase p97, performs various biological 
functions; included protein degradation, DNA repair, DNA replication, cell cycle 
regulation, membrane fusion and biogenesis of ER, Golgi and lysosomes and regulation 
of the Endoplasmic reticulum-associated degradation (ERAD) pathway 316. The ERAD 
allow the retrotraslocation of failed folded proteins from the ER into the cytosol to be 
further degraded by the proteasome 317.  
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6.3 RNAi mini-screen with FITC-A9K 
 
To establish whether there are differences between the two peptides used in this thesis 
FITC-A9K was screened investigating FITC-A9K internalisation pathway. Selected 
genes were knocked down using RNAi and cells were exposed to a fixed concentration 
of peptide according to the procedure previously explained. Adaptor related protein 
complex 2 subunit alpha 2 (AP2A2), adaptor related protein complex 2 subunit beta 
(AP2B1), actin related protein 2/3 complex subunit 1 B (ARPC1B), clathtrin light chain 
a (CLTA), clathrin light chain b (CLTB) and clathrin heavy chain (CLTC) siRNAs were 
selected to knock down the corresponding gene expression. The siRNAs were from 
SiGenome collection of design siRNAs from Dharmacon (see Table 5 for information 
regarding the genes IDs and functions). All these genes, with the exclusion of ARPC1B, 
are strictly related with the clathrin-dependent endocytic pathway. 
 
Table 5. List of the genes for which siRNAs were selected in the mini-screen for 
FITC-A9K peptide. Gene name, NCBI's database gene ID and gene function are 
provided.  
Gene ID Function 
AP2A2 161 Components of the adaptor protein complex 2, which is involved 
in cargo selection in the clathrin-dependent endocytosis 156 AP2B1 163 
ARPC1B 10095 
Subunit of the human Arp2/3 protein complex which is involved 
in the regulation of actin polymerization 157 
CLTA 1211 Clathrin light and heavy chain proteins components of a 
polyhedral structure of coated pits and vesicles which entraps 
specific molecules during receptor-mediated endocytosis 158 
CLTB 1212 
CLTC 1213 
 
Clathrin is a protein involved in coating vesicles, which are then endocytosed from the 
plasma membrane into endosomes. Clathrin is composed of three heavy chains and 
three light chains that rearrange in a typical triskelion shape. Humans possess two 
isoforms of clathrin heavy chain, Chc17 and Chc22, but only Chc17 is involved in 
membrane trafficking. Chc22 is expressed in skeletal muscle and has been reported to 
have a role in membrane organisation. Chc17 and Chc22 are encoded by CLTC and 
CLTD genes that share 85% of amino acid similarity. Moreover, CLTA and CLTB 
genes encode the only two clathrin light chains found in humans (a and b) which are 
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both involved in endocytosis and have 60% amino acid identity. When clathrin triskelia 
nucleate they form a polyhedral lattice (hexagonal or pentagonal) that surrounds 
vesicles and allows their transportation into the cell 158.  
The clathrin cages alone are not able to bind the membranes but they need specific 
adaptor protein complexes to do so. There are 5 different adaptor protein complexes 
(AP-1/5) which mediate intracellular endocytic membrane trafficking and secretory 
transport pathways but only AP-1, AP-2 and AP-3 are associated with clathrin. Each 
complex is composed by two large subunits (one each of γ/α/δ/ε/ζ and β1-5, 
respectively), one medium-sized subunit (μ1–5) and one small-sized subunit (σ1–5) 318. 
AP-2 contains α-, β2-, μ2-, and σ2-subunits and localises on the plasma membrane. It is 
involved in the clathrin-dependent endocytosis of many molecules included receptors, 
adhesion molecules. The large α- subunit binds to PIP2 (phosphatidylinositol (4,5)-
bisphosphate), positioning AP-2 on the membrane, while the other large subunit β2- 
binds to the terminal domain of Chc17 promoting the lattice assembly. The cargo 
proteins are recognised and bound by the medium μ2- subunit. The small subunit σ2- 
instead seems to have more a structural role 156. ARPC1B encodes for one of the seven 
subunits Arp2/3 complex, which is involved in the regulation of the actin filaments 
polymerisation. Arp2/3 complex is crucial for a variety of the eukaryotic cellular 
processes related with the actin cytoskeleton; including cell migration, endocytosis, 
vesicles trafficking and cytokinesis 157. 
 
To investigate whether the endocytic genes are involved in the peptide uptake, an 
siRNA knock down mini-screening experiment was done. Red fluorescent siGLO 
(Dharmacon) was selected as positive control for the transfection efficiency while 5 
non-targeting siRNAs (On-TARGET plus non-targeting control #1, #2, #3, #4 and Non-
targeting pooled - all 4 siRNAs) were selected as negative controls. 
 
Procedures for knock down and the assay are as before and once the cells were fixed 
and stained using the standard fixation protocol, a cell count analysis was performed to 
evaluate the cells health and ensure that the transfection with non-targeting siRNAs 
(negative controls) did not cause a decrease in cell viability. Cells were counted using 
the MetaXpress® Software 5.0.0.20 that recognizes the Hoechst stained nuclei. The 
results are shown in Figure 80. Panel (a) shows data from the negative control siRNAs. 
None of the non-targeting siRNAs gave cellular toxicity. Figure 80 (b) shows the cell 
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counts from the functional siRNAs. None of the chosen siRNAs induced a significant 
decrease in cell growth. Transfection using the red fluorescent siGLO did not decrease 
cell viability with a value of 92% compared to the negative control (data not shown). 
 
 
Figure 80. HCT-116 cell number evaluated with high-content microscopy after 
RNAi and FITC-A9K exposure. Cells were transfected with (a) non-targeting siRNAs; 
(b) endocytosis-related siRNAs for three days, exposed to the peptide for another day 
then fixed in formaldehyde and stain with Hoechst 33342 (2 µg/ml) to reveal the nuclei. 
Images were acquired using ImageXpress® Micro microscope and cell number was 
counted using the Multi Wavelength Scoring algorithm within the MetaXpress® 
software. The results are expressed as a percentage of number of cells normalized to the 
negative control (mean of the 5 non-targeting siRNAs). The values obtained are 
averages of independent experiments ± standard error mean (±SEM). Statistically 
significant differences from the negative control were determined by Student’s t-test 
(*p<0.05). 
 
Once established that the siRNAs were not toxic, the integrated intensity of the peptide 
fluorophore, FITC, was measured using High Content Microscopy. If endocytosis is 
involved in the peptide uptake, the RNAi knock down of the selected target mRNA will 
cause a significant reduction in peptide FITC signal inside the cells. The results of the 
quantitative analysis of the total FITC fluorescence intensity per cell are graphically 
expressed in Figure 81 (a) and represented as a percentage compared to the negative 
controls of total FITC fluorescence. It is possible to observe, when the cells were 
transfected with the functional siRNAs the amount of peptide internalised drastically 
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dropped by 70% or more, suggesting that endocytosis and possibly the clathrin-
mediated one plays a crucial role in the A9K internalisation. Images of the cells 
following siRNA transfection and peptide exposure (Figure 81 b) confirmed poor A9K 
uptake, especially compared to cells transfected with non-targeting siRNAs. 
 
Figure 81. Variation in the fluorescence intensity evaluated with high-content 
microscopy in HCT-116 cancer cells after RNAi and FITC-A9K exposure. Cells 
were transfected with siRNAs for three days, exposed to the peptide for another day 
then fixed in formaldehyde. A quantitative analysis of the green FITC fluorescence (a) 
was performed, the results expressed as a percentage of FITC Integrated Intensity and 
normalised to the negative control (mean of the 5 non-targeting siRNAs). The values 
obtained are averages of independent experiments ± standard error mean (±SEM). 
Statistically significant differences between non-targeting and targeting siRNA 
transfections were determined by Student’s t-test (***p<0.001). In (b) images showing 
the distinct levels of FITC intensity related to the different genes knocked down. 
Hoechst 33342 (2 µg/ml) (blue) was used as nuclear staining. Bar = 25 µm. All the 
images are scaled at the same size.  
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Table 6. List of genes in ASD2 siRNA library. Gene names and IDs provided. 
Gene ID Gene ID Gene ID Gene ID 
ACTR2 10097 CSNK1G1 53944 MYO5A 4644 PRKG1 5592 
ADP-GK 83440 DGKB 1607 MYO5B 4645 PSKH1 5681 
AK1 203 DNM2 1785 MYO5C 55930 PTK9 5756 
AK7 122481 DYRK4 8798 NAGK 55577 RAB7A 7879 
ALS2CR7 65061 EEF2K 29904 NEK11 79858 RIOK1 83732 
ANKK1 255239 EPHA10 284656 NEK4 6787 RIOK2 55781 
ARF6 382 EPHA5 2044 NME5 8382 RIPK2 8767 
AURKC 6795 ERK8 225689 NPR2 4882 RPS6KA4 8986 
BMP2K 55589 ETNK1 55500 PAPSS2 9060 RPS6KB2 6199 
CALM1 801 FGFR3 2261 PCTK3 5129 SGK2 10110 
CAV1 857 FLJ32685 152110 PDGFRL 5157 SNF1LK 150094 
CAMK2G 818 FRAP1 2475 PDK2 5164 SNRK 56861 
CAMKIINALPHA 55450 GOLGA5 9950 PFKP 5214 SRC 6714 
CAMKK2 10645 GUCY2D 3000 PFTK1 5218 STK17B 9262 
CDC7 8317 HCK 3055 PHKB 5257 STK24 8428 
CKMT1B 1159 IRAK1 2654 PIK3CA 5290 STK25 10494 
CKS1B 1159 IRAK4 51135 PIK3CG 5294 TNNI3K 51086 
CKSC1B 1163 ITPKC 80271 PRKAA1 5562 TRIO 7204 
CLK1 1195 KIAA1361 57551 PRKCE 5581 TRPM6 140803 
CLTC 1213 KIAA1639 57729 PRKCL1 5585 URKL1 54963 
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Table 7. List of genes in the Traffic-ome siRNA library. Gene names and IDs provided. In bold the hits found with the RNAi screen. 
Gene ID Gene ID Gene ID Gene ID Gene ID Gene ID Gene ID 
ACTR2 10097 ARPC1B 10095 CBLC 23624 EPN1 29924 ITSN2 50618 PIK4CA 5297 RAB7B 338382 
ACTR3 10096 ARPC2 10109 CDC42 998 EPN2 22905 LIMK1 3984 PIP5K1A 8394 RAB7L1 8934 
ADAM10 102 ARPC3 10094 CFL1 1072 EPN3 55040 MAP1LC3A 84557 PSCD3 9265 RAB8A 4218 
ALS2 57679 ARPC4 10093 CIB1 10519 EPS15 2060 MAP4K2 5871 RAB11A 8766 RAB8B 51762 
AMPH 273 ARPC5 10092 CIB2 10518 EPS15L1 58513 MAPK8IP1 9479 RAB11B 9230 RABEP1 9135 
ANKFY1 51479 ARRB1 408 CIB3 117286 EXOC6 54536 MAPK8IP2 23542 RAB1A 5861 RABGEF1 27342 
AP1B1 162 ARRB2 409 CLTA 1211 EXOC7 23265 MAPK8IP3 23162 RAB2 5862 RAC1 5879 
AP1M1 8907 ATG12 9140 CLTB 1212 FLOT1 10211 MICAL1 64780 RAB21 23011 RAPH1 65059 
AP1M2 10053 ATM 472 CLTC 1213 FYN 2534 MYO5A 4644 RAB22A 57403 RBSN 64145 
AP2A1 160 ATP6V0A1 535 CLTCL1 8218 GAF1 26056 MYOVB 4645 RAB31 11031 RHOA 387 
AP2A2 161 BECN1 8678 COPA 1314 GAPVD1 26130 MYO5C 55930 RAB3A 5864 RIN1 9610 
AP2B1 163 BET1 10282 DAB2 1601 GIT1 28964 NEDD4 4734 RAB3B 5865 RIN2 54453 
AP2M1 1173 BET1L 51272 DDEF2 8853 GOPC 57120 NEDD4L 23327 RAB3C 115827 RIN3 79890 
AP3D1 8943 BIN1 274 DIAPH1 1729 GORASP1 64689 NSF 4905 RAB3D 9545 ROCK1 6093 
AP4E1 23431 BNIP1 662 DNM1 1759 GOSR1 9527 OCRL 4952 RAB4A 5867 ROCK2 9475 
APPL1 26060 C13ORF9 51028 DNM2 1785 GOSR2 9570 PACSIN1 29993 RAB4B 53916 SARA1 56681 
APPL2 55198 CAMK1 8536 DNM3 26052 GRB2 2885 PACSIN3 29763 RAB5A 5868 SCFD1 23256 
ARF1 375 CAV1 857 EEA1 8411 HGS 9146 PAK1 5058 RAB5B 5869 SEC13L1 6396 
ARF6 382 CAV2 858 EFS 10278 HIP1 3092 PDCD6IP 10015 RAB5C 5878 SEC22A 26984 
ARFIP2 23647 CAV3 859 EHD1 10938 HIP1R 9026 PICALM 8301 RAB6A 5870 SEC22B 9554 
ARHGAP26 23092 CBL 867 ELKS 23085 IP6K3 117283 PIK3C2G 5288 RAB6B 51560 SEC22C 9117 
ARHGDIA 396 CBLB 868 ENTH 9685 ITSN1 6453 PIK3CG 5294 RAB7A 7879 SH3GL2 6456 
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Gene ID Gene ID Gene ID Gene ID Gene ID Gene ID Gene ID 
SH3GLB1 51100 SNX9 5148 STX8 9482 STXBP2 6813 TSG101 7251 VAPA 9218 VTI1A 143187 
SH3GLB2 56904 STAU 6780 STX10 8677 STXBP3 6814 USE1 55850 VAPB 9217 VTI1B 10490 
SNAP23 8773 STX1A 6804 STX11 8676 STXBP5L 9515 VAMP1 6843 VAV2 7410 WAS 7454 
SNAP25 6616 STX2 2054 STX12 23673 STXBP6 29091 VAMP2 6844 VCP 7415 WASF1 8936 
SNAP29 9342 STX3 6809 STX16 8675 SYNJ1 8867 VAMP3 9341 VIL2 7430 WASF2 10163 
SNAP47 116841 STX4 6810 STX17 55014 SYNJ2 8871 VAMP4 8674 VPS33A 65082 WASF3 10810 
SNAP91 9892 STX5 6811 STX18 53407 SYT1 6857 VAMP5 10791 VPS33B 26276 YKT6 10652 
SNX1 6642 STX6 10228 STX19 415117 SYT2 127833 VAMP7 6845 VPS45 11311   
SNX2 6643 STX7 8417 STXBP1 6812 TNIK 23043 VAMP8 8673 VPS4A 27183   
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7 DISCUSSION AND CONCLUSIONS 
7.1. Introductory background  
 
Cancer is one of the leading causes of death worldwide and, according to the World 
Health Organisation (WHO), in 2015 it was responsible for almost 9 million deaths, 
second only to ischaemic heart diseases and strokes, which together caused the death of 
nearly 15 million people (http://www.who.int/topics/cancer/en/). The National Cancer 
Institute, one of the eleven agencies of the U.S. Department of Health and Human 
Services, in its annual report predicted that in 2017 there will be almost 2 million new 
diagnosed cases and 600’000 deaths in the US alone 319.  
 
With these numbers, it is not a surprise to read that in the last decades many efforts have 
been made to find a successful approach to cure cancer. The standard strategies, 
especially when surgery is not an option, are chemotherapy and radiotherapy. 
Unluckily, these procedures are often ineffective and give severe short- and long-term 
side effects due to the lack of cell-selectivity 320. 
 
Novel cancer therapies have been proposed with the aim of improving the selectivity 
towards the malignant cells and, at the same time, to minimise the side effects. Targets 
of these new approaches are the so called “hallmarks of cancer”; specific characteristics 
that favour the tumour development, growth and metastasising. These include sustained 
proliferative signalling, evasion of growth suppressors, induced angiogenesis, genomic 
instability and evasion of immune detection and destruction 321. 
 
Examples are the immunotherapies such as antibodies or personalised cancer vaccines 
which in the recent years, have been object of intensive study 322. The main purpose of 
these therapies is to boost the immune system’s ability to target and destroy cancer 
cells. Cancer vaccines are designed to stimulate T-cells to target antigens normally 
overexpressed in cancer cells called tumour-associated antigens (TAAs). Sipuleucel-T 
was the first therapeutic cancer vaccine to treat prostatic tumours to be approved by the 
U.S. Food and Drug Administration (FDA) in 2011. It consists of autologous dendritic 
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cells activated in culture and presenting the human protein PAP–GM-CSF; a 
recombinant fusion protein of prostatic acid phosphatase (PAP) (antigen expressed in 
95% of prostate cancer) and granulocyte–macrophage colony-stimulating factor (GM-
CSF), an immune cell activator 323. Despite a few isolated successes, cancer vaccines 
still remain expensive treatments that rarely produce robust therapeutics benefits, 
mainly due to weak immunogenicity response combined with a lack of adequate 
infiltration to the tumour site 324. For this reason, the use of synthetic peptides was 
introduced. Peptide vaccines incorporate amino acid sequences of tumour antigens; they 
are cheaper to manufacture, easier to synthesise and safer to handle. However, current 
peptide vaccines have little success in promoting tumour regression, despite producing a 
good grade of T-cells stimulation. Susceptibility of peptidases degradation, poor 
bioavailability, high elimination rate and unspecific binding to non-professional 
antigen-presenting cells (APC) that cause tolerances and anergy effects, are all major 
problems that currently are limiting the use of peptide vaccines in cancer 
immunotherapy 325.  
 
The use of peptides as anticancer treatment, however, is not limited to vaccines. Indeed, 
many other peptide types have been studied and employed. First of all, the so called 
anticancer peptides (ACPs); natural or synthetic small cationic amphiphilic peptides 
discovered or designed for their antimicrobial effects but that also display strong 
anticancer properties 105, 115. Peptides that exhibit both anticancer and antimicrobial 
effects can be divided into two categories, depending on their behaviour towards normal 
mammalian cells; some are indiscriminately toxic towards any type of cells (e.g. 
Mellitin, Defensins and human LL-37) while some others are selectively harmful only 
against bacteria and cancer cells (e.g. Cecropins, Magainins) 107, 111.  
 
The cancer cells specificity displayed by ACPs is not completely understood yet. 
Evidence suggest that the differences in composition of cancer and non-cancer cells’ 
plasma membranes are the main reason of this behaviour; cancer cells’ membranes are 
slightly negatively charged with more fluid due to reduced levels of cholesterol, while 
the normal cells’ membranes are zwitterionic and enriched in cholesterol which protects 
them from the insertion of lytic peptides 105, 106, 108. 
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ACPs show several modes of action to target and kill cancer cells; direct ways include 
plasma and mitochondrial membranes lysis or DNA and protein synthesis inhibition. 
ACPs can also indirectly target cancer cells via recruitment and stimulation of the innate 
immune response, similarly to what happens with peptide vaccines 107, 115. Ultimately, 
ACPs can also be conjugated with a variety of cargoes and, exploiting their penetration 
abilities, to selectively deliver in cancer cells drugs, DNA or RNA molecules to inhibit 
the cellular growth 122, 326.  
 
Unfortunately, despite many promising studies that have been published regarding 
ACPs, there is still a remarkable absence of success when translated into clinical trials. 
The difficulties in accomplishing outstanding preclinical results may be linked to the 
complexity of the biological system involved, together with the partial lack of 
information concerning the interaction between peptides and eukaryotic cells. Further 
studies are necessary to elucidate what is still unclear and to improve the development 
of more efficient peptide-based anticancer systems.  
 
 
7.2. Achievements of the project 
 
This project was initiated with the aim of studying the effects on cancer cells of three 
synthetic peptides, initially designed to specifically target and kill bacteria but then 
found to have anticancer cell selectivity: A6K and A9K, two self-assembled β-sheet 
peptides and G(IIKK)3I-NH2, a monomeric α-helical peptide. FITC- fluorescently 
labelled versions of A9K and G(IIKK)3I-NH2 were also included in the experimental 
plan.  
 
A6K and A9K were part of a series of short and simple amino acid sequences composed 
by consecutives alanine residues, which together form the hydrophobic tail, and a 
positively charged lysine representing the hydrophilic head. Thanks to the interactions 
between the hydrophobic tails, the electrostatic repulsion between charged head and the 
hydrogen bonding between peptide backbones, these peptides self-assemble in aqueous 
solutions adopting bigger, more defined β-sheet nanostructures. A6K forms long 
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nanofibers with lengths of 1 μm or more and diameter of 8 nm, while A9K forms stable 
nanorods with diameters of 3 nm and lengths that do not exceed 100 nm 175.  
 
G(IIKK)3I-NH2 instead was part of G(IIKK)nI-NH2 (n=1-4), a short cationic peptide 
amphiphiles series containing the IIKK repeat. These peptides have the characteristic of 
maintain random coil conformation in aqueous solution but with the ability of adopting 
an amphipathic α-helical structure when interacting with negatively charged 
membranes. In the series, G(IIKK)3I-NH2 had the best antimicrobial effect and cancer 
cell selectivity and was therefore selected for further studies 117. 
 
7.2.1 What was previously known 
 
All the peptides used in this thesis were previously tested against strains of both Gram-
positive and Gram-negative bacteria and the obtained results are summarised in Table 8. 
The peptide that gave the best results was G(IIKK)3I-NH2, followed by A9K. A6K by 
contrast had only a mild effect 117, 126. The results are expressed as MIC50, the lowest 
concentration of peptides at which 50% of the bacteria were inhibited from growing. 
 
Table 8. Bactericidal effect of A6K, A9K and G(IIKK)3I-NH2 expressed as 
minimum inhibitory concentration (MIC50). These peptides were the best of their 
groups and amongst them G(IIKK)3I-NH2 was the one that showed the greater 
antimicrobial effect. MIC50 = the lowest peptide concentration at which 50% of the 
bacteria were inhibited. 
Peptides MIC50 (µM) References 
 E. coli B. subtilis S. aureus  
A6K 320 - 160 Chen et al.,126 
A9K 20 - 60 Chen et al.,126 
G(IIKK)3I-NH2 8 2 7.5 Hu et al.,117 
 
A9K and G(IIKK)3I-NH2 were further selected to be tested against cancer, non-cancer 
cell lines and human erythrocytes. The toxicity towards eukaryotic cells was assessed 
with the MTT assay and the results are showed in Table 9 and Table 10. G(IIKK)3I-NH2 
was the peptide that once again gave the best results in targeting and inhibiting the 
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growth of cancer cells but A9K resulted in less toxicity against normal mammalian cells 
or erythrocytes 116-118, 126, 327. 
 
The results in both tables are expressed as inhibitory concentration (IC50) or 
erythrocytes lysis (EC50) for cells and erythrocytes, respectively, which correspond to 
the peptides concentration needed to induce the 50% of cellular growth inhibition or 
50% erythrocytes lysis. 
 
Table 9. Inhibitory effect of A9K and G(IIKK)3I-NH2 on different human cancer 
cell lines expressed as inhibitory concentration (IC50). G(IIKK)3I-NH2 gives the 
higher toxicity against cancer cells. IC50 = inhibitory concentration corresponding to the 
peptide concentration needed to induce cellular growth inhibition of 50%.  
Peptides IC50 (µM) References 
 HeLa HL60 HepG2  
A9K 60 100 - 
Chen et al.,126  
Xu et al., 116 
G(IIKK)3I-NH2 15 25 25 
Hu et al.,117 
Chen et al., 118, 327  
 
Table 10. Inhibitory effect of A9K and G(IIKK)3I-NH2 on different normal 
mammalian cell lines expressed as inhibitory concentration (IC50) or erythrocytes 
lysis (EC50). A9K’s results showed it to be the safer peptide. IC50 = inhibitory 
concentration corresponding to the peptide concentration needed to induce cellular 
growth inhibition of 50%. EC50 = haemolytic activity of human erythrocytes expressed 
as EC50 and corresponding to the peptide concentration needed to cause the lysis of 50% 
of erythrocytes.  
Peptides IC50 (µM) EC50 (µM) References 
 NIH 3T3 Cos 7 HDFa   
A9K > 240 > 240 - 600 
Chen et al.,126 
Xu et al., 116 
G(IIKK)3I-NH2 - - >100 256 
Hu et al.,117 
Chen et al., 118, 327 
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7.2.2 The peptides and their impact on the cells’ metabolism and 
proliferation   
 
This PhD project started with the idea of focusing in more detail on the interactions 
between the peptides and cancer cells; A6K, which had not previously tested was 
included as well. The results obtained have been explained in detail in the previous 
chapters but will be briefly summarised here. The effect of the peptides on different cell 
lines, cancer and non-cancer was evaluated. A6K and A9K were tested on A431, 
epithelial human cancer cells and HDFs, human dermal fibroblasts using the MTT 
assay. A concentration range between 6.25 and 100 µM was chosen while 24, 48 or 72 
hrs were selected as exposure times. Table 11 shows the IC50 calculated at each 
experimental time-point. A6K peptide, with an average IC50 of 50 µM showed more 
consistence in inhibiting the metabolism of A431 compared to A9K, which, for the first 
two time-points did not induce any toxic effect. A9K induced a significant decrease in 
MTT reduction after 72 hrs exposure and the IC50 calculated was 28 µM. Both peptides 
showed no harm towards the fibroblasts, and for the tested concentrations it was not 
possible to extrapolate an IC50.  
 
Table 11. Metabolic inhibitory effect of A6K and A9K evaluated in A431 epithelial 
cancer cells and HDFs human fibroblasts. A6K was the peptide that gave the best 
results against cancer cells. Both peptides were found to be non-toxic towards 
fibroblasts. The graphs showing all the results can be find in Chapter 3, section “3.2.1 
MTT assay”. IC50 = inhibitory concentration corresponding to the peptide concentration 
needed to induce cellular growth inhibition of 50%. 
Peptides IC50 (µM) 
 A431 HDFs 
 24 hrs 48 hrs 72 hrs 24 hrs 48 hrs 72 hrs 
A6K 40 52 45 >100 >100 >100 
A9K >100 >100 28 >100 >100 >100 
 
Normally it is possible to estimate the cellular viability via comparison of the MTT 
assay absorbance values with the number of cells present in a plate. However, for the 
experiments just described, no visible changes in the cell number between the different 
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experimental conditions were observed. For this reason, a more precise quantification of 
the cell number was done; the experiment was repeated without adding the MTT in the 
final step but instead cells were fixed in formaldehyde and stained with Hoechst. A cell 
count was performed using high content microscopy and an algorithm written to 
recognise nuclear stain (Figure 23). The results confirmed what was anticipated; the cell 
number did not significantly vary when the A431 were exposed to different 
concentrations of peptides. Consequently, no IC50 was calculated. Later, when FITC-
A9K was used, the fluorescent version of A9K, a similar cell count experiment was 
performed, and the results obtained were consistent with the ones of the standard 
peptide (Figure 23).  
 
The selectivity of G(IIKK)3I-NH2 towards cancer cells was tested using HCT-116 colon 
cancer cells while the HDFs fibroblasts were chosen once again as a non-cancer model. 
The concentration range and the exposure times were the same used for the previous 
peptides, but a cell count was directly performed this time. For the fluorescently 
labelled FITC-G(IIKK)3I-NH2, 24 hrs only were chosen as the exposure time. The 
relative IC50 were calculated and are summarised in Table 12. G(IIKK)3I-NH2 
significantly decreased the cell number of HCT-116 cells at all time-points and an 
average IC50 of 50 µM per time was calculated. No evident decrease in cell number was 
observed against the fibroblasts. Interestingly, FITC-G(IIKK)3I-NH2 results showed 
more sensitivity towards fibroblasts and an IC50 of 86 µM was found. Against the 
cancer cells it maintained a similar level of sensitivity and the corresponding IC50 was 
60 µM.  
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Table 12. Effects on cell viability of G(IIKK)3I-NH2 and FITC-G(IIKK)3I-NH2 
evaluated in HCT-116 colon cancer cells and HDFs human fibroblasts. Both 
G(IIKK)3I-NH2 and its fluorescently labelled version had an effect on cancer cells and 
significantly decreased the cell number. Against fibroblasts, only FITC-G(IIKK)3I-NH2 
had a slight toxic effect. The graphs showing all the results can be find in Chapter 4, 
section “4.2.1 Cell counting assay as evaluation of peptide toxic effect”. IC50 = 
inhibitory concentration corresponding to the peptide concentration needed to induce 
cellular growth inhibition of 50%. 
Peptides IC50 (µM) 
 HCT-116 HDFs 
 24 hrs 48 hrs 72 hrs 24 hrs 48 hrs 72 hrs 
G(IIKK)3I-NH2 56 50 43 >100 >100 >100 
FITC-G(IIKK)3I-NH2 60   86   
 
After the results obtained with A6K and A9K peptides, it was clear that both peptides 
were interfering with the A431 cellular metabolism but without inducing cell death. 
 
The MTT tetrazolium salt reduction occurs intracellularly, mainly by mitochondrial 
enzymes and in small part also in endosomal and lysosomal vesicles 140, 141, 208, 211. It 
was hypothesised that the peptides were interacting with the mitochondria preventing 
them from functioning correctly. For this reason, two different fluorescent dyes were 
used to stain live mitochondria; MitoTracker® Red CMXRos and JC-1 (Thermo Fisher 
Scientific) 143, 212. A431 cells were exposed to three different concentrations of peptides 
(6.25, 25 and 100 µM) and stained with MitoTracker® Red CMXRos after 72 hrs 
exposure or with JC-1 after 24-48 hrs exposure (from Figure 26 to Figure 31). 
MitoTracker® Red CMXRos gives information about the mitochondria morphology 
while JC-1, since it fluoresces differently depending on the fluctuations of the 
mitochondrial membrane potential (Δψm), gives useful information regarding the 
mitochondrial health 215. The data collected from both staining showed that 
mitochondria changed their morphology from large interconnected networks to 
fragments circularly shaped and their Δψm was less negative, causing the membranes’ 
depolarisation. These two phenomena can be associated with unhealthy mitochondria 
and damaged cells 328. MitoTracker® Red CMXRos staining was performed as well on 
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HCT-116 colon cancer cells exposed to 6.25, 12 or 25 µM of FITC-A9K for 48 hrs and 
gave results comparable to its standard version. 
 
7.2.3 Could the peptides have a role as delivery vectors of nucleic acids 
molecules?  
 
Due to their cationicity A6K, A9K and G(IIKK)3I-NH2 could, at least on paper, all be 
able to bind negatively charged molecules. Therefore, their complexing ability with 
DNA or RNA molecules was examined to evaluate a possible usage as transfection 
vectors. Initially complexes at different cationic/anionic charge ratios (0.5/1; 1/1; 2/1; 
3/1 and 5/1) of A6K and A9K were made with FAM-labelled oligonucleotides (ODNs) 
and visualised using the gel electrophoresis technique (Figure 1). The results showed 
that A6K surprisingly did not bind the DNA molecules, while A9K was bound to the 
DNA in a dose-dependent manner (Figure 82).  
 
 
Figure 82. Schematic representation of A9K self-assembling and interacting with 
nucleic acid molecules. (redrawn from data published by Chen et al.,126). The positive 
hydrophilic lysine representing the peptide head is shown in green while the tail, 
composed by consecutives hydrophobic alanines, is shown in blue. Due to their 
hydrophilic nature, the lysines are exposed on the molecule surface and allow the 
interaction with the negatively charges phosphate groups of the nucleic acids. The 
alanines due to their hydrophobicity are buried instead in the core of the molecule. 
 
A9K and G(IIKK)3I-NH2 abilities in transfecting cancer and non-cancer cell lines were 
evaluated using high content microscopy. 0.05 µg/ml of FAM-labelled ODNs were 
initially chosen to be transfected in A431 and HDFs cells. Charge ratios between 0.1/1 
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and 3/1 were selected while transfection with Oligofectamine (Life Technologies) was 
added as positive control. The results showed a clear selectivity of both A9K (Figure 2) 
and G(IIKK)3I-NH2 (Figure 32) for cancer cells where many fluorescent puncta could 
be observed correctly internalised in the cytoplasm. In the fibroblasts, the transfection 
efficiency was in contrast quite poor (Figure 5 and Figure 33). Moreover, when high 
concentrations of A9K were used (2/1 and above), the peptide/nucleic acids complexes 
were visible as big agglomerates, mainly localised externally of the cellular membranes.  
On the other hand, with G(IIKK)3I-NH2, no matter which concentration was selected, 
the fluorescent ODNs always appeared as small distinct puncta. Subsequently, A9K and 
G(IIKK)3I-NH2 were complexed with 75 nM of fluorescently labelled siRNA molecules 
(red siGLO, Dharmacon) and transfected in A431, HCT-116 cancer cells or HDFs. 
Charge ratios between 0.1/1 and 3/1 were selected while transfection with 
DharmaFECT1 (DF1, Dharmacon) was added as a positive control. As happened with 
the ODNs, both peptides showed selectivity for the cancer cells and many red puncta 
were internally localised in the cells (Figure 6, Figure 34 and Figure 35). In fibroblasts, 
the transfection efficiency stayed poor, especially when compared to DF1 (Figure 9 and 
Figure 35). Fluorescently labelled FITC-A9K and -G(IIKK)3I-NH2 complexing and 
transfection abilities were tested as well using the red siGLO and the HCT-116 colon 
cancer cells. The results showed good transfection efficiency of both peptides and, 
depending on the concentration used, yellow puncta were observed as consequence of 
the red and green fluorescent signals overlapping, indicating the co-localisation in the 
same cellular compartment of siRNA molecules and fluorescent peptides (Figure 14 and 
Figure 38). 
 
A9K and G(IIKK)3I-NH2 were employed as well in transfecting 3D spheroids cancer 
cellular models. A431 were originally selected and transfected with 75 nM of red 
fluorescent siGLO and 2/1 or 5/1 peptides ratios. However, due to the frailty and 
irregular morphology of the A431 spheroids, HCT-116 were selected and used 
afterwards. Spheroids generated from the colon cancer cells were compact solid 
spherical masses with an average diameter of 600-800 µm. DF1 was once again used as 
positive transfection reagent. The spheroids were imaged using wide-field fluorescent 
and light-sheet fluorescence microscopes. Light-sheet microscopy is more ideal for 
bigger samples like spheroids and, moreover, allows the collection of multiple stacks to 
generate 3D images 194. The light-sheet images revealed that both peptides could 
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transfect the spheroids deeper than DF1, reaching the core of the masses. DF1 instead, 
was able to give only a superficial transfection showing the red siGLO puncta localised 
exclusively on the outer surface (Figure 12, Figure 13 and Figure 40). 
 
With G(IIKK)3I-NH2, a co-culture experiment was performed as well to prove its 
selectivity for cancer cells; HCT-116 and HDFs fibroblasts were seeded together in a 
plate. Transfection of 50 nM of red siGLO was performed using the peptide at different 
charge ratios (from 0.5/1 to 3/1) or with DF1 as positive control. The results illustrated 
in Figure 37 showed how, when the peptide was used as delivery vector, the red 
fluorescent siGLO was prevalently localised in the cancer cells while with DF1 both 
cell types had equally amounts of siRNA. 
 
Following these promising results, it was decided to test the ability of A9K, G(IIKK)3I-
NH2 and their fluorescently labelled versions to transfect functional siRNAs in both 
A431 and HCT-116 cancer cell lines. 30 nM of ECT2 (Epithelial Cell Transforming 2 
Oncogene) or Polo-Like Kinase 1 (PLK1) were therefore transfected using different 
ratios of peptides (between 0.5/1 and 10/1). The commercial reagent DF1 was employed 
as a positive control. ECT2 and PLK1 are two genes encoding for proteins involved in 
several cellular functions regarding the cell cycle progression and the mitotic phase 195, 
197. These genes are often overexpressed in cancers and their depletion causes a 
dramatically inhibition in the cellular proliferation and induces cell apoptosis 136-138, 198-
202. The transfections of either ECT2 or PLK1 siRNAs, performed with A9K or FITC-
A9K did not allow a successful knock down at any of the used ratios (Figure 15 and 
Figure 16) and the number of cells did not vary from the control. The transfection using 
DF1 by contrast regularly worked. On the other hand, when G(IIKK)3I-NH2 and FITC-
G(IIKK)3I-NH2 were used as delivery vectors, a good level of knock down was assessed 
for both ECT2 and PLK1 siRNAs and the cell population decreased accordingly (Figure 
41 and Figure 42). For PLK1, the peptide’s transfection efficiency resulted even better 
than with the commercial DF1. The reasons of such a different behaviour between A9K 
and G(IIKK)3I-NH2 peptides in modulate gene expression are probably related to their 
secondary structure and ability in self-assemble or not; A9K is a β-sheet peptide which 
self assembles in nanorods of several nanometres length while G(IIKK)3I-NH2 stays in 
monomeric form and adopts an alpha helical structure only in presence of a negatively 
charged molecules (or membranes). 
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7.2.4 Exploiting the peptides fluorescence to explore the interactions with 
the cells 
 
Due to the interesting results achieved with G(IIKK)3I-NH2 and FITC-G(IIKK)3I-NH2, 
it was decided to perform further experiments to study the interactions between these 
peptides and cancer cells and unravel some of the unanswered questions regarding their 
cell specificity. FITC-G(IIKK)3I-NH2, due to its fluorescence and easy ability to be 
tracked was the preferred choice. 
 
Electron microscopy was used to acquire high resolution images of HCT-116 cells after 
exposure to FITC-G(IIKK)3I-NH2. Scanning electron microscopy (SEM) was 
performed to obtain detailed images of the cell membranes while transmission electron 
microscopy (TEM) was used to localise the peptide once internalised in the cells. For 
SEM three peptides concentrations were selected (0.3, 6.25 and 100 µM) and images up 
to 20000X magnification acquired (Figure 48 and Figure 49) Interestingly, cells 
exposed to the highest peptide concentration had a drastic change in their membranes 
morphology showing the complete loss of filopodia and lamellipodia, thin protrusions 
made of actin filaments essential for cell migration, adhesion, morphogenesis, 
endocytosis and phagocytosis 329.  
For the TEM, a single concentration of FITC-G(IIKK)3I-NH2 was selected (6.25 µM) 
and complexed with an antibody anti-FITC conjugated with 10 nm gold nanoparticles. 
The antibody was used to localise the peptide under the microscope; indeed, due to their 
high electron density, gold nanoparticles can be easily recognised as dark spheres. Cells 
were exposed to the peptide for 3 or 24 hrs then fixed, embedded in resin and cut in 
ultrathin sections (85 nm). Untreated cells, or cells exposed to a solution of antibody 
only were considered as negative controls. The images illustrated in Figure 50 and 
Figure 51 show the presence of many gold nanoparticles (and therefore FITC-
G(IIKK)3I-NH2) internalised in endosomal vesicular compartments. The anti-FITC 
antibody except where complexed with the peptide was not found in the cells. The 
presence of the peptide in vesicles suggested the possibility that an active mechanism, 
such as endocytosis, was involved in its internalisation. For this reason, more 
experiments were undertaken to decide whether or not an energy-dependent process was 
responsible for the peptide uptake.  
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The cellular speed in internalising FITC-G(IIKK)3I-NH2 complexed with siGLO or on 
its own was assessed in both HCT-116 and HDFs cell lines. For the transfection, DF1 
was included as well as a positive control. Different time-points were selected, between 
15 minutes and 24 hrs. The results showed a diverse internalisation speed between 
colon cancer cells and fibroblasts, with the second ones much slower in taking up the 
fluorescent peptide; while for the colon cancer cells 30 minutes were enough to see 
fluorescent puncta internally localised and for the fibroblasts nothing was visible until 
24 hrs of exposure time. The complexes peptide/siRNA, unless a high ratio was used, 
required at least an hour in both cell types to be observed, while with DF1 few red dots 
were already visible after 15 minutes (Figure 52 and Figure 54). A wider range of 
FITC-G(IIKK)3I-NH2 concentrations was used (from 6.25 to 100 µM) on HCT-116 and 
HDFs for 24 hrs (Figure 53 and Figure 55). The fluorescent intensity of the peptide in 
both the cell lines increased proportionally, with the concentration used.  
The peptide uptake by HCT-116 was live imaged over a 24 hrs time period, acquiring a 
picture every 30 minutes and mounting a video with the image stacks. Two different 
concentrations of FITC-G(IIKK)3I-NH2 were used; 6.25 to 100 µM while untreated 
cells corresponded to the negative control. In 24 hrs, a normal healthy cell population 
proliferate and migrate along the well surface and this is what was observed in the 
unexposed cells. However, cells treated with the peptide behaved differently; in the 
video of cells exposed to 6.25 µM it was possible to see the peptide uptake which made 
the cells brighter and brighter. The brightest cells adopted a rounded-up morphology 
and stopped moving, remaining still for hours. Nevertheless, this behaviour was not 
homogenous in the population and only a few cells presented this phenotype. Cells 
exposed to 100 µM were crammed almost instantaneously with peptide and the 
microscope green fluorescent channel got saturated. The behaviour adopted by these 
cells was the same already observed for 6.25 µM; cells were motionless. Interestingly, 
no apoptotic cells were observed (Figure 59). 
 
The live videos and SEM images showed that FITC-G(IIKK)3I-NH2 has probably a 
more cytostatic effect than a cytotoxic effect and at high concentration is able to 
partially destroy the membrane features and block the cells ability to move. To evaluate 
the impact of peptide on the cellular functions, the following experiment was 
performed; cells were exposed to 100 µM of fluorescent peptide for 30 minutes (enough 
time to completely be saturated by the peptide) or overnight. In the first case, the 
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medium containing the peptide was replaced with new complete medium. The next day, 
cells were fixed, imaged under the fluorescent microscope and the cell population 
counted (Figure 61). Surprisingly, cells left overnight in normal medium were able to 
recover from the peptide uptake, pump it out from the cytoplasm and start proliferating 
again. 
 
The peptide uptake by cancer cells was evaluated also in cold conditions when all the 
cellular energy-dependent processes are blocked, included endocytosis, which is strictly 
reliant on the cell temperature. Indeed, if the temperature goes down to 4 °C, the 
internalisation of molecules via endocytic pathways becomes strongly inhibited 152, 153, 
238. HCT-116 were left in ice and exposed to a cold solution of FITC-G(IIKK)3I-NH2 
(12.5 µM) for 30 minutes. After that, cells were rapidly fixed and the fluorescence in 
the cells quantified. Some HCT-116 instead of being fixed were switched back to 37 °C 
for 3 hours. This helped to evaluate the cellular efficiency in regaining the ability of 
internalising FITC-G(IIKK)3I-NH2 when moved to a more suitable environment. 
Medium containing the peptide was removed and substituted with complete culture 
medium prior to the 3 hours incubation at 37 °C. In this way, the ability of the peptide 
in binding the cell membranes, even if not internalised, was analysed.  Control plates of 
cells exposed to the peptide and left for 30 minutes or 3 hours at 37 °C were added as 
well. Since cells have a certain level of green auto-fluorescence, a plate of HCT-116 not 
exposed to the peptide was added as additional control. The background green 
fluorescence was then measured and subtracted from the other quantification data. The 
analyses revealed that in cold conditions, cells were unable to uptake the peptide but 
when moved back to 37 °C, they could restore their endocytic functions and 
fluorescence was again observed in the cells. If the medium containing FITC-
G(IIKK)3I-NH2 was discharged before the switch to warm conditions, very little peptide 
was observed in the cells afterwards, suggesting that an energy-dependent mechanism 
could also be necessary for the initial interaction with the cellular membrane (Figure 
56).  
 
To analyse the effective amount of FITC-G(IIKK)3I-NH2 internalised in cells and to 
distinguish differences between cancer and noncancer cells, an acid stripping was 
applied to cells (both colon cancer and fibroblasts) exposed to a various range of FITC-
G(IIKK)3I-NH2 concentrations (between 6.25 and 50 µM) but prior to fixation. This was 
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because, the fixation procedure formaldehyde mediated, can permeabilize the 
membranes, allowing the translocation inside the cells of materials attached on the outer 
surface 154. 
The acid washes remove from the membranes anything not covalently bound and 
therefore could detach all the peptide molecules attached on the extracellular 
membranous surface. The quantitative analyses of FITC fluorescence intensities of 
washed and unwashed cells revealed that the acid stripping was able to remove the 
peptide that was just attached on the outside of the membranes. Significant differences 
between washed and unwashed cells were obtained especially with fibroblasts, which 
confirmed their poor ability in taking up the fluorescent peptide (Figure 57.). The cells 
were also stained with Cell Mask Orange (Thermo Fisher) to better visualise and define 
the cellular borders. In doing so, an interesting phenomenon was observed: cells in 
mitosis were not internalising the peptide (Figure 58). This was also spotted when cells 
were stained with Alexa Fluor® 568 Phalloidin (Thermo Fisher), another dye used to 
enhance the cellular boundaries (Figure 46). This new evidence supports once more the 
idea of an endocytic mechanism being involved in the internalisation process since it is 
generally believed that the endocytosis is strongly inhibited during the early mitotic 
phases 226.  
 
7.2.5 RNAi screens to elucidate the endocytic pathway involved in the 
peptide uptake 
 
Exploiting the fluorescence of FITC-A9K and FITC-G(IIKK)3I-NH2, a mini-screen and 
a high-content screen were performed on HCT-116 cells with the goal of isolating the 
endocytic genes responsible for peptides internalisation and identifying, if possible, the 
pathway(s) involved. Before executing the high content screen, an assay development 
screen was prepared and several experimental parameters were simultaneously checked 
in order to find the perfect conditions to successfully perform the screen afterwards. 
More importantly, few genes were selected to be tested as possible “hits” if knocked 
down using RNAi. 
 
The assay development screen for FITC-G(IIKK)3I-NH2 was composed by a siRNA 
library called assay development plate 2 (ASD2), specifically designed for genome-
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wide RNAi screens. The library was mainly composed by a selection of siRNAs which 
knock down kinases, enzymes that catalyse the phosphorylation between high-energy 
and specific substrates and regulate many cellular functions 330. Some of the siRNAs 
were related with endocytic pathways and therefore chosen as possible “hits”; Actin 
Related Protein 2 Homolog (ACTR2), ADP-ribosylation factor 6 (ARF6), Caveolin 1 
(CAV1), Clathrin heavy chain (CLTC), Dynamin 2 (DNM2), Myosin Va (MYO5A), 
Myosin Vb (MYO5B), Myosin Vc (MYO5C) and Ras-related protein 7a (RAB7A).  
 
CLTC and CAV1 are specific of the clathrin-dependent and caveolin-dependent 
endocytic pathways while the others have a more generic role in endocytosis: ACTR2 
encodes for a component of actin related protein 2/3 complex which is involved in the 
regulation of the actin filaments polymerisation; Arf 6 is GTP-binding that regulates 
endocytic recycling and cytoskeleton remodelling; Dynamin 2 is another GTP-binding 
protein associated with microtubules and implicated in endocytosis and cell motility; the 
Myosin V are motor proteins involved in the endocytic vesicular trafficking and 
endosomes recycling in neuronal and epithelial cells while Rab 7a is key regulator in 
endo-lysosomal trafficking and in the early-to-late endosomal maturation 157-164. Four 
non-targeting siRNAs were included in the assay as negative controls.  
 
Clathtrin light chain a (CLTA), Clathrin light chain b (CLTB), Clathrin heavy chain 
(CLTC), Adaptor related protein complex 2 subunit alpha 2 (AP2A2), Adaptor related 
protein complex 2 subunit beta (AP2B1) and Actin related protein 2/3 complex subunit 
1 B (ARPC1B) siRNAs were selected to knock down the correspondent genes in the 
FITC-A9K mini-screen. All the siRNAs were picked from the SiGenome collection of 
design siRNAs from Dharmacon.  
 
With the exclusion of ARPC1B which encodes for one of the seven subunits of the 
already cited Arp2/3 complex, all the other genes are related with the clathrin-dependent 
endocytic pathway 156-158. Red fluorescent siGLO was selected as the positive control 
for the transfection efficiency while 5 non-targeting siRNAs were selected as negative 
controls. 
 
In both experiments, a cell count analysis was performed to evaluate the cellular 
viability after siRNA transfection and RNAi. The averages of the non-targeting siRNAs 
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viabilities were considered as negative controls and all the other cell counts were 
normalised to this. In the assay development with FITC-G(IIKK)3I-NH2 ACTR2, 
CAV1, MYO5A and MYO5B siRNAs significantly decreased the cellular viability 
(Figure 75) while in the mini-screen with FITC-A9K none of the siRNAs employed 
decreased the cell viability (Figure 80). The green fluorescence associated within the 
cells was quantitatively analysed as well and compared to the negative controls in order 
to evaluate possible phenotypic changes in the peptides internalisation following RNAi. 
In the FITC-G(IIKK)3I-NH2 development assay CAV1, CLTC, DNM2, MYO5A, 
MYO5B and MYO5C siRNAs knock down caused a significant reduction in the peptide 
uptake. On the contrary, ARF6 had the opposite effect and it significantly increased the 
amount of peptide found in the cells. No effects were observed instead for ACTR2 and 
RAB7A (Figure 77). In the mini-screen with FITC-A9K, all the selected siRNAs 
significantly decreased the peptide uptake (Figure 81). 
 
The cell count analysis was performed in all the ASD2 plate and, as expected, the knock 
down of kinases had a severe impact on the cellular viability. The bottom 5% (95% of 
cells dead) was plotted in a graph (Figure 76) and it is represented by FRAP1, RIOK2, 
PDJ2, KIAA1804, IRAK1, PFTK1 and NAGK. All genes that encode for kinases play a 
pivotal role in cellular growth, differentiation, cell cycle and apoptosis and are often 
overexpressed in tumours, especially in colon cancer 331-342. 
For the focused high-content screen on cells exposed to FITC-G(IIKK)3I-NH2, a 
designed library of Traffic-ome targeting siRNAs was used. Following transfection and 
exposure to the peptide, cells were fixed and any phenotypic change in the fluorescence 
intensity distribution of the peptide quantified. The data obtained were subsequently 
normalized using the robust z-score method which is less sensitive to outliers than the 
standard z- score and preferable for use in RNAi screens 294, 295. The possible “hits” 
were 31, identified in the outliers scoring ≤ - 3.5 or ≥ + 3.5 (Figure 78). The biological 
functions of the hits are illustrated in Figure 83; the majority of these genes can be 
divided into two main clusters; one related to vesicles recycling to the cell surface and 
the other related to vesicle trafficking within different organelles but mainly associated 
with the Trans-Golgi network. Three genes were excluded from the clusters; ADAM 10 
which encodes for a cell membrane metalloproteinase, IP6K3 which encodes for a 
protein that regulates inositol phosphate-stimulated vesicle formation and trafficking 
and WASF3 that encodes for a protein involved in the actin polymerization through the 
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activation of Arp 2/3 complex and is essential for filopodia formation and cell motility 
296-298. 
 
 
Figure 83. Schematic representation of the hits main functions in the cell 
endocytosis.  The hits could be divided into two main clusters, one related to the 
vesicles trafficking to and from the Golgi network and one associated with the early 
endosome and vesicles recycling. Adam 10, metalloproteinase (cleaves the extracellular 
domain of transmembrane proteins), Wasf3 (involved in filopodia formation and 
motility) and Ip6k3 (regulator of inositol phosphate-stimulated vesicle formation and 
trafficking) instead do not fall in any category. Legend: N = nucleus; ER = endoplasmic 
reticulum.  
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7.2.6 In vivo toxicity and bio distribution in Danio rerio embryos 
 
Microinjections in one cell stage zebrafish embryos (Danio rerio) were performed to 
evaluate the toxicity of A9K and FITC-G(IIKK)3I-NH2 using a wide range of 
concentrations (from 6.25 pg to 4 ng per embryo). A9K induced only a mild toxicity in 
the embryos and exclusively at high peptide concentrations (from 1 to 4 ng per embryo). 
On the other hand, FITC-G(IIKK)3I-NH2 caused severe toxicity even at very low 
concentrations (6.25 pg). The LC50 calculated for A9K were 1.7 and 1.4 ng in 1 or 3 
days post fertilisation embryos (dpf) corresponding respectively to 2 and 1.7 mM. LC50 
calculated for FITC-G(IIKK)3I-NH2 were instead 7 and 2 pg in 1 or 3 dpf embryos, 
corresponding respectively to 3,5 and 1 µM (Table 13).  
 
Table 13. In vivo toxicity of A9K and FITC-G(IIKK)3I-NH2 on zebrafish embryos. 
FITC-G(IIKK)3I-NH2 gave the strongest toxic effect and even a few pg of it were 
enough to kill most of the embryos. The complete results can be find in Chapter 5, 
sections “5.4 Microinjections of A9K peptide in zebrafish embryos” and “5.5 
Microinjections of FITC-G(IIKK)3I-NH2 peptide in zebrafish embryos”. LC50 = lethal 
concentration which corresponds to peptides concentration needed to kill 50% of 
embryos. 
Peptides LC50 (pg) 
 1 dpf 3 dpf 
A9K 1700 1400 
FITC-G(IIKK)3I-NH2 7 2 
 
FITC-G(IIKK)3I-NH2 was so toxic that even at the first check-point (5 hours post-
fertilisation), with the exclusion of 6.25 pg, in all the other concentrations the surviving 
rate was already below 50% (Figure 65) To evaluate if FITC-G(IIKK)3I-NH2 would 
decrease its toxicity if injected in an embryo when complexed with negatively charged 
molecules, another injection experiment was performed; the peptide was complexed 
with siGLO red at two charge ratios (1/1 or 4/1). To decide which amount of siGLO it 
was appropriate to use, a dose-curve experiment was initially performed with the 
fluorescent siRNA, testing siGLO concentrations between 20 and 80 pg per embryos. 
The LC50 calculated for siGLO were 76, 73 and pg in 5 hpf, 1 or 3 dpf embryos, 
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respectively (Table 14). 20 pg was therefore selected as safe concentration to use in the 
complexation with FITC-G(IIKK)3I-NH2. 
 
Table 14. In vivo toxicity of siGLO red on zebrafish embryos. The siRNA is toxic to 
zebrafish embryos only at concentrations above 60 pg, therefore 20 pg was selected as 
concentration to be used complexed with FITC-G(IIKK)3I-NH2. The results can be find 
in Chapter 5, section “5.6.1 Microinjections of siGLO to estimate the siRNA toxic 
threshold”. LC50 = lethal concentration which corresponds to peptides concentration 
needed to kill 50% of embryos. 
siRNA LC50 (pg) 
 5 hpf 1 dpf 3dpf 
siGLO 76 73 56 
 
When the complexes peptide/siRNA were injected in 1 cell stage embryos and the 
viability checked it was found that the peptide overall toxicity decreased and more than 
50% of embryos were still alive even after 3 days at both charge ratios (1/1 and 4/1 
corresponding to 20 and 80 pg of FITC-G(IIKK)3I-NH2) (Figure 71). 
 
Ultimately, the bio distribution of FITC-G(IIKK)3I-NH2 in the blood circulation of 4 dpf 
larvae was assessed. The peptide together with FITC fluorophore used as a negative 
control were injected in the larvae at the concentration of 25 pg/nl. To be able to 
visualise the blood vessels under the fluorescent microscope the transgenic zebrafish 
line, TG(kdrl:HRAS-mCherry), was used 147. Larvae were injected in a caudal vein and 
then mounted in a solution of agarose and Tricaine (anaesthetic) to be visualised under 
the light-sheet microscope. Unfortunately, both peptide and fluorophore leaked out from 
the fish system too quickly, preventing the correct development of the planned 
experiment (Figure 73 and Figure 74). 
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7.3. Discussion  
 
7.3.1 Membranolytic or mitochondrial target? 
 
The strategies adopted by the so-defined anticancer peptides (ACPs) to target and kill 
cancer cells are believed to be similar to the ones used by the antimicrobial peptides 
(AMPs) when targeting bacteria, which can be generalised into two main mechanisms: 
membrane permeabilization and membrane translocation to hit intracellular targets 106, 
343. The cationic amphiphilic peptides discussed in this thesis exert their antimicrobial 
effects destroying the bacterial membranes and are believed to display membranolytic 
activity also towards mammalian cancer cells 117, 126. Moreover, previous published 
studies on A9K and G(IIKK)3I-NH2 suggested that these peptides can also target 
intracellular organelles such as mitochondria and induce apoptosis 116, 118 .  
 
However, the results obtained in this study and previously described, tell a slightly 
different story. For example, when the MTT assay was performed on A431 cancers cells 
exposed to A6K and A9K peptides, a significant decrease in the MTT salt reduction was 
observed, but a direct sign of growth inhibition was only weakly detected, at least at the 
tested concentrations. The cell counting experiments afterwards showed absence of cell 
death induced by the peptides, which might exclude membrane permeabilization as 
mechanism of targeting cancer cells. 
The staining using Mitotracker and JC-1 dyes subsequently showed that mitochondria 
dramatically changed in morphology and had more depolarised membrane potential 
(Δψm) in cells exposed to the peptides. Mitochondria are dynamic organelles and their 
shape and morphology can change rapidly in response to the cellular environment or to 
stressful conditions 344. Because of their critical role in the energy production and also 
in the regulation of other various pathways, including cell apoptosis, Ca2+ signalling and 
redox homeostasis, mitochondria have the ability to remodel their architecture and 
undergo a series of balanced membrane fusion and fission events within the cytoplasm. 
Normally a shift toward fusion creates large interconnected mitochondria networks 
associated with healthy and metabolic active cells while a shift towards fission produces 
instead many mitochondrial fragments with the shape of small spheres or short rods and 
is generally associated with quiescent or damaged cells 328. Mitochondrial fusion and 
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fission are clearly antagonistic process and the rates of fusion and fission must be 
precisely controlled to keep the right balance required for the maintenance of 
mitochondrial morphology during changes of the physiological conditions. 
Perturbations or failures in the maintenance of this delicate equilibrium are signs of 
defective cells and normally lead to the triggering of mitophagy (autophagy of 
mitochondria) or apoptosis signalling 213.  
 
The presence of altered mitochondria could suggest that both the β-sheet peptides have 
a more cytostatic effect than cytotoxic. ACPs often affect the mitochondria of cancer 
cells and a few examples can be cited from literature: the bovine antimicrobial peptide 
BMAP-28 which induced the mitochondrial membrane depolarisation in the U937 
(promonocytic) cells 214; Lactoferricin B, another bovine antimicrobial peptide which 
depolarised Δψm and also induced the activation of caspase-6, -7 and -9 in 
neuroblastoma cell lines 345; Mastoparan obtained from the Vespula lewisii venom that 
induced apoptosis in a the murine melanoma cell line B16F10 via permeabilization of 
the mitochondrial membrane 346 and hCAP18 that induced mitochondrial depolarization 
and apoptosis in SAS-H1, high invasive cells derived from the human squamous cell 
line SAS 347.  
 
The JC1, Mitotracker and MTT data combined together suggest that something critical 
happens to the cells and, specifically, to the mitochondria when exposed to A6K and 
A9K. However, it is still not clear if the observed effects are related to a direct 
interaction between the peptides and the mitochondrial membranes or if it is just a 
secondary effect. 
 
The cell counting on G(IIKK)3I-NH2 showed a decrease in HCT-116 cell number 
depending on the peptide concentration and exposure time. The maximum effect was 
observed with 100 µM at which, on average, 90% of cell reduction was observed at 
each time point. It is not clear from the initial results whether this α-helical peptide is 
cytotoxic and membranolytic. However, further evidence showed that the peptide 
interacts very differently with the cells. Moreover, thanks to the opportunity of using the 
FITC-labelled fluorescent version it was possible to directly observe how this peptide 
was interacting with cells.  
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7.3.2 Endocytosis as mechanism of cellular internalisation 
 
The first clues that a different mechanism was involved in the peptide internalisation 
came when Alexa Fluor® 568 Phalloidin and CellMask Orange were used to stain the 
F-actin filaments and the plasma membrane, respectively. Thanks to these stainings it 
was possible to visualise the cellular boundaries and better localise FITC-G(IIKK)3I-
NH2 in the cells. It was noticed that if a cancer cell was in a clear mitotic phase, the 
fluorescent peptide was not able to become internalised, but it was mainly bound to the 
external leaflet of the cell membrane. A possible explanation would be that the peptide 
could be internalised via endocytosis, which is believed to be inhibited during mitosis 
348. For example, a recent study published by Fielding et al., showed that a fluorescent 
CD8 chimera system, normally used to study sorting signals of transmembrane proteins 
349 and fluorescent transferrin molecules were both not internalised in early mitotic 
stages suggesting that clathrin-mediated endocytosis was temporarily switched off 226.   
 
After this first indication that the peptide might have an alternative way to get inside the 
cells, more experiments were conducted to evaluate if an energy-dependent mechanism 
was actually involved. From the literature, it is well known that all the energy-
dependent biological functions are strictly reliant on the temperature, and if 4 °C is 
reached, all the active process in the cell are inhibited, endocytosis included 152, 153, 238. 
When the FITC-G(IIKK)3I-NH2 uptake was evaluated in HCT-116 cells in cold 
conditions, it was shown that at 4 °C cells were unable to internalise the peptide, 
suggesting that endocytosis-dependent pathways could be the major uptake 
mechanisms. Moreover, TEM images also showed that the peptide molecules were 
localised in big vesicular compartments, indicating endocytosis as a plausible mode of 
entry. In the literature, many studies are published regarding the mechanisms of entry of 
cationic peptides in cancer cells showing how differently these small molecules can 
behave, depending on multiple environmental factors. For example, Wang et al., 
recently published an interesting study on L-K6 (IKKILSKIKKLLK-NH2), a synthetic 
lysine/leucine-rich cationic antimicrobial peptide with anticancer activity, analogue of 
the natural temporin-1CEb, isolated from the skin secretions of the Chinese brown frog 
(Rana chesinensis). Their results showed that the peptide exerted cancer cell selectivity 
and induced cytotoxicity on different cancer cell lines (especially MCF-7) in dose-, 
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time- and energy- dependent ways. If the temperature was dropped down to 4 °C or if 
the ATP pool was depleted by pre-incubating the cells with sodium azide (NaN3), the 
cytotoxic effect of the peptide diminished. They also showed how L-K6 induced 
permeabilization and morphological changes in the cancer cells membranes but without 
causing the membranes disruption. Methyl-β-cyclodextrin (Mβ-CD), cytochalasin D 
(CyD) and chlorpromazine (CPZ) inhibitors were used to selectively block caveolae-
mediated endocytosis, macropinocytosis and clathrin-mediated endocytosis, 
respectively. The results showed a partial blocking of FITC-labelled L-K6 
internalisation when caveolae-mediated endocytosis was inhibited and a more 
significant block with macropinocytosis inhibition but no effect with the clathrin-
mediated endocytosis inhibitor, suggesting that macropinocytosis was majorly involved 
in the internalization of L-K6 by cancer cells 350. 
 
Lim et al., instead studied the toxicity and the internalisation pathways of BH2, a novel 
cancer specific peptide derived from the synthetic buforin IIb, analogue of the natural 
antimicrobial peptide buforin and extract from stomach tissues of the Asian toad Bufo 
bufo which displays membrane penetrating activity in bacteria. BH2 was tested against 
various cancer (HeLa, HCT-116 and mouse melanoma B16/F10) and non-cancer (NIH 
3T3, HaCat and human fibroblast BJ) cell lines, showing selectivity for the cancer cells 
but no cytotoxicity for the normal mammalian cells. To further understand the peptide 
uptake, the effects of temperature (cells kept at 4 °C) and metabolic inhibitors (pre-
treatment with NaN3) were investigated in HeLa cells using a FITC-labelled version of 
BH2. Moreover, the role of endocytosis was examined by pre-treating cells with 
amiloride, nocodazole and methyl-ß-cyclodextrin (MßCD), endocytic inhibitors which 
block macropinocytosis, clathrin-mediated pathway and lipid raft-mediated 
macropinocytosis (which produces larger vesicles that do not fuse with early 
endosomes), respectively. The results showed that both temperature and ATP depletion 
caused a reduction of peptide uptake and the lipid raft-mediated macropinocytosis was 
the major internalisation pathway 351. 
 
In another study the synthetic lytic-peptide K8L9 designed by Ohara and co-workers 
showed to enter human glioma U251 via clathrin-mediated endocytosis, 
macropinocytosis but also with direct penetration and the pre-treatment of the cancer 
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cells with endocytosis inhibitors (Cytochalasin D, chlorpromazine and 5-(N-ethyl-N-
isopropyl)) amiloride (EIPA) decreased the peptide internalisation 352.  
 
There are several factors that could affect the cellular uptake of a selected peptide, 
including aminoacidic composition, peptide amphiphaticity, temperature, cell surface 
components, cell culture medium composition and peptide concentration 73, 74. Thus, a 
peptide could enter in a cell using both direct penetration or endocytosis and sometimes 
this can even occur simultaneously.  
 
For example, the internalisation of fluorescent oligoarginines (Rn) peptides (where n = 
4, 8, 12, 16) was investigated in HeLa and CHO cells by Kosuge et al., The presence of 
serum in the culture medium, the temperature and the peptides concentrations were 
determinant factors in the internalisation pathways adopted by the cells. Results showed 
that in absence of serum, higher amounts of R12 and R16 were retrieved in the cells 
incubated at 37 °C. The peptides were mainly internalised via an energy-independent 
non-endocytic mechanism which however, did not cause the membrane disruption. 
Minimal variations in cellular uptake were observed instead for R4 and R8. The 
temperature played an important role as well and if the cells were incubated in complete 
culture medium at 37 °C the peptides were internalised via endocytosis while, when the 
cells were kept at 4 °C and without serum, peptides entered the cells by direct 
translocation. Wild-type CHO-K1 line, and its mutant variant, A-745 defective in 
proteoglycans biosynthesis were also incubated with increasing concentrations of 
fluorescent R12 peptide in medium lacking serum. Proteoglycans are essential for a 
rapid interaction with arginine-rich peptides and considered the first step for 
internalisation. At low concentrations, no differences were observed between the cell 
lines but with the increase of the peptide concentration the mutant cell line generally 
accumulated less peptide. Moreover, the distribution of R12 in the cells changed 
depending on the peptide concentration; fluorescent puncta were predominantly 
observed at low concentrations suggesting endocytic uptake, while with higher 
concentrations, the peptide diffused in the cytosol indicating a direct membrane 
translocation. For the wild type cell line, the cytosolic diffusion was observed even at 
relatively low concentrations while for the mutant cell line a higher peptide 
concentration was needed, suggesting that the lack of membrane-associated 
proteoglycans was responsible for the decrease in R12 peptide translocation 75. 
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The SEM images of HCT-116 exposed to different concentrations of FITC-G(IIKK)3I-
NH2 showed how the cellular membranes were affected by the peptide. At lower (0,3 
μM) and medium concentrations (6.25 μM), no visible differences were observed when 
compared to an untreated sample, but when the cells were exposed to 100 µM, the 
membranes drastically changed morphology, showing a complete loss of filopodia, the 
thin protrusion made of actin filaments essentials to probe the nearby environment 329. 
Filopodia are particularly active in cancer cells, where they promote invasion through 
3D micro-environments and are essential for driving cancer cell metastasis and helping 
survival and proliferation 353. Clinical data revealed that several filopodia proteins, such 
as fascin, are upregulated in many human cancers and are essential for cancer cell 
invasion in vitro 354. 
 
This particular phenotype observed in cells after exposure to 100 µM of peptide could 
suggest that a direct translocation occurred and caused intensive membrane disruption. 
However, cells exposed to the same concentration for 30 minutes and then kept 
overnight with fresh replaced medium showed the ability to recover from their damaged 
status, expelling the peptide from their cytoplasm and proliferating again. This may 
suggest that even at extremely high concentrations, the peptide is internalised by the 
cells via endocytosis and has a more cytostatic effect, but under favourable conditions 
cells can still pump the peptide out. The secretory methods used by cells to expel 
nanomaterials have only just started to be studied and there is still little information 
available 241.  
 
Missirlis et al., recently conducted some studies on Peptide Amphiphiles (PAs), a class 
of amphiphilic molecules that self-assemble in organised nanostructures similarly 
toA6K and A9K. It was shown how the peptides internalisation and trafficking inside the 
cells was dependent on the composition of their hydrophobic tail. For example, 
diC16p53 PA used the clathrin-mediated endocytosis to enter SJSA-1 human 
osteosarcoma cells 355, while RPARPAR PAs mostly used a clathrin-independent uptake 
(lipid raft-mediated macropinocytosis) to enter in PPC-1 humane prostate cancer cells. 
Moreover, the fate of the peptides after the uptake was investigated and it was found 
that after 24 hrs while some peptides molecules were still associated with the plasma 
membrane while the majority of them were co-localised either in endocytic vesicles Rab 
4-; Rab 11- positive, which are markers for ‘short loop’ or long-loop’ recycling 
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endosomes, or with the late-endosomal marker Rab 7, suggesting that they were 
directed towards lysosomes 356. The “short loop” is a fast recycling pathway regulated 
by Rab 4, and is characterised by cargoes that rapidly exit the early endosome to recycle 
to the plasma membrane, while the ‘long-loop’ is slow and is regulated by Rab 11 and 
the cargoes are recycled from recycling endosomes 357.  
 
A few studies are also found about exocytosis of nanoparticles, for example Panyam et 
al., studied endocytosis, exocytosis and intracellular retention of biodegradable poly 
(D,Llactide-co-glycolide) nanoparticles on human arterial vascular smooth muscle cells 
(VSMCs). The results showed that both uptake and secretion of nanoparticles were 
energy dependent processes and fluid-phase pinocytosis and nonspecific receptor-
mediated endocytosis were the internalisation pathways. The uptake was time and dose-
dependent but, when higher concentrations were used, the internalisation speed was 
reduced probably due to the cell saturation. Endocytosis and exocytosis were 
proceeding simultaneously but secretion started to be effective only when the 
nanoparticles were removed from the external media 239. 
 
Thanks to the time-lapse videos it was possible to observe the internalisation of the 
fluorescent FITC-G(IIKK)3I-NH2 occurring live. The results so obtained are extremely 
important because they added valuable information about the cell physiology and 
morphology in presence of the peptide which were not possible to acquire with just 
standard fixed fluorescent pictures. For example, with 100 µM, cells became rapidly 
saturated, stopped moving and dividing but did not appear apoptotic. Over a period of 
24 hrs they did not decrease in number suggesting that the peptide has a cytostatic effect 
but without inducing the lysis of the plasma membranes.  
 
7.3.3 RNAi screen reveals the importance of having functional recycling 
and vesicle trafficking systems 
 
With the mini-screen involving FITC-A9K, it was suggested that clathrin-dependent 
endocytosis was responsible for the peptide internalisation since the fluorescence 
intensity quantified in the cells with knock down of CLTA, CLTB, CLTC, AP2A2, 
AP2B1 or ARPC1B was drastically reduced compared to the cells transfected with non-
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functional siRNAs. However, the results obtained for the screen development assay 
performed on cells exposed to FITC-G(IIKK)3I-NH2 showed that probably more than 
one pathway could be involved, since both CAV1 and CLTC loss of expression induced 
a decrease in the peptide internalisation compared to the controls. The decrease in 
fluorescence intensity observed in DNM2, MYO5A, MYO5B and MYO5C knocked 
down cells confirmed the role of energy dependent pathways in the peptide uptake. 
Moreover, the increased fluorescence intensity in cells ARF6 knocked down anticipated 
the importance of vesicle recycling for the intracellular movements of the peptide.  
With the more focused high-content screen, many endocytic proteins levels were altered 
and despite observing an effective decrease in the peptide internalisation, no obvious 
phenotypes could be distinguished, probably due to gene or pathway redundancies 286. 
 
Interestingly, the knocking down of genes involved in the recycling of more general 
vesicular trafficking between secretory compartments induced drastic changes in the 
cellular phenotypes. The cellular uptake of cationic amphipathic peptides with cell 
penetrating properties is fairly well characterised. However, what happens next is still 
poorly understood and the internal trafficking is still relatively unknown 358.  
 
Once internalised, a cargo is sent to the early endosomes where it will be sorted to its 
final destination. From there, it could go to late endosomes and then lysosomes to be 
degraded; to the trans-Golgi network (TGN) or to recycling endosomes, which bring the 
cargo back to the plasma membrane. Indeed, the internalisation of extracellular material, 
proteins, lipids or ligands via endocytosis is normally followed by endosomal recycling 
pathways that bring it back to the cell surface most of the molecules that belong to the 
plasma membrane; the composition of the membrane is maintained by this delicate 
equilibrium which supports many biological functions, such as nutrient uptake, signal 
transduction, cell adhesion, cell migration and cytokinesis 359. Misfolded proteins, 
activated growing factors or anything that has to be degraded go the late endosomes via 
Multivesicular bodies (MVBs); a specialised type of endosomes transporting 
intraluminal vesicles (ILVs). ILVs and their content are degraded, via fusion with 
lysosomes, or released externally, via fusion with the plasma membrane 360. The 
specific transport of a cargo that exits the endosomes and reaches biosynthetic or 
secretory compartments (TGN, Golgi membranes, or ER) is defined as retrograde and 
can happen in different parts of the endocytic pathway. Pathogens or pathogenic 
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products such as viruses and bacteria toxins can use this route as well to promote their 
infectious mechanisms 361.  
 
Several studies showed that Cell Penetrating Peptides (CPPs) can escape endosomes 
and be transported through the Golgi network and the ER via retrograde trafficking; for 
example, the uptake and intracellular trafficking of fluorescently labelled Penetratin, 
R9, and Tat peptides were investigated on adherent MC57 mouse fibrosarcoma cells 
and HeLa cells by Fischer et al., Initially, Wortmannin, which affects early endosome 
fusion, bafilomycin A1 and chloroquine, which instead bind protons and inhibit 
vacuolar H+-ATPases, were used to inhibit endocytosis and endosomal acidification in 
MC5-7 cells, respectively. R9 and Penetratin uptake was reduced with the three 
inhibitors, while with Tat only a small effect and even an increased intracellular 
concentration were observed. This outcome was further analysed with pulse/chase 
experiments and MALDI MS analysis showing that Tat peptide is highly susceptible to 
intracellular proteases which generate fragments that could easily exit the cells. The 
peptides uptake was evaluated as well in HeLa cells showing that this cell line can 
internalize 3 times more peptides than MC5-7 cells but when the treatment with 
bafilomycin A1 occurred, a similar reduction in intracellular fluorescence was still 
observed. Subsequently, the involvement of the Golgi complex in the intracellular 
trafficking was better evaluated. MC5-7 cells were incubated with the three peptides 
with or without the presence of brefeldin A and Nordihydroguaiaretic acid (NDGA), 
two drugs that interfere with the integrity of the Golgi apparatus. For both compounds 
the cellular fluorescence of R9 and Penetratin was reduced while Tat fluorescence was 
reduced only by brefeldin A and enhanced instead by NDGA. NDGA blocks protein 
transport from the ER to the Golgi complex and induces the redistribution of Golgi 
proteins into the ER until both organelles are not functional anymore. For this reason, 
NDGA can be used as Golgi-disrupting drug or as an inducer of retrograde transport. 
The ability of NDGA in affecting the subcellular localisation of Tat was further 
evaluated in HeLa cells following a pulse/chase experiment. If incubated with medium 
alone, cells showed only vesicular fluorescence, but when incubated with NDGA-
containing medium a cytoplasmic fluorescence was instead visible. Finally, both cell 
lines were exposed to the peptides and incubated with a cell-permeable Golgi tracer 
(Bodipy ceramide) or an acidic compartment-specific probe (Lysotracker) for 
lysosomes; the images showed partially co-localisation of the peptides with the Golgi 
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complex but little or no co-localisation with the lysosomes. Altogether, the data 
collected in this paper supported the hypothesis that CPPs can escape the endocytic 
compartments, retrograde transported to the Golgi and then enter the cytosol 362.  
 
Missirlis et al., in the previously discussed paper, showed how amphiphilic peptides can 
also be recycled to the membrane following both rapid (Rab 4 mediated) or slow (Rab 
11 mediated) recycling pathways 357.  
 
To date, this was the first time that an RNAi screen was performed on an amphiphilic 
cationic peptide showing that even with no evident cell penetrating abilities, it could 
enter cells via endocytosis, exit the endosomal compartments, possibly be retrograde 
transported to TGN and recycled back to the plasma membrane. 
 
7.3.4 Cancer cell selectivity is maintained 
 
Consistent with the previously published data, all the peptides resulted in no harm to 
HDFs, human dermal fibroblasts, the mammalian cell line chosen as non-cancer model. 
Interestingly, the cancer cell selectivity of the fluorescently labelled FITC-G(IIKK)3I-
NH2 diminished compared to the non-fluorescent version and when it was tested on 
fibroblasts it caused a decrease in cell number at the highest used concentration (100 
µM). The presence of the fluorophore could have modified the physicochemical 
properties of the peptide reducing its selectivity for cancer cells. Indeed, studies have 
showed that depending on the modifications, the translocation efficacy and the activity 
of a peptide could be drastically altered 363, 364.  
 
The standard formaldehyde fixation could cause the membrane permeabilization 
allowing the translocation inside the cells of any molecules attached to the outer surface 
154. To avoid this, an acid stripping was performed. The procedure allows the removal of 
anything not covalently bound from the membranes and gives the possibility of 
quantifying the amount of peptide properly internalised by the cells. Results showed 
that, especially for the fibroblasts, after acid washes, significantly less amount of 
fluorescent peptide was observed in the cells consolidating the selectivity of FITC-
G(IIKK)3I-NH2 for cancer cells. 
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7.3.5 Antibodies binding as a possible new strategy to kill cancer cells 
 
The complexation of FITC-G(IIKK)3I-NH2 with anti-FITC monoclonal antibodies 
labelled with gold nanoparticles not only allowed the localisation of the peptide inside 
cellular vesicles, thus implanting the idea of an active process as a mechanism of 
internalisation, but also it proved that FITC-G(IIKK)3I-NH2 is able to bind to antibodies 
and more importantly it could transport them inside the cells. In the recent years, there 
has been an increased interest in what are called therapeutic monoclonal antibodies 
(TMAs) which can be used to recognize and kill cancer cells. Moreover, antibodies that 
can be conjugated with drugs (antibodies-drug conjugated ADCs) have been developed 
to deliver anti-cancer drugs directly into cancerous cells, reducing in this way the side 
effects of normal chemotherapy 365. Due to its cancer cell selectivity, FITC-G(IIKK)3I-
NH2 could potentially be used to complex ADCs and deliver them in targeted cancer 
cells, consequently increasing the antibodies specificity and opening the doors to a new 
totally functionality for this peptide. 
 
For example, in the already discussed paper by Lim et al., the BR2 penetrating peptide 
was also fused with a single-chain variable fragment (scFv) antibody against mutated 
K-ras and tested on HCT-116 colon cancer cells. The results showed that the peptide 
fused with the antibody was quickly internalised by the cells and inhibited the cell 
proliferation of Ras-mutated cells promoting apoptosis 351. 
 
Cell penetrating peptides can also be used together with radiolabelled antibodies to 
enhance tumour uptake and retention. Jain et al., co-administered Penetratin in LS174T 
colon carcinoma xenograft-bearing mice with 125I-labeled, divalent [sc(Fv)2] antibody 
derived from the anti–tumor-associated glycoprotein 72 monoclonal antibody (mAb) 
CC49. The results showed that co-injection of peptide with the radiolabelled antibody 
fragment improved the retention and homogenous distribution of sc(Fv)2 in the tumour 
without alterations of pharmacokinetics and uptake in non-target tissues. The increased 
penetration was probably due to electrostatic interaction through linker regions between 
the positively charged Penetratin and the negative sc(Fv)2 molecules 
366. 
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7.3.6 The ability of efficiently deliver nucleic acid molecules in cancer 
cells 
 
A big part of this project was the focus on studying the ability of A6K, A9K and 
G(IIKK)3I-NH2 in binding negative molecules such us DNA or RNA and to investigate 
their possible usage as delivery vectors to specifically target cancer cells.  
 
A6K was unable to bind ODNs or siRNA molecules while A9K, despite transfecting 
both types of molecules in cancer cells, was unable to release the siRNAs which 
prevented their gene silencing activity. Only G(IIKK)3I-NH2 (and its fluorescent 
version) were successful in binding, transfecting and releasing nucleic acids, especially 
siRNA molecules. An endosomal escape by this peptide was already proposed 
following the results obtained with high-content RNAi screen. With the discovery of 
RNAi (interference), the biological process which mediates the knock down of targeted 
mRNA transcripts, a new field of therapeutics delivery was born: small interfering RNA 
(siRNAs) could be introduced in the cells to precisely modulate gene expression 367. 
Naked siRNA molecules cannot trespass the plasma membrane due to their size and 
overall negative nature, therefore they need carriers. Over the years, a long series of 
carriers were introduced to be used with siRNAs, including viral and non-viral vectors 
such as polymers, lipids, nanoparticles and of course peptides 368-370. Host cells toxicity, 
immunogenicity, RNA degradation, poor cell selectivity and distribution, endosomal 
escape are just few of the several barriers which preclude the use of siRNAs as 
therapeutics 187, 371. 
 
For example, MPG-8, a 21-residue amphipathic peptide was able to deliver siRNA 
molecules in cultured mammalian cells and in vivo on mice upon injection. This short 
peptide is an improved variant of the amphipathic peptide MPG derived from the fusion 
sequence of the hydrophobic HIV protein gp41, the hydrophilic nuclear localization 
sequence of SV40 large T antigen and a short linker that separates these domains. In the 
study conducted by Crombez et al., Cyc-B1 siRNA targeting cyclin B1, a non-
redundant mitotic partner of cyclin-dependent kinase 1 (cdk1) a regulatory protein 
involved in mitosis, was complexed with MPG-8 forming stable non-covalently bound 
nanoparticles. The complexes were transfected in Adherent HS68 fibroblasts, HeLa, 
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PC3 (prostate cancer), MCF-7 (breast cancer) and SCK3-Her2 (breast cancer) cell lines 
or intravenously and intra-tumoural injected in athymic female nude mice previously 
subcutaneously inoculated with PC3 or SCK3-Her2 cells. The peptide efficiently 
delivered the siRNA into cells inducing G2 arrest with downregulation of both cyclin 
B1 protein and mRNA levels. The effect was remarkably significant in cancer cells but 
only moderate on fibroblasts because the knock down of proteins required for the G2/M 
transition, has normally only a limited effect on non-cancer cells with an active G2/M 
checkpoint machinery. Also in vivo, both topic and systemic injections blocked the 
tumour growth making MPG-8 a promising candidate for clinical trials 372. 
 
Another example is given by PepFect14 (PF14), an amphipathic peptide designed to 
improve the nucleic acid delivery and whose structure is based on that of transportan‐10 
(TP10), a 21-residue peptide derived from Mastoparan, of the wasp Vespula lewisii 
venom. PF14 was complexed with two siRNAs targeting firefly luciferase and 
hypoxanthine phosphoribosyl transferase (HPRT1), an enzyme involved in the purines 
recycling, important process for the production of DNA and RNA. Luciferase-
expressing BHK21 (baby hamster kidney), HepG2 (human hepatocellular carcinoma) 
and HEK293 (embryonic kidney) cell lines were used for the luciferase knockdown 
while HUH 7 (human hepatocellular carcinoma) and Jurkat (acute T cell leukaemia) cell 
lines were used for assessing HPRT1 endogenous gene knockdown. PF14/siRNA 
complexes were successful in mediating the RNAi knock down of both, luciferase and 
HPRT1 and the transfection efficiency of the peptide was even higher than the standard 
transfection reagents (Lipofectamine 2000 and Lipofectamine RNAimax®). Moreover, 
the stability of the complexes peptide/siRNA was tested to evaluate a possible usage for 
oral administration. Prior transfection in HEK293 cells, the nanocomplexes were left in 
the simulated gastric fluid (SGF), a highly acidic solution with or without pepsin. 
Results showed that the complexes gave good knock down efficiency when left up to 2 
hrs in the SCF but in presence of pepsin the limit was set to 30 minutes 373. 
 
Interestingly, both A9K and G(IIKK)3I-NH2 were able to deeply transfect 3D spheroids 
model of colon cancer cells, unlike the commercial lipid transfection reagent. Tumour 
penetration is a crucial quality that an anticancer treatment should have to be effective. 
If a therapy is unable to reach all the cells in a tumour that have regenerating properties, 
then its efficacy is highly reduced 189. Cells in the centre of a solid tumour are hypoxic 
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and much evidence suggest that this type of cell is not only resistant to radiation 
treatment, but it is also able to regenerate the tumour after intense chemotherapy 217. A 
good way to study tumour penetration and develop better anticancer therapies is to work 
with 3D models of immortalized established cancer cells lines. 3D cultures have many 
of the real tumours characteristics, such as cell-cell interactions, drug penetration 
resistance, hypoxia and production of extracellular matrix. In vitro 3D cultures could 
potentially be a good intermediate between the standard in vitro 2D monolayer cultures 
and in in vivo animal models 134.  
 
To date this was the first time that amphiphilic cationic peptides without clear cell 
penetrating sequences were able to selectively transfected 2D and 3D cancer models 
with siRNA molecules and in some extensions also modulate gene expression  
 
7.3.6 In vivo toxicity 
 
The results obtained with the in vivo microinjections in zebrafish embryos showed how 
β-sheet and α-helical peptides can behave differently in a living complex organism. The 
extreme toxicity of FITC-G(IIKK)3I-NH2 when compared to A9K gives rise to a few 
questions regarding the mechanism of interaction of these peptides with zebrafish 
embryos. Their different structures (α-helical and single monomer the first or β-sheet 
and self-assembled in long nanorods the latter) might play a crucial role in the way they 
behave, once injected. From the transfection experiments described in Chapter 3 and 
Chapter 4, it had already emerged how, despite both peptides being able to correctly 
transfect small nucleic acids molecules inside human cancer cells, only FITC-
G(IIKK)3I-NH2 was releasing its “cargo” and modulated gene expression. 
 
Zebrafish embryos are often used as a model for assessing the toxicity of chemical 
compounds, nanomaterials and drugs due to their rapid development, a physiology, 
compatible with the human one, relative cheap maintenance and optic clear 
embryogenesis that allows one to easily score phenotypical changes 242, 374, 375. 
 
Normally, the material which needs to be tested is directly dissolved in the embryos’ 
medium and any changes from the standard embryonic development are carefully 
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recorded. However, in some cases microinjections in one cell stage embryos could be 
performed instead 253, 254. Microinjections could be a suitable alternative for the 
environmental toxicity testing of compounds of large size or a net charge, like A9K and 
FITC-G(IIKK)3I-NH2, which might not be able otherwise to cross the chorion, a thick 
acellular envelope that naturally protects the embryos 376. Moreover, if microinjected, 
the concentration to be tested could be much higher than when simply dissolved in 
medium, allowing the exploration of the effect of wider ranges. For example, for A9K 
and FITC-G(IIKK)3I-NH2 concentrations up to 5 mM and 2 mM respectively have been 
tested.  
 
Schubert et al., used the microinjection technique on one-cell stage zebrafish embryos to 
evaluate the effects of four vehicle substances which are normally used as solvents in 
bioassays; autoclaved tap water, dimethyl sulfoxide (DMSO), methanol, and triolein. 
The survival rate of injected embryos was recorded after 24 or 96 hrs and varied 
depending on the substance or the injected volume (0.5 and 4.2 nl). Between the two 
time points there were no significant differences while larger injected volumes caused 
more mortality (for some substances the difference in survival rate was 20% or more). 
This is because high injected volumes (≥4.2 nL) could cause swelling of the yolk sac 
with consequent leakage of its content through the injection pierce. Overall, methanol 
and DMSO caused higher mortalities than triolein and water with the survival rates 
decreased up to 60% when higher volumes were injected. This study confirmed the 
possibility of using the microinjection technique to administer substances into newly 
fertilized fish eggs and test their toxicity. In this way, any type of compound can be 
easily administered, overcoming all the embryos’ natural barriers 256. 
 
Cationic amphipathic peptides have been tested on zebrafish embryos and their acute 
toxicity evaluated. For example, in the previously cited paper by Wang et al., several 
rhodamine B-conjugated peptides derived from vipericidin (pit viper venom) 
hypervariable C-terminal regions were tested in 3 dpf larvae in a range of 1-100 µM. 
Rhodamine B-conjugated EVP50 was the most toxic, exhibiting an LD50 of 6 µM and 
therefore selected for further studies. The distribution of RhoB-EVP50 was assessed in 
3dpf larvae which were incubated with 10 µM of peptide for 24 hrs and the fluorophore 
accumulation and emission observed under the fluorescent microscope. Free rhodamine 
B was used as negative control. The images showed that, while the free fluorophore 
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accumulated only in the yolk sac, the peptide was distributed in the cardiovascular 
system, especially in the posterior cardinal vein, in the intersegmental vessels and in the 
cardiomyocytes of the heart. Experiments on breast cancer cells (MCF-7 and MDA-
MB-231) showed that this peptide is toxic to both cancer cell lines in a dose-dependent 
manner and can uniformly accumulate in the cells damaging the membranes and 
causing their lysis within few minutes 363. 
 
Crotamine, another cationic peptide derived from snake venom (rattlesnake) was 
conjugated with the fluorophore Rhodamine-B and tested on 3dpf zebrafish larvae. 
Chan and collaborators assessed the survival rate of zebrafish embryos exposed to 
different concentrations of the peptide (0-16 µM) at several time points (10 min, 30 
min, 3 hrs and 24 hrs). The results showed that the peptide at concentrations higher than 
4 µM induced death in all the individuals after only 10 minutes. Moreover, the 
distribution of the peptide was evaluated using a fluorescent microscope and the images 
showed that, when the embryos were exposed for 24 hrs to 1 µM of RhoB-crotamine, 
the peptide being mainly localised in the yolk sac and intestine 377.   
 
Since A9K and FITC-G(IIKK)3I-NH2 were injected directly inside zebrafish oocytes, 
they could potentially have directly or indirectly damaged the DNA, inducing 
genotoxicity and causing, depending on the concentration, apoptosis. The images taken 
with the stereomicroscope of embryos at 1 or 3 dpf injected with A9K showed that, at 
low doses (150-500 pg), the peptide did not alter the fish development and the 
phenotype of the injected embryos was comparable with the relative controls. At higher 
concentrations (1000-4000 pg) however, the embryogenesis was affected, and 
malformations or tissue degradation were observed. However, these effects could be not 
peptide-specific but associated with increased volumes introduced in the embryos 256. 
For example, morpholino-modified antisense oligonucleotides (MOs) have a threshold 
of 3-4 ng per embryo and higher amounts (> 5 ng) cause non-specific toxic effects, such 
as cell death (often in the brain) or general developmental delays via activation of p53 
378-380. A normal 1 dpf embryo should display several somites, rudimental organs, 
budded tail, primordial neuronal system and a principle of eyes 146. However, embryos 
injected with 1000-4000 pg of A9K (Figure 63) showed tissue darkening compatible 
with widespread necrosis or apoptosis and progressive growth retardation. Stronger 
phenotypes showed an almost complete suppression of head and tail structures. These 
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effects could be associated with an induction of p53 signalling 381. 3 dpf embryos should 
display complete blood circulation, advanced neuronal system, most of the organs 
morphologically defined and developed eyes 146. The embryos injected with higher 
volumes of peptide (Figure 64) kept presenting major defects; pericardial and yolk sac 
oedemas were the most prominent followed by spine malformation and severe brain 
development retardation. Oedemas are accumulations of organic fluids due to swelling 
and persistent inflammation. In zebrafish, the pericardial oedema is a common 
phenotype of a defective cardiovascular system. It is caused by the absence of structural 
development contractility or electrophysiological coordination due to defects in the 
specification or differentiation of cardiac progenitor cells, failures during the hearth 
tube, cardiac chambers or vasculature morphogenesis 382, 383. Exposure in early 
developmental stages to chemical compounds such as 2,3,7,8-Tetrachlorodibenzo-p-
dioxin (TCDD) or nanomaterials such as fullerenes can induce cardiac malformations 
and hemodynamic alterations with consequent pericardial or yolk swelling 384, 385.  
 
FITC-G(IIKK)3I-NH2 clearly had a more devastating effect, especially considering the 
amount of eggs found with coagulation signs already after only 5 hpf. To evaluate if the 
peptide toxicity could decrease if unable to interact with DNA or RNA, FITC-
G(IIKK)3I-NH2 was complexed with siGLO and injected in the embryos. The new set of 
data showed indeed that FITC-G(IIKK)3I-NH2 reduced its toxicity. Evidently, FITC-
G(IIKK)3I-NH2 is a quite active molecule and when injected on its own could interact 
with the cellular material inside the embryo, causing extreme toxicity even in the first 
few hours following fertilisation. But once mixed with siGLO the overall toxicity 
decreased by a significant 50% showing that in its complexed form it could be less 
prone to kill the embryos. It would not be the first case that a cationic peptide with 
anticancer properties damages the embryos’ DNA. Morash et al., conducted a study on 
26 natural variants of Pleurocidins, a family of positively charged α-helical 
antimicrobial peptides secreted by the mucosal surfaces of flatfish. Their cytotoxicity 
and anti-cancer activities were assessed in vitro on HL60 human leukaemia cells and in 
vivo on zebrafish embryos at different developmental stages (4 hpf, 28 hpf and 52 hpf). 
14 peptides were not toxic against the cancer cells while 12 caused more than 50% of 
cell death for concentrations of ≤ 32 µg/ml. Four peptides were not toxic against the 
embryos even at the highest tested concentration (25 µM) while one peptide was found 
to be extremely toxic and killed immediately with 1 µM all the 4 hpf embryos. Another 
   
242 
 
four peptides induced toxicity at the same concentration but only after 24 hrs exposure 
while most of the peptides caused mortality at one or more developmental stages at 
concentrations of ≥ 5 µM after 24 hrs exposure. One of the highly toxic peptides, NRC-
03, was further studied and its impact on 48 hpf embryos analysed with different 
fluorescent stainings. Superoxide-sensitive dye dihydroethidium (DHE) assay 
demonstrated the production of reactive oxygen species (ROS) as a sign of damaged 
mitochondria; the TUNEL-staining of nicked DNA ends, together with the phalloidin 
staining showed that the peptide caused DNA fragmentation in association with actin 
condensation while the Vybrant apoptosis assay indicated that cells death was caused by 
membrane permeabilization 386.   
 
When the embryos, injected with the peptide/siGLO complexes were observed under 
the fluorescent microscope, it appeared that while in 1 dpf embryos the fluorescence of 
both siRNA and peptide was uniformly distributed across the embryo’s body, in 3 dpf 
embryos, the fluorescence was instead mainly concentrated in the yolk. A possible 
explanation of this phenomenon is that in the yolk the fluorescent molecules might be 
more stable and less prone to be degraded compared to other tissues. Moreover, the 
yolk, the embryo’s main food source, shrinks more and more during the developmental 
stages while the cells of the rest of the body undergo several divisions increasing in 
number and augmenting in embryo’s volume. This means that, in the yolk the amount 
of initial siRNA and peptide was progressively concentrated in a smaller area resulting 
in a more intense fluorescence, while in the rest of the body, they were instead 
distributed in a bigger volume of cells and as a consequence the fluorescence started 
fading. The retention of the fluorescent peptide in the yolk sac could also indicate 
potential liver toxicity. Indeed, several chemical compounds known to be hepatotoxic 
have been found to firstly accumulate in the yolk sac, then reduce the liver size and 
induce morphological abnormalities 387. 
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7.3.7 Caudal injections of FITC-G(IIKK)3I-NH2 in 4 dpf larvae leaked out 
 
The assessment of FITC-G(IIKK)3I-NH2 distribution in the vascular system of zebrafish 
larvae was important to evaluate its efficacy in targeting tumours or as possible vector 
for systemic therapies. Unfortunately, the outcome of the experiment was unsuccessful 
and both peptide and the negative control, FITC, leaked out almost immediately from 
the fish system. However, it is unclear why the leakage was only concentrated in two 
exit points (gills and choroid plexus) while the rest of the larvae’s bodies did not show 
any traces of fluorescence. A possible explanation could be that the endothelium of the 
gills between the 4th and 5th days under goes an extensively remodelling process with 
many integrity changes to increase the surface area for respiration 146. At the same time, 
brain perycites, important regulators of vascular integrity and permeability have just 
started actively proliferating and being recruited to the brain area 388. Even the blood-
brain barrier (BBB) and its tight-junction proteins, which would have easily retained the 
compounds, are not completely formed yet 389. At this stage of embryonic development, 
it was not possible to determine whether, FITC-G(IIKK)3I-NH2 would be retained in the 
vascular system and eventually be used as delivery vector for systemic drugs or to 
selectively target cancer cells. Fish at a later embryonic developmental stage (> 5 dpf) 
should have been employed for this type of experiment but the licence in possession at 
the time did not allow for maintaining the embryos alive for so long. 
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7.4. Conclusions, future works and perspectives  
 
The data collected and explained in this thesis helped give a better understanding of the 
interactions of three amphipathic small cationic peptides with mammalian (cancer and 
non-cancer) cells. The mode of action towards cancer cells, initially hypothesised to be 
mainly membranolytic had been found to be more complex than expected. The peptides 
did not show lysing abilities but instead accumulate in the cytoplasm in a dose-
dependent manner. 
 
An energy-dependent endocytic pathway seems to be responsible for the peptides 
uptake and low temperatures (4 °C) drastically inhibits their internalisation. According 
to the RNAi mini-screen performed on HCT-116 cells exposed to FITC-A9K, the 
clathrin-dependent endocytic pathways could be involved in the cellular uptake, 
however with the high-content screen performed on the cells exposed to FITC-
G(IIKK)3I-NH2, an exact pathway could not be identified due to redundancy effects. For 
many knocked down genes a general decrease in the internalisation of the fluorescent 
peptide was observed. Combinatorial RNAi screens, in which two genes are 
simultaneously silenced could be used to overcome this problem. The robust Z-score 
was calculated identifying several 31 outliers and possible hits. A careful analysis 
revealed that recycling to the cell surface and vesicle transport trafficking within 
secreting organelles were the processes generally associated with the outliers. This 
discovery suggests that FITC-G(IIKK)3I-NH2 can escape the endosomes and retrograde 
transport to the Trans Golgi Network (TGF), eventually being recycled on the cell 
surface, but when the vesicular trafficking is disrupted the peptide accumulates instead 
in endosomal compartments. To date this was the first time that the intracellular 
trafficking of a cationic amphiphilic peptide was investigated and the results discussed 
in this thesis could be the starting point to better understanding of the cellular 
mechanisms between this class of peptides and mammalian cells. A9K and G(IIKK)3I-
NH2 but not A6K were able to bind DNA and RNA molecules and transfect them 
selectively in 2D and 3D cancer models without decreasing the cell viability. However, 
only the α-helical peptide could escape the endosomes and correctly release the siRNA 
to allow the gene knock down via the RNAi machinery. The toxicity of A9K and 
G(IIKK)3I-NH2 was assessed as well in Danio rerio embryos in vivo models. In 
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literature, it is possible to find studies where zebrafish embryos are used to assess the 
acute and chronic toxicity of cationic amphiphilic peptides, but normally the peptide 
solution is dissolved into the medium of embryos between 4 hpf and 3 dpf old which are 
consequently exposed to it. To our knowledge, this was the first time that the 
microinjection procedure was applied to evaluate the toxicity of amphiphilic cationic 
peptides. The results generated good dose-response curves, confirming that this method 
could be successfully applied for in vivo toxicity assessments. A9K was less toxic 
compared to FITC-G(IIKK)3I-NH2. However, if the α-helical peptide was complexed 
with negative molecules prior to injection, the overall toxicity massively decreased. 
This suggests that the peptide could still potentially be used as systemic drug vector 
upon carefully investigation of its toxic thresholds.  
 
These promising results lay the foundation for an interesting novel approach in cancer 
therapy where, cationic amphiphilic peptides such as G(IIKK)3I-NH2 could potentially 
be used as carriers for siRNA, drugs or antibody to selectively target cancer cells and 
induce their death. Further investigations should be done to evaluate the ability of this 
peptide to inhibit the cell growth of 3D spheroidal tumours or to identify the pathway(s) 
of internalisation as a method to increase their cancer cell specificity.  
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